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Global epidemic and consequences       Section 1 
Non-alcoholic fatty liver disease (NAFLD) constitutes a spectrum ranging from simple fatty liver to 
steatohepatitis (NASH) and liver cirrhosis. In the last three decades its prevalence increased 
tremendously due to the global obesity epidemic and accompanied insulin resistance (IR). When 
features of NASH (i.e. inflammation or fibrosis) are present, patients are at risk for complications 
of liver cirrhosis (and concomitant portal hypertension) and cardiovascular disease. In a general 
population prevalence numbers for NAFLD are thought to be approximately 10-24% worldwide [1] 
and 2-3% for NASH in the United States population. These numbers can be transposed to an 
increased need for liver transplantation and nowadays NASH is ranking as the third indication for 
livertransplantation (2001: 1.2% to 2009: 9.7%) [2].  One of the most severe complications of liver 
cirrhosis is the development of hepatocellular carcinoma (HCC). In a recent study carried out in 6 
European countries, 160 cases of HCC were detected in 22 months of which 43% was detected in 
the absence of any other risk factor such as alcohol abuse, cirrhosis or infection with hepatitis B or 
C [3].    
Therefore the high prevalence of NAFLD will lead to a higher incidence of HCC in the general 
population with a concomitant burden on treatment availability, including liver transplantation. In 
addition, patients with NAFLD are poor liver graft donors as the use of severe steatotic allografts 
results in poorer outcome on recipient and graft survival [4]. 
 
NAFLD, diabetes and pathophysiology        Section 2 
The accumulation of lipids in the liver is a consequence of a deranged metabolism that also 
includes type 2 diabetes mellitus (T2DM), hyperinsulinemia, dyslipidemia and hypertension. The 
close association of hepatic steatosis with obesity, and cardiometabolic risks has led to the 
suggestion that hepatic steatosis is a novel component of the metabolic syndrome, alternatively it 
may be regarded as a key causal factor of the metabolic syndrome. The co-existence of NAFLD 
and T2DM results in a 22-fold increase of liver-related death as well as a 2.6-3.3-fold increase in 
overall death [5]. Chapter 1 contains a full description of the available data on epidemiology, 
pathophysiology, diagnosis and treatment of NAFLD.  
Although NAFLD is usually associated with type 2 diabetes, occasionally NAFLD patients present 
with type 1 diabetes mellitus , in contrast to type 2 patients these patients are often slim rather 
than obese.  
As in NAFLD, patients with chronic hepatitis C can also present with considerable steatosis. This 
often concerns patients infected with HCV genotype 1 and 3. During a recent clinical trial, 
performed at the AMC Liver Center of Amsterdam, in which naïve HCV-infected patients were 
treated with either standard treatment pegylated interferon and ribavirin or with trial medication 
including amantadine and high dose interferon followed by standard therapy, some of the 
patients showed significant hyperglycemia during treatment. Chapter 2 presents the results of 
this study in which the contribution of autoimmune phenomena (measured by antibodies and 
compatible HLA-subtyping) and an HCV-induced IR as the underlying cause for hyperglycaemia 
was studied.  
In several clinical conditions lipids accumulate  not only in the liver but also in other organs 
 
 
including the heart and the pancreas can also be affected. Studies in the 1960s and 1970s 
correlated pancreatic lipomatosis with age, obesity, and type 2 diabetes [6,7]. Later imaging 
studies have correlated pancreatic lipomatosis with obesity [8,9]. Clarification on whether there 
are evident associations is needed since pancreatic lipomatosis, also known as non-alcoholic fatty 
pancreas disease (NAFPD), may (1) promote the development of chronic pancreatitis and 
pancreatic cancer, (2) may exacerbate the severity of acute pancreatitis, (3) may increase the risk 
of pancreatic surgery and (4) causes the development of overt diabetes. In chapter 3 the 
association of histologically proven NAFLD and NAFPD is studied.  
Fibroblast growth factor-19 (FGF19), a hormonally active subfamily of fibroblast groth factors, 
exerts endocrine functions and has emerged as a novel regulator of hepatic lipid homeostasis 
[10]. FGF19 appears to influence both hepatic fatty acid oxidation (inhibition of acetyl-CoA 
carboxylase 2) and hepatic lipid synthesis (suppression of insulin-induced fatty acid synthesis). Bile 
salts stimulate the expression of intestinal (ileum) FGF19, which sorts its effects on hepatocytes in 
a feed-forward fashion. In Chapter 4, we studied the FGF19 response in patients with NAFLD after 
an oral fat challenge.  
  
Diagnostic challenges; invasive or non-invasive?      Section 3 
Diagnosis of NAFLD is based on confirmation by imaging studies and/or liver histology [11] in 
combination with the exclusion of excessive alcohol abuse and viral hepatitis. Most patients 
present asymptomatically, the minority have nonspecific physical findings (hepatomegaly) 
unreliable for assessing disease severity. However, as aforementioned, distinguishing simple fatty 
liver from its inflammatory variant (NASH) is of importance due to the potential development of 
life-threatening conditions. Since the number of patients with NAFLD is increasing and liver 
biopsy, with its potential complications, remains the golden standard, reliable non-invasive 
diagnostic tools are needed.     
The liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) often 
used for diagnosis are neither sensitive nor specific for detecting the presence of inflammation or 
fibrosis. Moreover, in up to 78% of patients, liver enzymes may even be normal in the presence of 
NAFLD [12,13]. Some other frequently used biomarkers as -glutamyl-transferase (Gt) have 
shown to be correlated with advanced fibrosis (AUROC 0.74) [14]. Thrombocytopenia, 
hyperbilirubinemia, hypoalbuminemia and increased prothrombin time are suggestive for 
cirrhosis and portal hypertension.  
Elevated ferritin and transferrin saturation have been demonstrated in approximately 50% of 
NASH patients [15]. Genetic studies have convincingly shown that these findings are not the 
consequence of underlying hemochromatosis. However, after studying a panel of genes involved 
in fatty acid and iron metabolism, measuring transcript levels demonstrated that during liver 
disease progression, steatosis-related metabolism is diminished and iron-metabolism increased 
[16]. In NASH patients, a clear down-regulation of ferroportin-1 (FP-1), the iron exporter, mRNA in 
duodenal biopsies was found. This was in turn correlated with body mass index and TNF-α-
concentrations, suggesting a down-regulation of FP-1 by visceral adipose tissue and associated 
inflammation [17]. A recent study in over 600 patients with NAFLD concluded that an increased 
serum ferritin was associated with worsened histological activity and was an independent 
predictor of advanced hepatic fibrosis [18]. However, others have reported conflicting data. In 
Chapter 5 we performed a cross-sectional analysis of the association between levels of ferritin 
and hepatic steatosis in T2DM patients in a general teaching hospital in the Netherlands.  
 
 
Imaging in NAFLD; what you see is what you get?      Section 4 
The most frequent and readily available method to measure hepatic steatosis is by 
ultrasonography, by which patients with more than 30% liver fat can be diagnosed accurately 
(sensitivity 91% and PPV 89%) [19]. In more obese patients sensitivity decreases and 
differentiations between simple fat accumulation and concomitant inflammation/fibrosis cannot 
be made.  
Computed tomography (CT) allows for more quantitative assessment of liver fat by measuring the 
liver:spleen attenuation [20,21]. However its use is limited due to radiation exposure and, again, 
the inability to diagnose inflammation.  
Transient elastography (Fibroscan, Echosens, France), a non-invasive method to assess liver 
stiffness, uses ultrasound-based technology at the bedside. The AUROCs for this technique in two 
separate studies are excellent (for significant fibrosis 0.88 and 0.84, [22,23], but it needs to be 
further investigated in more obese patients. 
Magnetic resonance imaging (MRI) has been shown to most accurately detect liver fat (even in 
amounts less than 3%) [24]. More recently, 1.5 Tesla 1H-Magnetic Resonance Spectroscopy (1H-
MRS) has been introduced as a novel technique to quantify liver fat and its results correlate with 
histological data from liver biopsies. It measures the nuclear chemical shift generated by 
hydrogen atoms of fatty acid chains in a magnetic field. The various fatty acids can be 
differentiated by the small shifts in nuclear resonance of the hydrogen atoms bound to different 
structured carbon chains. In Chapter 6, we studied the feasibility to assess more accurately these 
chemical shifts and spectra in a 3.0 Tesla MR-scanner (stronger magnetic field) in well-defined 
patients with NAFLD. In addition, an open bore MR-scanner can be useful for patients with more 
severe obesity (BMI > 35 kg/m2) who do not fit in a standard MRI scanner. Its use for hepatic fat 
measurement is described in Chapter 7.  
 
This thesis focuses on pathophysiology of NAFLD by reviewing available data and investigating the 
effects of FGF-19, a novel endocrine regulator, in patients with NAFLD. Secondly, it investigates 
the importance of non-invasive biomarkers (ferritin) and imaging tools (magnetic resonance 
spectroscopy) for grading and staging patients suffering from NAFLD.  
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Abstract 
Estimates of people suffering from overweight (one billion) and obesity (300 million) are 
increasing. The accumulation of triglycerides in the liver, in the absence of excess alcohol intake, 
has been described in the early sixties. It was not until 1980 however that Ludwig et al. named 
this condition nonalcoholic steatohepatitis (NASH). Subsequently, nonalcoholic fatty liver disease 
(NAFLD) has been used as a general name for conditions ranging from simple steatosis through 
steatohepatitis to end-stage liver disease (cirrhosis). Many studies demonstrated the strong 
correlation between obesity, insulin resistance and this disease extending from simple hepatic 
steatosis through steatohepatitis (NASH) to severe fibrosis (cirrhosis). Other studies revealed a 
significant correlation between hepatic steatosis, cardiovascular disease and increased intima-
media thickness. 
Calculations by the WHO estimate at least two million patients developing cirrhosis due to hepatic 
steatosis in the future. Longitudinal cohort studies demonstrated a similar increased risk in the 
development of hepatocellular carcinoma in those suffering from cirrhosis. Taken all together, 
NAFLD has become the third most important indication for liver transplantation. Therefore 
training in internal medicine and gastroenterology and hepatology should emphasize the 
awareness for this entity to avoid complications of portal hypertension and prevent the 
associated cardiovascular disease.  
This review will focus on clinical characteristics, pathophysiology, imaging techniques and 
therapeutic opportunities.  
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Introduction 
When they have a surplus of food to their disposition, the most living creatures start to hoard 
energy for future scarce times. The breakthrough of agriculture and founding of villages around 9 
500 BC in several independent parts of the world not only laid the pavement for modern society, 
but also gave people the opportunity to cultivate and store more food than needed for their 
support and their families. This excess of energy has led to the current situation nowadays where 
the caloric availability exceeds the caloric needs by far. The human body still possesses the quality 
to store excess energy in adipocytes, a quality that now works in its disadvantage. The extreme 
storage of energy excess and a reduction in physical activity has lead to a worldwide epidemic of 
obesity. The world health organization (WHO) estimates the number of overweight (BMI > 25) 
individuals over one billion, of whom 300 million obese (BMI > 30) (1). In future prospects this 
number will only increase further (2,3). Although most obese or overweight persons’ biggest 
concern seems their appearance, obesity has been recognised as a pathogenic factor for a vast 
array of other pathologies (Table 1). A subset of diseases often occurring in the same patient have 
been clustered, now known as the metabolic syndrome (4-6). Vehement research has unravelled 
major parts of the pathophysiological mechanisms linking obesity and metabolic syndrome, 
although many issues have not been explained yet (7,8). One of the entities research focussed on 
is non-alcoholic fatty liver disease (NAFLD), which has a strong relation with the metabolic 
syndrome (9-16). This disease with mainly the accumulation of triglycerides in the liver, in the 
absence of excess alcohol intake, has been described in the early sixties (17,18). It was not until 
1980 however that Ludwig et al. named this condition non-alcoholic steatohepatitis (NASH) (19). 
Subsequently, non-alcoholic fatty liver disease (NAFLD) has been used as a general name for 
conditions ranging from simple steatosis through steatohepatitis to end-stage liver disease 
(cirrhosis) (20). The first being rather benign (21,22), the second of significant clinical importance 
(23) and the last one with an increased risk of hepatocellular carcinoma (24,25). An almost 
universal association with hepatic, as well as adipose tissue insulin resistance (IR) was established 
in a number of studies (26-34). In a large study, Browning et al. used 1H–NMR-spectroscopy to 
measure hepatic triglyceride content in a multi-ethnic urban US population-based study (35). 
Hepatic steatosis was found in 31% of their population, increasing up to 67% in obese subjects. 
Other studies confirmed this positive correlation between BMI and hepatic steatosis. A few 
studies focussed on the natural history of NAFLD and found that only 1%-5% of patients with 
simple steatosis eventually develop actual cirrhosis. Calculations by the WHO estimate at least 2 
million people developing cirrhosis due to hepatic steatosis. Taken all together, NAFLD has 
become the third most important indication for liver transplantation and is already estimated to 
become the leading indication in the next decades. In this respective, the finding of NASH in 
young obese children is very alarming (36). Training in paediatrics, internal medicine and 
gastroenterology and hepatology should emphasize the awareness for this entity to avoid 
complications of portal hypertension, minimize the need for liver transplantations and prevent 
the associated cardiovascular disease.  
This review will focus on clinical characteristics, pathophysiology, imaging techniques and 
therapeutic opportunities. 
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Table 1. Obesity related pathologies 
 
Diabetes mellitus + obesity  
 
= metabolic 
syndrome 
Heart disease Hepatobiliary disease 
Insulin resistance - Coronary disease GERD/esophageal cancer 
Hypertension - Heart failure Osteoarthritis 
Dyslipidemia - Myocardial steatosis Skin changes 
Endocrine changes - Atrial fibrillation/flutter Gout 
Kidney disease Stroke Dementia 
- Kidney stones Venous thrombosis Psychosocial 
Cancer (overall and specific) Respiratory system   
 
Clinical characteristics 
Most patients with NAFLD are asymptomatic and when symptoms occur they are usually non 
specific. Frequent complaints are fatigue and vague right upper quadrant abdominal discomfort. 
Because of the latter, steatosis is often found on ultrasound examinations made for suspicion of 
biliary disease. Ultrasound abnormalities and elevated levels of alanine transaminase (ALT) are 
often found at routine check-up or when patients present themselves with physical complaints 
due to other diseases. Given that NAFLD is widely accepted as a part of the metabolic syndrome, 
or at least being related with, most patients present with other pathologies linked to this 
syndrome. Once other pathologies (Table 2) are ruled out as a cause of steatosis, NAFLD can be 
allocated as the most common cause for elevated ALT levels and/or steatosis. Mildly raised levels 
of ALT were found in hospitalized NASH patients, but no higher than four times the upper limit of 
normal (ULN) (37-41). These levels fluctuated but never returned to normal values. Abnormal AST 
levels were also found, especially in cirrhotic patients. Gamma-glutamyl transpeptidase (γGT) 
and alkaline phosphatase levels can be raised although in unknown frequency. In conclusion, 
these mild laboratory abnormalities won’t be very helpfull in diagnosing this disease since their 
low sensitivity and specificity. In more advanced disease stages, liver stigmata like jaundice, spider 
naevi and erythaema palmare develop. In these patients laboratory abnormalities are consistent 
with progressed liver disease.  
 
Table 2. Possible causes for steatosis hepatis 
 
Metabolic  Drugs  
 Alfa-betalipoproteinemia  Methotrexate 
 Glycogen storage diseases  Diltiazem 
 Weber-Christian disease  HAART†† 
 Wolmans disease  Amiodarone 
 Acute fatty liver of pregnancy  Glucocorticoids 
 Lipodystrophy Toxins  
 Iron overload syndromes  Alcohol 
 Alfa-1-antitripsin deficiency  Environmental toxins (e.g. 
toxic mushroom) 
 Wilsons disease   
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Nutritional Malnutrition Autoimmune  
 Total parenteral nutrition  Autoimmune hepatitis 
 Severe weight loss  Celiac disease 
 Refeeding syndrome   
 Jejuno-ileal bypass   
 Gastric bypass   
 
Jejunal diverticulosis with 
bacterial overgrowth   
Inflammatory    
 HIV†   
 Chronic Hepatitis C infection   
†
 HIV = Human Immunodeficiency Virus, 
††
 HAART = Highly Active AntiRetroviral Therapy 
 
 
Pathophysiology 
 
Healthy Subjects 
Within the body’s system of controlling fatty-acid and triglyceride (TG) metabolism, the liver plays 
a crucial role. It synthesizes, stores, secretes and oxidizes free fatty acids (FFA’s). The liver 
responds to and manages fatty acids that originate from ingested foods, from adipose stores and 
from its own de novo production. Oxidation of FFA’s is considered the main energy source for 
gluconeogenesis in a fasting state. TG is incorporated into very low density lipoproteins (VLDL) 
particles while being transported out of the liver to peripheral tissue. The main storage for fatty 
acids in human is adipose tissue. In healthy individuals, while fasting lipolysis causes TG to be 
released into the plasma nonesterified fatty acid (NEFA) pool, while being fed adipocytes will take 
up fatty acids. Postprandial, the pancreas releases insulin which increases lipogenesis and 
decreases lipolysis and fatty acid mitochondrial oxidation. The second source of fatty acids that 
contribute to the livers total supply is hepatic de novo lipogenesis (DNL). In healthy individuals 
this source is a minor contributor while fasting and insulin levels are low. A third mechanism that 
provides fatty acids is the absorption of dietary fats.  
In 1998 Day launched the “two-hit-theory”, stating that two succeeding wallops have to be 
delivered to the liver to cause NASH (42). The first hit, development of hepatic steatosis, consists 
of the accumulation of TG, consisting of 3 fatty acids and a glycerol backbone, in the hepatocytes. 
The development of hepatic steatosis is a form of ectopic lipid accumulation, resulting from a 
disturbance in the balance between supply, formation, consumption and hepatic oxidation or 
disposal of TG. Consumption includes mitochondrial β-oxidation, production of ketone bodies, 
and secretion of TG in VLDL particles. Many animal and human studies have shown there is an 
inextricable relation between obesity and IR (43-47) and that IR is a key pathogenic factor in the 
development of hepatic steatosis (26-34).  
 
Insulin Resistance (IR) 
Insulin resistance is the disruption of the signalling pathways in cells, leading to a diminished 
capability to execute the normal cellular response to insulin. For details of the insulin pathway the 
reader is referred to excellent reviews by Herman (48) and Taniguchi (49). In summary, the insulin 
receptor is tyrosine phosphorylated upon binding to insulin, which in turn causes tyrosine 
phosphorylation of the insulin receptor substrate (IRS) proteins. There are two important IRS. IRS-
1 is the initiator in the pathway of glucose metabolism. Upon phosphorylation IRS-1 induces 
stimulation of the phosphatidylinositol 3-kinase (PI3K)–AKT/protein kinase B (PKB) pathway, 
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resulting in recruitment of glucose transporters (GLUT). IRS-2 cranks up lipid metabolism in the 
cell and is a main regulator in DNL via sterol regulatory element binding protein 1c (SREBP-1c). 
SREBP-1c is a member of the SREBP family, a group of transcription factors that play a 
fundamental role in cellular lipid metabolism (50). Three different SREB proteins have been 
identified; together they activate the complete program of cholesterol and fatty acid synthesis in 
the liver (51). SREBP-1c is the isoform that plays a role in synthesis of fatty acids and TG in the 
liver, by stimulating the formation of enzymes in the formation of TG, most importantly Acetyl 
CoA Carboxylase (AAC) and Fatty Acid Synthase (FAS) (52). The most enzymes that SREBP-1c 
stimulates are also regulated by carbodehydrate response element binding protein (ChREBP) (53). 
For a long time it was assumed that a defect in muscle tissue was the first step in the origination 
of insulin resistant states. In the last decade however this doubtful honour shifted towards the 
adipocyte. Besides the lump storage of fat, in the mid 90’s the exocrine functions of fat, were 
recognised and it became clear that fat is the choirmaster in the aetiology of IR (54). It has been 
found that mice lacking GLUT4 in adipocytes develop IR in muscle and liver tissue (55). This 
suggests that fat cells secrete a substance that can induce IR in other tissues.  
Adipocytes excrete a number of bioactive peptides that are collectively called “adipokines”. Leptin 
(Greek for ‘thin’), discovered by Zhang et al. in 1994 (56) is the prototype, but since then a other 
adipokines, such as adiponectin (57), ghrelin (58), resistin (59) and recently retinol binding protein 
4 (RBP4) (60), have been identified and characterized. RBP4 works partly by blocking the action of 
insulin in muscle and liver (60,61). Depending on the amount of lipids an adipocyte has stored, it 
releases adipokines that either say the storage maximum is reached (leptin, RBP4) or that more 
capacity is available (adiponectin). Each adipocyte secretes a small amount of these peptides into 
its direct surroundings. In obese states, adipocytes also excrete inflammatory cytokines (47). TNF-
α levels were found to be over expressed in obese people (62). Since this discovery more 
inflammatory mediators were recognised and investigated (63). Excretion of inflammatory 
cytokines attracts macrophages, probably as a natural response to clear the body of extreme 
swollen and malfunctioning fat cells. The macrophages themselves also release inflammatory 
substances. In the copious blood flow in adipose tissue these peptides readily manoeuvre into the 
blood, which enables them to exert a number of endocrine and autocrine functions. Together, all 
adipocytes make up the largest endocrine organ resulting in a considerable influence of 
adipokines on body function (64-66). Especially because adipocytes grow and proliferate in an 
overfed situation, this will lead to more adipokines being excreted navigating lipids to certain 
specific areas of the body. Muscle and liver tissue are main sites for ectopic fat accumulation (67). 
In myocytes and hepatocytes FFA’s cause IR in genetically susceptible subjects through defects in 
the insulin signalling pathway. Although the search for specific defects in the pathogenesis is 
complicated by the complexity of the insulin signalling cascades, one of the major problems is a 
disturbance in the IRS1/PI3-kinase/Akt/GLUT pathway. IRS-1 tyrosine phosphorylation leads to 
serine phosphorylation, thereby interrupting the pathway for the transport of glucose via the 
GLUT transporters to the membrane. A number of inflammatory kinases have been found to 
induce this inhibitory serine phosphorylation, such as IKB-kinase-β (IKK- β), jun-kinase-1 (JNK-1) 
and suppressor-of-cytokine-signalling-3 (SOCS3). Interestingly, SOCS3 receptors have also been 
found in the hypothalamus, were it may be involved in leptin signalling. JNK-1 is found to be an 
important mediator in the development of inflammation in obese tissue (68). Özcan et al found 
the protein is triggered by endoplasmatic reticulum (ER) stress (69). In obese states, the metabolic 
demand on the ER is maximal and sometimes even more. As a response to the continuously high 
workload the ER initiates a complex response system, referred to as the unfolding protein 
response (UPR). This UPR leads to activation of JNK-1, IKK-β and TNF-α. More evidence comes 
available that the ER in this way translates the metabolic stress into an inflammatory signal.  
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Interestingly, it has been found that in hepatic IR states the IRS-2 signalling is relatively intact. 
Insulin downregulates the IRS-2 receptor, resulting in overexpression of SREBP-1c and 
upregulation of DNL (70).   
 
Supply 
Plasma FFA: The plasma nonesterified fatty acid (NEFA) pool contributes to the majority of fatty 
acids that flow to the liver in the fasting state and thus provides the bulk of FFA’s secreted by the 
liver in VLDL particles (71). The storage of TG and FFA’s in adipose tissue is mediated by insulin, 
especially in visceral fat. In healthy individuals consumption of a meal induces an increase in 
plasma insulin concentration and subsequent suppression of adipocyte lipolysis, thereby reducing 
the plasma NEFA pool. Thus adipose tissue, especially visceral adipocytes, functions as a depot for 
energy that can be released in times of need. IR develops after long-term excess energy intake, 
leading to decreases in insulin's inhibitory effects on peripheral lipolysis and increasing FFA’s 
availability. FFA’s released in the bloodstream by visceral adipocytes flow to the liver without any 
circumbendibus. Paradoxically, the contribution of FFA’s derived from the plasma pool flowing 
into the liver is relatively smaller in NAFLD patients compared to healthy subjects. This is due to 
the increased contribution of other mechanisms in these patients.  
 
Dietary fat intake: Dietary fats are supplied to the liver by two different routes. Chronic intake of 
energy enriched food challenges the adipocytes processing capacity, with an overflow of NEFA 
into the plasma as a result (72). Lipid accumulation in non-adipose tissue, mainly muscle and the 
liver, is a characteristic of obesity, but is also seen in lipodystrophy. Where in obesity the 
adipocytes overflow, in lipodystrophy there are no or insufficient adipocytes to store lipids; both 
being a factor in the increased ectopic lipid accumulation. A second route is via remnant 
chylomicrons. FFA’s and monoglycerides are absorbed separately and packaged into TG in the 
intestinal epithelial cells. They are then secreted in chylomicrons (lipoproteins with a very high 
lipid content), which release FFA to adipose and muscle cells, mediated by lipoprotein lipase. 
Chylomicrons depleted of most lipids (known as chylomicron remnants) are absorbed by the liver. 
Studies have shown that in the remnant delivered to the liver up to 50% of the FFA’s can still be 
present, which then have to be processed by the liver. Dietary fat intake is responsible for 
approximately 15% of the FFA’s supply to the liver (73). 
 
De novo liponeogenesis (DNL): The term lipogenesis refers to the biosynthesis of lipids. DNL 
indicates that the synthesis of fatty acids occurs from various non-fat precursors. Most important 
precursors are glucose, aminoacids and ethanol which produces acetyl-CoA during their 
catabolism and are therefore susceptible to be converted to fatty acids in the intermediary 
metabolism. SREBP-1c is a key player in the regulation of DNL. SREBP-1c is activated by insulin, 
endocannabinoid receptor CB-1 (74), liver X receptor (LXR)-α (75), oxysterol binding protein (76) 
and suppressor of cytokine signalling (SOCS)-3 (77). Leptin and glucagon have antagonising 
effects. The suppressing effect of leptin on SREBP-1c seems paradoxal, as obese persons often 
exhibit high levels of leptin and high expression of SREBP-1c. This is the consequence of on the 
one hand an increase of leptin production by the expanding mass of fat cells and on the other 
hand a decrease in leptin sensitivity (78). 
LXR-α is an oxysterol activated nuclear receptor. Activation of LXR-α induces SREBP-1c 
transcription through retinoid X receptor (RXR)-α co-activation. Grefhorst et al. showed that 
exogenous administration of LXR-α ligands resulted in extensive hepatic steatosis (79).  
The observation of an increase in apetite in association with the use of cannabis, led to the 
hypothesis that the endocannabinoid pathway might play a role in energy intake and fat 
metabolism. The most prominent receptors are the cannabinoid receptor 1 (CB-1) and 
cannabinoid receptor 2 (CB-2). CB-2 is mostly expressed in the immune system, while CB-1 is 
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found to be involved in the SREBP-1c pathway in liver and brain. In these pathways the effect of 
CB-1 compared to CB-2 is twofold. There is regulation of the hypothalamic driven feeding 
behaviour (80,81), which has direct effects on energy intake. A second effect is on hepatic fatty 
acid synthesis, hepatic TG quantity and activation of the release of fatty acids from adipose tissue 
(74,82). 
SOCS3 is an adipocyte-excreted cytokine that upregulates hepatic SREBP-1c. Although the 
mechanisms have not been fully elucidated, TNF-α, interleukin (IL)-6 and leptin seem to augment 
excretion of SOCS3, whereas adiponectin is found to have inhibitory effects (77). In healthy 
individuals DNL is a minor supplier of fatty acids to the hepatocyte in the fasting state, when 
insulin levels are low. Less than 5% of the total supply of fatty acids originates from DNL. In the 
postprandial state, insulin stimulates DNL which then accounts for over 26% of the FFA supplies. 
This more or less diurnal rhythm is not seen in NAFLD patients where the contribution of DNL is 
continuously 26% (73).  
 
Oxidation 
In normal conditions the mitochondria take up FFA’s as a substrate for β-oxidation. While fasting 
fatty acid oxidation is the main substrate for the production of energy used in gluconeogenesis. In 
IR states the amount of FFA’s available for oxidation exceeds the mitochondrial capacity. A bulk of 
Acetyl CoA enters the citric acid cycle, which results in the delivery of electrons to the respiratory 
chain, where they generate reactive oxygen species (ROS). 
 
Outflow 
In physiological conditions, transport of TG from hepatocytes occurs through formation of VLDL 
by the ER in two steps. First apolipoprotein B (ApoB) becomes lipidated, creating a so-called pre-
VLDL. This lipidation of ApoB is catalyzed by the microsomal triglyceride transfer protein (MTTP). 
The pre-VLDL is transported to the smooth ER and further lipidated before it’s migrating to the 
cell membrane again. MTTP is the catalysator in this process. The progression of ApoB to pre-VLDL 
is dependent on the amount of TG available. If insufficient lipids are available, the ApoB protein 
will degrade. Insulin is a strong promotor of ApoB degradation via the PI3K pathway and can thus 
influence the number of VLDL particles synthesized. SREBP-1c inhibits the formation of MTTP, 
thereby reducing the amount of VLDL particles produced. In IR states the PI3K pathway is 
eliminated to certain extend but the upregulated SREBP-1c leads to a decrease of VLDL synthesis. 
The size of the particle is dependent on the amount of TG stored in the cell. It has been shown 
that in fatty livers VLDL particles are sufficiently larger, most likely as a result of the decreased 
production (79). It is likely that export of TG is impaired in IR states. 
 
From hepatic steatosis to NASH 
Steatohepatitis is characterized microscopically by hepatic fat accumulation, mixed lobular 
inflammation, ballooning degeneration of hepatocytes, Mallory bodies, glycogenated hepatocyte 
nuclei, and pericellular fibrosis. The characteristic "chicken wire" pattern of the pericellular 
fibrosis, which affects portal areas only secondarily in later stages. The accumulation of FFA’s and 
TG’s in hepatocytes by mechanisms described above, spreads the bed for the second hit in Day’s 
widely accepted theory. By far not all people with fatty livers progress to steatohepatitis (83,84). 
Although a considerable amount of evidence is available for environmental influences, there is 
inevitably a genetic compound that contributes to the origination and progression of the disease. 
The factors that are responsible for the progression from simple fatty liver to NASH are heavily 
researched. TNF-α expression, lipid peroxidation and mitochondrial dysfunction are likely to be 
involved. The mechanism is triggered and starts a sequence that leads to inflammatory response 
and the release of inflammatory cytokines eventually resulting in the  development of fibrosis and 
cirrhosis. The lipid laden liver of steatotic patients does not increase in size, so the entire lipid 
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content must come in place of existing structures and compress them somewhat. To resolve this 
disadvantageous condition hepatocytes need to clear FFA’s and TG, for which they have can use 
two mechanisms. The first is the above described excretion of TG through formation of VLDL 
particles. It is postulated that in hepatic steatosis this mechanism is impaired. The other 
mechanism is metabolising of FFA’s by mitochondrial β-oxidation, reviewed by Begriche et al 
(85). In summary, these metabolic changes in steatotic livers results in the formation of reactive 
oxygen species (ROS) by mitochondria as a result of increased mitochondrial β-oxidation, hepatic 
microsomal cytochrome P450 2E1(CYP2E1) upregulation and kupffer cell ROS formation. 
The mechanisms by which mitochondrial β-oxidation is upregulated in steatotic livers are not 
cleared up entirely, but it is thought that especially DNL derived FFA’s and peroxisome 
proliferator-activated receptor (PPAR)-α are important stimulators of carnitine 
palmitatoyltranferase-1 (CPT-1), the enzyme responsible for the entry of FFA’s into mitochondria. 
The massive influx of FFA’s from peripheral tissue and mostly the increased DNL within 
hepatocytes exceeds the metabolic capabilities of the mitochondria, with the formation of ROS 
and an inflammatory response as a result.  
CYP2E1 is predominantly found in the ER, but significant amounts are present in the cytosol and 
mitochondria where it stimulates microsomal fatty acid oxidation. Increased CYP2E1 activity and 
expression is found in NASH patients (86), but the mechanisms behind this remain unclear. 
Recently Rahman et al. found that CCAAT/Enhancer binding protein (C/EBPbeta) expression may 
be an important factor in the upregulation of CYP2E1 (87). Other authors postulated the influence 
of IR (88,89) and increased ketogenesis (90).  
In various models of steatosis endotoxin receptors on Kupffer cells are increased, which may 
trigger the assemblage of NAD(P)H oxidase on the plasma membrane of the hepatocyte and 
thereby causes ROS formation (91). 
The surplus of FFA’s within the liver causes the formation of excess amounts of ROS. 
Mitochondria in non-fat-laden hepatocytes also produce rather large amounts of ROS, but 
enzymatic processes can change ROS into “safe water”. Excessive ROS formation can lead to 
overburdening of this escape mechanism and ROS can leave the mitochondria. In the cytosol ROS 
enhance lipid peroxidation. Lipid peroxidation products alter the mitochondrial DNA (mtDNA). 
Increased mitochondrial ROS formation could also directly oxidize mitochondrial DNA, proteins 
and lipids, trigger hepatic TNF-α formation by activating nuclear factor(NF)-κb and deplete 
antioxidants, thus further increasing mitochondrial ROS formation. The induction of the 
inflammatory cascade can also be the result of the reduced availability of anti-inflammatory 
products as adiponectin (92).  
Another worsening and possible triggering factor might be tumour necrosis factor (TNF)-α 
(93,94). In obese and IR patients serum levels of TNF-α are proportionally increased and one of 
the striking difference between patients with NASH and those with simple steatosis is the serum 
level of TNF-α (95). Not hepatic, but mainly adipose tissue is the main supplier of TNF-α. In 
normal conditions the hepatocyte that frequently comes into contact with a variety of endo- and 
exotoxins is not very sensitive to TNF-α, but in NASH patients it might be possible that the 
increased levels cause leakage of the mitochondrial outermembrane and thereby increasing ROS 
formation (85). TNF-α also has direct effects on IRS phosphorylation and via interleukin 6 (IL-6) 
and inhibitory κB-kinase (IKK) stimulates SOCS3 formation, thereby worsening IR and steatosis 
(96,97) (Figure 1) . 
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Figure 1. Pathogenesis of 
nonalcoholic steatohepatitis 
during insulin resistance: 
FFA’s are supplied to the liver 
through dietary intake, lipolysis in 
adipocytes and via chylomicron 
remnants. Transcription of SREBP-1c 
is chronically upregulated resulting 
in DNL. Simultaneous, inhibition of 
VLDL synthesis results in a disruption 
of triglycerides export. The surplus 
of fatty acids is stored in triglycerides 
or metabolised via peroxisomal and 
mitochondrial oxidation. The 
excessive oxidation will lead to 
production of ROS and oxidative stress. This will trigger the inflammatory response and apoptosis as well activation of 
stellate cells.  
 
 
Diagnosis 
General 
As noted before, NAFLD patients are mostly asymptomatic and referred because of accidentally 
found slightly elevated liver enzymes. There is some debate about the question when to perform 
further investigations, in particular performing liver biopsy. Generally it is reasonable to 
undertake action when the ALT level is > 2x ULN measured at two different occasions (98).  When 
the diagnosis NAFLD is considered it is important to exclude other pathological conditions that are 
associated with elevated ALT levels and or steatosis (table 2). Especially the difference between 
alcoholic and non-alcoholic liver disease can be difficult, as not all patients are honest about their 
alcohol intake and there is no adequate diagnostic difference between the two. An abdominal 
ultrasound is performed to exclude hepatobiliary obstructions or tumours.  
 
Imaging techniques 
Ultrasonography, computerized tomography (CT) scan, and magnetic resonance imaging (MRI) 
can all be used to diagnose hepatic steatosis. Ultrasonography is the most commonly used and 
least expensive method and can be used to diagnose moderate to severe steatosis. Studies 
conducted in the 80’s found a sensitivity and specificity varying from 60% to 94% and 88% to 95% 
respectively. A recent study by Palmentieri et al. investigated a subgroup of patients with hepatic 
steatosis > 30% in which sensitivity and specificity of US increased up to 90% and 97% (99). 
Although the diagnostic capacity of ultrasonography increases with higher degrees of steatosis 
(99-101), accurate quantification of hepatic fat and comparison between simple hepatic steatosis 
and steatohepatitis is impossible. Unenhanced CT imaging can accurately detect and quantify the 
amount of steatosis in patients (102,103). Greyscales (representing the amount of radiation 
absorbed) of the liver and spleen are measured and expressed in Houndsfield units (HU). For 
quantification of the amount of fat-infiltrated hepatocytes the difference in greyscale between 
the liver and spleen can be measured in HU. This measurement correlates well with the 
percentage of hepatocytes with fatty infiltration (103) where the hepatic attenuation decreases 
with the increase of fat. For steatosis >33% sensitivity and specificity was 82%-93% and 100% 
respectively (102). There is no difference in diagnostic value between a non-contrast CT scan and 
a contrast-enhanced one, with specifically more attenuation in the blood vessels than in the liver 
parenchyma. Contrast enhanced CT-scans do not provide more information; in fact sensitivity and 
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specificity for steatosis are lower than for unenhanced CT imaging. Another drawback for contrast 
enhanced measurement of steatosis is the greater difficulty in measurement due to the more 
complicated protocol.  
The most accurate available technique for detection and quantification of hepatic steatosis is 
NMR (104-106). T1 weighted dual-echo chemical shift gradient-echo NMR is commonly used to 
obtain images. The main advantage of this technique is the possibility of acquiring in-phase 
(water) and opposed-phase (fat) images in one breath hold, thereby reducing the influence of 
breathing movements and contrast absorption. Besides, this technique is useful for follow up due 
to the lack of the use of fluoroscopy. Qualitative measurement or detection of steatosis is 
assessed on opposed-phase images. On T1 weighted images a shorter relaxation time is 
represented by a higher signal intensity (SI). In healthy individuals the SI of the liver is higher than 
the SI of the spleen. Steatosis causes a drop in SI on opposed-phase images. When SI of the liver 
equals that of the spleen, a diagnosis of mild steatosis is made. Moderate or severe steatosis is 
diagnosed when SI of the liver is less then the splenic SI. Quantification of steatosis is possible 
with MRI by calculating the mean SI of the liver on in-phase and opposed-phase images. A number 
of regions of interest (ROI) are drawn in sections of the liver, from which the mean can be 
calculated. By the same method the mean SI of the spleen or fat issue surrounding the liver can 
be calculated as a reference. The difference in SI on opposed-phase images and in-phase images 
can be calculated and expressed as a percentage of fatty infiltration of the liver. MRI shows good 
correlation with histological examination, and sensitivity and specificity is for MRI 100% and 
92.3% respectively (106). 
Another relatively new and partially under development NMR technique, that’s widely used to 
quantify hepatic triglyceride content is magnetic resonance spectroscopy (MRS) (107,108). MRS of 
in vivo biological tissues was first reported in 1973 and used in the field of chemistry before NMR 
was introduced in hospitals. The principle of MRS is based on differences in resonance 
frequencies of protons. The electron cloud surrounding molecules shields protons to varying 
degrees depending on the specific molecule structure and the specific position of protons in the 
molecule. This shielding causes protons in different molecules or even in different places in the 
same molecule to have a slightly different resonance frequency. Instead of using resonance 
frequencies for creating anatomical images, in spectroscopy the differences in frequency are used 
to identify different chemical compounds. By using these differences, protons in water molecules 
can be differentiated from protons in lipids. Quantifying the amount of a certain biochemical 
component is possible by calculating the area under the “fat resonance peak” and comparing it to 
the “water resonance peak” (Figure 2). 
 
Figure 2. The spectrum of a 
fatty liver measured in 1H-
magnetic resonance 
spectroscopy: 
The water peak is at 4,3 ppm.   
Legenda: 1: residual water (partially 
suppressed, 2: glycerol/phospholipids 
3:  (-CH2-)n of saturated fat. 
 
 
 
 
Technically coronal, axial and sagital images of the liver are acquired and a volume of interest is 
defined, avoiding major blood vessels and bile ducts.  
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Unfortunately, to date, there is no conventional diagnostic imaging method available that can 
accurately distinguish NASH from simple steatosis (107,109). Transient elastography (fibroscan) is 
a technique that is under development. Studies in chronic hepatitis C (CHC) patients showed that 
cirrhosis (severe fibrosis) can adequately be distinguished from mild fibrosis, but this accuracy is 
much less in distinguishing various degrees of fibrosis. Another drawback of the fibroscan method 
is that it is difficult to use and inaccurate in obese patients (110). A combination of serologic 
markers have been under investigation to assess severity of fibrosis (111). Although results seem 
promising, more research is wanted.  
 
Therapeutic options 
Life style modifications and weight reduction 
Since the majority of patients suffer from obesity, insulin resistance and concomitant increased 
cardiovascular disease, weight reduction of approximately 10% has been advised by the American 
Gastroenterological Association (112). An analysis by Wang et al. of all published articles and 
meeting abstracts revealed no randomized controlled trials (113). Besides, the use of variable 
primary endpoints and control groups worsened the analysis of this comprehensive review. 
Although on a theoretical basis reduced caloric intake, exercise and weight loss would eventually 
result in improvement of hepatic steatosis, very scarce evidence is available to support this 
hypothesis. The limited data is due to low numbers and lack of histological evidence. Recently a 
study by Huang et al. analyzed the effect of a 12 months standardized nutritional counseling of 16 
patients (of 23 included patients). Mean weight reduction was 2.9 kg with histological 
improvement in 9 patients (114).  
There are no available long-term data on the effect of weight loss on liver-related outcome such 
as cirrhosis or its complications. 
 
Pharmacological interventions 
Drug-induced weight reduction: The only two registered drugs for pharmacological weight 
reduction, Orlistat (n=4) and Sibutramine (n=1), have been investigated in four small non-
randomized studies (n=59 subjects). Orlistat, a gastric and pancreatic lipase inhibitor resulting in 
fat malabsorption (approximately 30%), has been studied in one case series (115), three pilot 
studies (116-118) and one RCT (119). Overall, patients achieved impressive weight losses (10-15 
Kg) with improvements in liver enzymes but variable results on histology.  
Sibutramine, a serotonin and norepinephrin reuptake inhibitor, acts to enhance satiety via central 
mechanisms. There is only one published study on NAFLD in 25 patients that demonstrated 
weight loss, an improvement in liver enzymes and reduction of hepatic steatosis on ultrasound. 
Unfortunately, repeat liver biopsy was not performed.  
 
Antioxidants: Since the pathogenesis is thought to be in a two hit fashion, it is believed that 
oxidative stress causes a second hit leading to inflammation. In vitro and in vivo animal (120) and 
human studies (121,122) have investigated the effects of vitamin E and C as antioxidants. The 
promising results in one study were counteracted by another. In the randomized controlled trial 
by Harisson et al. a between group analysis could not show any beneficial effect of the 
combination of vitamin E and C after 6 months, compared to placebo. Recently, a cochrane review 
by Lirussi et al. identified 6 trials that were analysed according to the intention-to-treat principle. 
Although significant improvements in liver enzymes and minor adverse events were noticed, 
radiological and histological data were too limited to support or repudiate the use of antioxidants 
in patients with NAFLD (123). 
 
Ursodeoxycholic acid (UDCA): UDCA, approved as the treatment of choice in patients with PBC, 
sorts its effect by reducing the portion of hydrophobic bile acids contributing to oxidative stress. 
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Four clinical trials, of which only one assessed histology (124) and had a low-bias risk, have been 
conducted. No significant differences in degree of steatosis, inflammation or fibrosis could be 
found between the treated and placebo group. Unfortunately, these studies are suffering from 
heterogeneity in respect to inclusion criteria, sample size, duration of treatment and methods of 
outcome assessment. Therefore, the Cochrane analysis by Orlando et al. concludes that there is 
insufficient data to use UDCA in patients with NAFLD (125).  
 
Metformin: Metformin, a biguanide used in the treatment of patients with type 2 diabetes 
mellitus, suggested to be effective in an animal study with ob/ob mice in 2000 (126) where the 
administration resulted in a decrease of hepatic steatosis and hepatomegaly. In addition to this 
observation some human pilot studies were performed with variable results. The only two 
randomized trials performed could not demonstrate a beneficial effect of metformin compared to 
a calorie-restricted diet (127,128). Similar to the previous mentioned therapies, histological data 
were limited to support an association between improvement of liver enzymes and histological 
findings.   
 
Thiazoledinediones (TZD): This class of agents acts as agonists of the peroxisome proliferator-
activated receptor gamma ameliorating insulin resistance and glucose and lipid metabolism. The 
first generation, e.g. troglitazone, appeared to be effective on ALT levels, although was withdrawn 
from the market due to severe hepatotoxicity (129,130). In addition, second generation TZD 
(pioglitazone and rosiglitazone) are safer. A Cochrane analysis by Angelico et al (131), (excluding 
trials treating patients with type 2 diabetes mellitus, extracted only one RCT by Sanyal et al. In this 
study with small numbers, combination therapy with vitamin E and pioglitazone was significantly 
superior compared to vitamin E alone in terms of degree of hepatic steatosis, but not at all other 
histological variables (132). 
An open label trial of rosiglitazone in 26 biopsy-proven NASH (133) and two pilot studies with 
pioglitazone (134,135) (n=73) during 48 weeks demonstrated both improvements in liver 
chemistry and histological features like steatosis, necroinflammation an fibrosis. Weight gain 
seems to be the most important adverse event. Recently the use of rosiglitazone has been 
associated with slightly increased bone loss in postmenopausal women and elderly diabetics (136-
138) and an increased risk at cardiovascular events i.e. myocardial infarction (136,139,140). 
Further research focusing on larger randomized controlled trials with this class of drugs will be 
valuable.  
 
Lipid lowering drugs: Use of statins or fibrates has not been investigated in large randomized 
trials. Primary endpoints of these studies are liver enzymes and not histology. No definite 
conclusions can be made from these limited studies (118,141).  
 
Adipokines: As mentioned before, adipocytes act as hormonal active tissue producing several 
cytokines, like leptin, resistin, adiponectin and tumour necrosis factor-α (TNF-α). In patients with 
NASH increased levels of TNF-α were found (95). As a potential proinflammatory cytokine it 
promotes insulin resistance and thereby hepatic steatosis (97). Some animal and even fewer 
human studies focused on the effect of blocking this adipocytokine. In total 38 patients were 
treated with pentoxifyllin either 6 or 12 months with a significant improvement in liver enzymes 
with the lack of the availability of histological data (142,143). 
Administration of synthetic adiponectin, exposing opposite effects to TNF-α, in two animal models 
ameliorates hepatomegaly, steatosis and elevated ALT-levels (144). 
Leptin, a 16 kDa protein hormone, has been shown to play a pivotal role in energy homeostasis 
through the activation and inhibition of certain neurons (145). The administration of leptin 
infusions in patients with generalized lipodystrophy revealed a clear amelioration of insulin 
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resistance, glucose and triglyceride levels as well as hepatic steatosis (146,147). In NAFLD no such 
studies have been performed yet. 
Resistin, another adipocytokine, is subject of controversy regarding to its causal role in obesity 
and type 2 diabetes mellitus. Due to this controversy no published data are available investigating 
beneficial effects of inhibition of resistin.  
 
Future directions 
Up until now the exact treatment strategy in patients with NAFLD is not well established in RCT. 
Research topics in this field are challenging. In the United States and Europe some research 
groups are focusing on comparing different treatment options and identifying those patients the 
most in need for treatment. Evolving new imaging techniques like proton magnetic resonance 
spectroscopy might differentiate between those patients having type 1 NAFLD (defined as simple 
steatosis without features of inflammation) and type 2 (containing patients with variable grades 
of inflammation and fibrosis eventually resulting in cirrhosis).  
Several registered drugs aiming at improving the metabolic syndrome should be further 
investigated on their exact anti-steatotic effect. The most promising drugs are insulin sensitizers 
(especially thiazoledinediones), which should be further investigated in larger RCT’s aiming at 
establishing the optimal dosage, time of treatment and adverse effects. 
After the discovery of two cannabinoid receptor antagonist receptors (CB1 and CB2) in the late 
80’s and begin 90’s in the brain (148,149) accompanied by the gastrointestinal tract (150), it has 
gained more and more interest from both researchers and clinicians. CB1 appears to be 
extensively found in central nervous system and affect many neurological and psychological 
phenomena, like appetite, mood and spatial coordination muscle tone (151). In contrast, CB2 can 
be detected in peripheral cells of the immune system (lymphocytes, monocytes and neutrophils) 
and exerts additional effects on the gut (inhibition of motility) and vasodilation (152,153). 
Research in animal models have revealed that activation of the endocannabinoid system leads 
(partially) to the development of portal hypertension and arterial hypotension through activated 
macrophages and platelets by bacterial lipopolysacharides (154,155). Secondly, anandamide, a 
endogenous ligand for CB-receptors, appeared to be upregulated in patients with endotoxic shock 
(156) and subsequently hepatocellular apoptosis was linked to anandamide and its lipid-lipid 
plasma membrane interaction, resulting in enhanced susceptibility to oxidative stress (157). 
Thirdly, another hypothesis is that an activated CB-system may have influence on hepatic 
encephalopathy (158). In humans, endocannabinoids have been used in the treatment of three 
patients with cholestatic-related intractable pruritus (159). In a phase III study SR141716A 
(Rimonabant, Sanofi-Aventis, Paris, France) is under investigation in the treatment of patients 
with obesity and metabolic syndrome. In obese Zucker rats the administration of this drug 
ameliorated markers of hepatic damage (defined as increased liver enzymes, focal hepatic TNF-α 
and decreased adiponectin), decreased hepatomegaly (160). Preliminary results in humans are 
promising since the used drug is safe, effective in achieving weight reduction and amelioration of 
the lipid profile and metabolic syndrome (80,161,162).  
In conclusion, the development of drugs acting on the cannabinoid system, influencing the central 
nervous system through inhibition of appetite and on peripheral tissue ameliorating hepatic 
hemodynamics, inflammation and weight reduction accompanied by improvement in metabolic 
syndrome, will lead to new research aims in the field of hepatology. In particular, the 
development and conductance of RCT’s with synthetic, non-psychotropic cannabinoids might 
result in optimizing treatment strategies for patients with NASH. 
 
Conclusions 
NAFLD and especially NASH form a definite threat to human health. With the increase in obesity 
an increase in NAFLD patients can be expected and with that eventually an increased number of 
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liver transplantations. The pathophysiological mechanism is the subject of research all around the 
world, leading to a continuous current of new evidence and more knowledge of the complex 
mechanisms behind the disease. At the same time diagnostic methods for detecting steatosis and 
steatohepatitis are under development. 1H-magnetic resonance spectroscopy is accurate in the 
detection and quantification of fat in the liver, but the eagerly wanted non-invasive tool for the 
detection of fibrosis or inflammation in steatotic livers is not available. Therapeutic options do 
increase. Weight loss by dietary and lifestyle intervention remains the cornerstone of treatment, 
but motivated patients can be supported by medication. Most promising results are found with 
thiazolidinediones, but recent upheaval around rosiglitazone meant a setback for this drugs.  
 
 
References 
1. World Health Organization. Obesity and Overweight. 2003. Available from: URL: 
http://www.who.int/dietphysicalactivity/media/en/gsfs_obesity.pdf  
2. James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obes Res 9 Suppl 4: 228S-
233S, 2001 
3. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology 32: 2087-
2102, 2007 
4. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus 
Statement from the International Diabetes Federation. Diabet Med 23: 469-480, 2006   
5. Day C. Metabolic syndrome, or What you will: definitions and epidemiology. Diab Vasc Dis Res 4: 32-38, 
2007 
6. Johnson LW, Weinstock RS. The metabolic syndrome: concepts and controversy. Mayo Clin Proc 81: 
1615-1620, 2006 
7. Bergman RN, Kim SP, Catalano KJ, Hsu IR, Chiu JD, Kabir M, Hucking K, Ader M. Why visceral fat is bad: 
mechanisms of the metabolic syndrome. Obesity (Silver Spring) 14 Suppl 1: 16S-19S, 2006  
8. Laclaustra M, Corella D, Ordovas JM. Metabolic syndrome pathophysiology: the role of adipose tissue. 
Nutr Metab Cardiovasc Dis 17: 125-139, 2007 
9. Chavez-Tapia NC, Mendez-Sanchez N, Uribe M. The metabolic syndrome as a predictor of nonalcoholic 
fatty liver disease. Ann Intern Med 144: 379, 2006   
10. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, 
Shimazaki M, Kato T, Okuda J, Ida K. The metabolic syndrome as a predictor of nonalcoholic fatty liver 
disease. Ann Intern Med 143: 722-728, 2005   
11. Kida Y, Sato T. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern 
Med 144: 379-380, 2006   
12. Marchesini G, Babini M. Nonalcoholic fatty liver disease and the metabolic syndrome. Minerva 
Cardioangiol 54: 229-239, 2006 
13. Moseley RH. Progress in understanding the pathogenesis of nonalcoholic fatty liver disease. Hepatology 
41: 204-206, 2005 
14. Neuschwander-Tetri BA. Fatty liver and the metabolic syndrome. Curr Opin Gastroenterol 23: 193-198, 
2007   
15. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular 
disease: the plot thickens. Diabet Med 24: 1-6, 2007 
16. Watanabe T, Murata C, Watanabe Y. Metabolic syndrome from the view point of public health: with 
special reference to nonalcoholic fatty liver disease. Nippon Koshu Eisei Zasshi 52: 934-942, 2005 
17. Thaler H. [Fatty liver, its causes and concomitant diseases.]. Dtsch Med Wochenschr 87: 1049-1055, 
1962   
18. Thaler H. [The fatty liver and its pathogenetic relation to liver cirrhosis.]. Virchows Arch Pathol Anat 
Physiol Klin Med 335: 180-210, 1962 
30 
 
19. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a 
hitherto unnamed disease. Mayo Clin Proc 55: 434-438, 1980 
20. Saadeh S, Younossi ZM. The spectrum of nonalcoholic fatty liver disease: from steatosis to nonalcoholic 
steatohepatitis. Cleve Clin J Med 67: 96-4, 2000 
21. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 129: 
375-378, 2005 
22. Ioannou GN. The natural history of NAFLD: impressively unimpressive. Gastroenterology 129: 1805, 
2005 
23. Ratziu V, Poynard T. Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. 
Hepatology 44: 802-805, 2006 
24. Bugianesi E. Non-alcoholic Steatohepatitis and Cancer. Clin Liver Dis 11: 191-207, 2007 
25. Mori S, Yamasaki T, Sakaida I, Takami T, Sakaguchi E, Kimura T, Kurokawa F, Maeyama S, Okita K. 
Hepatocellular carcinoma with nonalcoholic steatohepatitis. J Gastroenterol 39: 391-396, 2004  
26. Angelico F, Del BM, Conti R, Francioso S, Feole K, Fiorello S, Cavallo MG, Zalunardo B, Lirussi F, 
Alessandri C, Violi F. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J 
Clin Endocrinol Metab 90: 1578-1582, 2005 
27. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver 
disease. Hepatology 42: 987-1000, 2005 
28. Camma C, Bruno S, Di M, V, Di BD, Rumi M, Vinci M, Rebucci C, Cividini A, Pizzolanti G, Minola E, 
Mondelli MU, Colombo M, Pinzello G, Craxi A. Insulin resistance is associated with steatosis in 
nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 43: 64-71, 2006 
29. Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin 
Liver Dis 8: 575-94, ix, 2004   
30. Choudhury J, Sanyal AJ. Insulin resistance in NASH. Front Biosci 10: 1520-1533, 2005   
31. Diehl AM, Clarke J, Brancati F. Insulin resistance syndrome and nonalcoholic fatty liver disease. Endocr 
Pract 9 Suppl 2: 93-96, 2003 
32. Eguchi Y, Eguchi T, Mizuta T, Ide Y, Yasutake T, Iwakiri R, Hisatomi A, Ozaki I, Yamamoto K, Kitajima Y, 
Kawaguchi Y, Kuroki S, Ono N. Visceral fat accumulation and insulin resistance are important factors in 
nonalcoholic fatty liver disease. J Gastroenterol 41: 462-469, 2006 
33. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of 
insulin resistance. Gastroenterology 131: 934-945, 2006   
34. Utzschneider KM, Kahn SE. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J 
Clin Endocrinol Metab 91: 4753-4761, 2006 
35. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. 
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. 
Hepatology 40: 1387-1395, 2004 
36. Wieckowska A, Feldstein AE. Nonalcoholic fatty liver disease in the pediatric population: a review. Curr 
Opin Pediatr 17: 636-641, 2005 
37. Adams LA, Talwalkar JA. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol 
40: S34-S38, 2006 
38. Chang Y, Ryu S, Sung E, Jang Y. Higher Concentrations of Alanine Aminotransferase within the 
Reference Interval Predict Nonalcoholic Fatty Liver Disease. Clin Chem 2007 
39. Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the 
proposed new normal range for serum ALT in obese women. Hepatology 42: 650-656, 2005 
40. Oh SY, Cho YK, Kang MS, Yoo TW, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI, Son BH, Shin JH. 
The association between increased alanine aminotransferase activity and metabolic factors in 
nonalcoholic fatty liver disease. Metabolism 55: 1604-1609, 2006 
41. Ratziu V, Imbert-Bismut F, Messous D, Poynard T. The elusiveness of "normal" ALT in fatty liver. 
Hepatology 39: 1172, 2004 
42. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 114: 842-845, 1998 
31 
 
43. Boden G. Free fatty acids-the link between obesity and insulin resistance. Endocr Pract 7: 44-51, 2001 
44. Seidell JC. Obesity, insulin resistance and diabetes--a worldwide epidemic. Br J Nutr 83 Suppl 1: S5-S8, 
2000 
45. Sesti G. Pathophysiology of insulin resistance. Best Pract Res Clin Endocrinol Metab 20: 665-679, 2006   
46. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 
diabetes. Nature 444: 840-846, 2006 
47. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 132: 
2169-2180, 2007  
48. Herman MA, Kahn BB. Glucose transport and sensing in the maintenance of glucose homeostasis and 
metabolic harmony. J Clin Invest 116: 1767-1775, 2006 
49. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. 
Nat Rev Mol Cell Biol 7: 85-96, 2006 
50. Ferre P, Foufelle F. SREBP-1c Transcription Factor and Lipid Homeostasis: Clinical Perspective. Horm Res 
68: 72-82, 2007  
51. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty 
acid synthesis in the liver. J Clin Invest 109: 1125-1131, 2002   
52. Dentin R, Pegorier JP, Benhamed F, Foufelle F, Ferre P, Fauveau V, Magnuson MA, Girard J, Postic C. 
Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and 
lipogenic gene expression. J Biol Chem 279: 20314-20326, 2004 
53. Postic C, Dentin R, Denechaud PD, Girard J. ChREBP, A Transcriptional Regulator of Glucose and Lipid 
Metabolism. Annu Rev Nutr 2007 
54. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. 
Nature 444: 847-853, 2006 
55. Abel ED, Peroni O, Kim JK, Kim YB, Boss O, Hadro E, Minnemann T, Shulman GI, Kahn BB. Adipose-
selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409: 729-733, 
2001 
56. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse 
obese gene and its human homologue. Nature 372: 425-432, 1994 
57. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and 
expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene 
transcript 1). Biochem Biophys Res Commun 221: 286-289, 1996 
58. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-
releasing acylated peptide from stomach. Nature 402: 656-660, 1999 
59. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The 
hormone resistin links obesity to diabetes. Nature 409: 307-312, 2001 
60. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum 
retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436: 
356-362, 2005 
61. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson 
PA, Smith U, Kahn BB. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic 
subjects. N Engl J Med 354: 2552-2563, 2006 
62. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of 
tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95: 2409-2415, 1995   
63. Vettor R, Milan G, Rossato M, Federspil G. Review article: adipocytokines and insulin resistance. 
Aliment Pharmacol Ther 22 Suppl 2: 3-10, 2005 
64. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol 
(Oxf) 64: 355-365, 2006  
65. Hutley L, Prins JB. Fat as an endocrine organ: relationship to the metabolic syndrome. Am J Med Sci 
330: 280-289, 2005 
32 
 
66. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 55: 1537-
1545, 2006 
67. Yki-Jarvinen H. Ectopic fat accumulation: an important cause of insulin resistance in humans. J R Soc 
Med 95 Suppl 42: 39-45, 2002 
68. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role 
for JNK in obesity and insulin resistance. Nature 420: 333-336, 2002   
69. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun C, Glimcher LH, 
Hotamisligil GS. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 
306: 457-461, 2004 
70. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL. Decreased IRS-2 and 
increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob 
mice. Mol Cell 6: 77-86, 2000 
71. Barrows BR, Timlin MT, Parks EJ. Spillover of dietary fatty acids and use of serum nonesterified fatty 
acids for the synthesis of VLDL-triacylglycerol under two different feeding regimens. Diabetes 54: 2668-
2673, 2005   
72. Unger RH. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends 
Endocrinol Metab 14: 398-403, 2003 
73. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in 
liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115: 
1343-1351, 2005 
74. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler 
L, Wang L, Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis 
and contributes to diet-induced obesity. J Clin Invest 115: 1298-1305, 2005 
75. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, 
Lustig KD, Shan B. Role of LXRs in control of lipogenesis. Genes Dev 14: 2831-2838, 2000 
76. Yan D, Lehto M, Rasilainen L, Metso J, Ehnholm C, Yla-Herttuala S, Jauhiainen M, Olkkonen VM. 
Oxysterol binding protein induces upregulation of SREBP-1c and enhances hepatic lipogenesis. 
Arterioscler Thromb Vasc Biol 27: 1108-1114, 2007 
77. Ueki K, Kadowaki T, Kahn CR. Role of suppressors of cytokine signaling SOCS-1 and SOCS-3 in hepatic 
steatosis and the metabolic syndrome. Hepatol Res 33: 185-192, 2005   
78. Unger RH. Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine. 
Biochimie 87: 57-64, 2005   
79. Grefhorst A, Elzinga BM, Voshol PJ, Plosch T, Kok T, Bloks VW, van der Sluijs FH, Havekes LM, Romijn JA, 
Verkade HJ, Kuipers F. Stimulation of lipogenesis by pharmacological activation of the liver X receptor 
leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 277: 
34182-34190, 2002  
80. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor 
blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year 
experience from the RIO-Europe study. Lancet 365: 1389-1397, 2005 
81. Wierzbicki AS. Rimonabant: endocannabinoid inhibition for the metabolic syndrome. Int J Clin Pract 60: 
1697-1706, 2006 
82. Woods SC. The endocannabinoid system: mechanisms behind metabolic homeostasis and imbalance. 
Am J Med 120: S9-17, 2007 
83. Adams LA, Lymp JF, St SJ, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of 
nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129: 113-121, 2005 
84. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term 
follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44: 865-873, 2006 
85. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, 
consequences and possible means to prevent it. Mitochondrion 6: 1-28, 2006  
33 
 
86. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is 
increased in patients with nonalcoholic steatohepatitis. Hepatology 27: 128-133, 1998 
87. Rahman SM, Schroeder-Gloeckler JM, Janssen RC, Jiang H, Qadri I, Maclean KN, Friedman JE. 
CCAAT/enhancing binding protein beta deletion in mice attenuates inflammation, endoplasmic 
reticulum stress, and lipid accumulation in diet-induced nonalcoholic steatohepatitis. Hepatology 45: 
1108-1117, 2007 
88. Moncion A, Truong NT, Garrone A, Beaune P, Barouki R, de W, I. Identification of a 16-nucleotide 
sequence that mediates post-transcriptional regulation of rat CYP2E1 by insulin. J Biol Chem 277: 
45904-45910, 2002 
89. Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, Crabb DW. Hepatic cytochrome P450 
2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 37: 544-550, 2003 
90. Gonzalez FJ. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. 
Mutat Res 569: 101-110, 2005 
91. Pessayre D, Fromenty B, Mansouri A. Mitochondrial injury in steatohepatitis. Eur J Gastroenterol 
Hepatol 16: 1095-1105, 2004 
92. Nishida M, Funahashi T, Shimomura I. Pathophysiological significance of adiponectin. Med Mol Morphol 
40: 55-67, 2007 
93. Miele L, Forgione A, Gasbarrini G, Grieco A. Noninvasive assessment of fibrosis in non-alcoholic fatty 
liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res 149: 114-125, 2007 
94. Diehl AM. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver 
disease. Clin Liver Dis 8: 619-38, 2004 
95. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small 
intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor 
alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48: 206-211, 2001 
96. Day CP. From fat to inflammation. Gastroenterology 130: 207-210, 2006 
97. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123: 1705-1725, 
2002 
98. Palmentieri B, de S, I, La M, V, Masarone M, Vecchione R, Bruno S, Torella R, Persico M. The role of 
bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver 
Dis 38: 485-489, 2006 
99. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol 
Hepatol 15: 539-543, 2003 
100. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, Fernandez-
Escalante JC, Pons-Romero F. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 
and p75, in nonalcoholic steatohepatitis patients. Hepatology 34: 1158-1163, 2001  
101. Valls C, Iannacconne R, Alba E, Murakami T, Hori M, Passariello R, Vilgrain V. Fat in the liver: diagnosis 
and characterization. Eur Radiol 16: 2292-2308, 2006 
102. Karcaaltincaba M, Akhan O. Imaging of hepatic steatosis and fatty sparing. Eur J Radiol 61: 33-43, 2007 
103. Duman DG, Celikel C, Tuney D, Imeryuz N, Avsar E, Tozun N. Computed tomography in nonalcoholic 
fatty liver disease: a useful tool for hepatosteatosis assessment? Dig Dis Sci 51: 346-351, 2006 
104. Fishbein M, Castro F, Cheruku S, Jain S, Webb B, Gleason T, Stevens WR. Hepatic MRI for fat 
quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol 39: 619-
625, 2005   
105. Hussain HK, Chenevert TL, Londy FJ, Gulani V, Swanson SD, McKenna BJ, Appelman HD, Adusumilli S, 
Greenson JK, Conjeevaram HS. Hepatic fat fraction: MR imaging for quantitative measurement and 
display--early experience. Radiology 237: 1048-1055, 2005 
106. Kim SH, Lee JM, Han JK, Lee JY, Lee KH, Han CJ, Jo JY, Yi NJ, Suh KS, Shin KS, Jo SY, Choi BI. Hepatic 
macrosteatosis: predicting appropriateness of liver donation by using MR imaging--correlation with 
histopathologic findings. Radiology 240: 116-129, 2006 
34 
 
107. Machann J, Thamer C, Schnoedt B, Stefan N, Haring HU, Claussen CD, Fritsche A, Schick F. Hepatic lipid 
accumulation in healthy subjects: a comparative study using spectral fat-selective MRI and volume-
localized 1H-MR spectroscopy. Magn Reson Med 55: 913-917, 2006 
108. Szczepaniak LS, Babcock EE, Schick F, Dobbins RL, Garg A, Burns DK, McGarry JD, Stein DT. 
Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol 276: 
E977-E989, 1999 
109. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. 
The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123: 745-750, 
2002 
110. Foucher J, Castera L, Bernard PH, Adhoute X, Laharie D, Bertet J, Couzigou P, de L, V. Prevalence and 
factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 
2114 examinations. Eur J Gastroenterol Hepatol 18: 411-412, 2006 
111. Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, Massard J, Bonyhay L, 
Tahiri M, Thabut D, Cadranel JF, Le BB, de L, V. Diagnostic value of biochemical markers (NashTest) for 
the prediction of non alcoholic steato hepatitis in patients with non-alcoholic fatty liver disease. BMC 
Gastroenterol 6: 34, 2006   
112. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. 
Gastroenterology 123: 1702-1704, 2002 
113. Wang RT, Koretz RL, Yee HF, Jr. Is weight reduction an effective therapy for nonalcoholic fatty liver? A 
systematic review. Am J Med 115: 554-559, 2003  
114. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, Emick D, Lok AS, Conjeevaram 
HS. One-year intense nutritional counseling results in histological improvement in patients with non-
alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 100: 1072-1081, 2005   
115. Harrison SA, Ramrakhiani S, Brunt EM, Anbari MA, Cortese C, Bacon BR. Orlistat in the treatment of 
NASH: a case series. Am J Gastroenterol 98: 926-930, 2003 
116. Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic FB. The effects of sibutramine and orlistat on the 
ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-
alcoholic steatohepatitis. Rom J Gastroenterol 12: 189-192, 2003 
117. Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, 
non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 20: 623-628, 2004 
118. Hatzitolios A, Savopoulos C, Lazaraki G, Sidiropoulos I, Haritanti P, Lefkopoulos A, Karagiannopoulou G, 
Tzioufa V, Dimitrios K. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty 
liver disease with dyslipidemia. Indian J Gastroenterol 23: 131-134, 2004 
119. Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, Leshno M, Blendis L, Halpern Z, Oren 
R. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty 
liver disease. Clin Gastroenterol Hepatol 4: 639-644, 2006 
120. Parola M, Muraca R, Dianzani I, Barrera G, Leonarduzzi G, Bendinelli P, Piccoletti R, Poli G. Vitamin E 
dietary supplementation inhibits transforming growth factor beta 1 gene expression in the rat liver. 
FEBS Lett 308: 267-270, 1992 
121. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 136: 
734-738, 2000 
122. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves 
fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98: 2485-2490, 2003   
123. Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for non-alcoholic fatty liver disease and/or 
steatohepatitis. Cochrane Database Syst Rev 2007; CD005165 
124. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P. 
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. 
Hepatology 39: 770-778, 2004 
125. Orlando R, Azzalini L, Orando S, Lirussi F. Bile acids for non-alcoholic fatty liver disease and/or 
steatohepatitis. Cochrane Database Syst Rev 2007; CD005160 
35 
 
126. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in 
obese, leptin-deficient mice. Nat Med 6: 998-1003, 2000 
127. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K. Metformin 
in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 19: 537-544, 
2004 
128. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G. A 
randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver 
disease. Am J Gastroenterol 100: 1082-1090, 2005 
129. Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. Hepatotoxicity due to troglitazone: report 
of two cases and review of adverse events reported to the United States Food and Drug Administration. 
Am J Gastroenterol 95: 272-276, 2000  
130. Menon KVN, Angulo P, Lindor KD. Severe cholestatic hepatitis from troglitazone in a patient with 
nonalcoholic steatohepatitis and diabetes mellitus. Am J Gastroenterol 96: 1631-1634, 2001 
131. Angelico F, Burattin M, Alessandri C, Del BM, Lirussi F. Drugs improving insulin resistance for non-
alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2007; 
CD005166 
132. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Clore J, 
Mills AS. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic 
steatohepatitis. Clin Gastroenterol Hepatol 2: 1107-1115, 2004 
133. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic 
steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38: 
1008-1017, 2003 
134. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, 
Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A 
placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355: 
2297-2307, 2006   
135. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park 
Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH. A pilot study of pioglitazone treatment for 
nonalcoholic steatohepatitis. Hepatology 39: 188-196, 2004 
136. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR. The Peroxisome Proliferator-
Activated Receptor-{gamma} Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral 
Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial. J Clin Endocrinol Metab 
92: 1305-1310, 2007 
137. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, 
Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR. Thiazolidinedione use 
and bone loss in older diabetic adults. J Clin Endocrinol Metab 91: 3349-3354, 2006 
138. Schwartz AV, Sellmeyer DE. Thiazolidinediones: new evidence of bone loss. J Clin Endocrinol Metab 92: 
1232-1234, 2007 
139. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from 
cardiovascular causes. N Engl J Med 356: 2457-2471, 2007 
140. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ. 
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med 357: 28-38, 
2007 
141. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with 
nonalcoholic steatohepatitis. J Hepatol 31: 384, 1999 
142. Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of 
tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic 
parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 99: 1946-1952, 2004 
143. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. 
Am J Gastroenterol 99: 2365-2368, 2004 
36 
 
144. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates 
alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112: 91-100, 2003 
145. Jequier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci 967: 379-388, 2002   
146. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, 
Taylor SI, Gorden P, Garg A. Leptin-replacement therapy for lipodystrophy. N Engl J Med 346: 570-578, 
2002 
147. Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyanaga F, Kobayashi N, Tanaka T, Chusho H, Miyazawa 
T, Hayashi T, Hosoda K, Ogawa Y, DePaoli AM, Fukushima M, Nakao K. Efficacy and safety of leptin-
replacement therapy and possible mechanisms of leptin actions in patients with generalized 
lipodystrophy. J Clin Endocrinol Metab 92: 532-541, 2007 
148. Devane WA, Dysarz FA, III, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a 
cannabinoid receptor in rat brain. Mol Pharmacol 34: 605-613, 1988 
149. Munro S, Thomas KL, bu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. 
Nature 365: 61-65, 1993 
150. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and 
functional expression of the cloned cDNA. Nature 346: 561-564, 1990   
151. Goutopoulos A, Makriyannis A. From cannabis to cannabinergics: new therapeutic opportunities. 
Pharmacol Ther 95: 103-117, 2002  
152. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le FG, 
Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and 
leukocyte subpopulations. Eur J Biochem 232: 54-61, 1995 
153. Gallily R, Breuer A, Mechoulam R. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor 
necrosis factor-alpha production in murine macrophages, and in mice. Eur J Pharmacol 2000; 406: R5-
R7, 2000 
154. Varga K, Wagner JA, Bridgen DT, Kunos G. Platelet- and macrophage-derived endogenous cannabinoids 
are involved in endotoxin-induced hypotension. FASEB J 12: 1035-1044, 1998   
155. Batkai S, Jarai Z, Wagner JA, Goparaju SK, Varga K, Liu J, Wang L, Mirshahi F, Khanolkar AD, Makriyannis 
A, Urbaschek R, Garcia N, Jr., Sanyal AJ, Kunos G. Endocannabinoids acting at vascular CB1 receptors 
mediate the vasodilated state in advanced liver cirrhosis. Nat Med 7: 827-832, 2001   
156. Wang Y, Liu Y, Ito Y, Hashiguchi T, Kitajima I, Yamakuchi M, Shimizu H, Matsuo S, Imaizumi H, 
Maruyama I. Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-
selective adsorption and subsequent high-performance liquid chromatography analysis: increase in 
endogenous cannabinoids in the sera of patients with endotoxic shock. Anal Biochem 294: 73-82, 2001 
157. Biswas KK, Sarker KP, Abeyama K, Kawahara K, Iino S, Otsubo Y, Saigo K, Izumi H, Hashiguchi T, 
Yamakuchi M, Yamaji K, Endo R, Suzuki K, Imaizumi H, Maruyama I. Membrane cholesterol but not 
putative receptors mediates anandamide-induced hepatocyte apoptosis. Hepatology 38: 1167-1177, 
2003   
158. Gabbay E. Endocannabinoids and liver disease - review. Liver int 25:921-926, 2005 
159. Neff GW, O'Brien CB, Reddy KR, Bergasa NV, Regev A, Molina E, Amaro R, Rodriguez MJ, Chase V, 
Jeffers L, Schiff E. Preliminary observation with dronabinol in patients with intractable pruritus 
secondary to cholestatic liver disease. Am J Gastroenterol 97: 2117-2119, 2002 
160. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C, Chabbert M, Cruccioli N, 
Pfersdorff C, Roque C, Arnone M, Croci T, Soubrie P, Oury-Donat F, Maffrand JP, Scatton B, Lacheretz F, 
Le FG, Herbert JM, Bensaid M. Rimonabant reduces obesity-associated hepatic steatosis and features of 
metabolic syndrome in obese Zucker fa/fa rats. Hepatology 46: 122-129, 2007   
161. Cleland JG, Ghosh J, Freemantle N, Kaye GC, Nasir M, Clark AL, Coletta AP. Clinical trials update and 
cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, 
CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J 
Heart Fail 6: 501-508, 2004 
162. Black SC. Cannabinoid receptor antagonists and obesity. Curr Opin Investig Drugs 5: 389-394, 2004 
37 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 
 
 
TCMA Schreuder, HC Gelderblom, CJ Weegink, HW Reesink, JH DeVries, JB Hoekstra, PLM Jansen 
Liver International 2008;28: 39-46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
Development of diabetes mellitus (DM) during or shortly after treatment with interferon a (IFN-a) 
in patients with chronic hepatitis C virus (HCV) infection has been reported sporadically. We 
prospectively screened for DM during and after IFN-a therapy for chronic HCV infection.  
Blood glucose levels of patients with chronic HCV infection were routinely assessed at all 
outpatient visits during and after treatment with pegylated-IFN-a (Peg-IFN-a) and ribavirin (Riba). 
Between December 2002 and October 2005, 189 non-diabetic patients were treated with Peg-
IFN-a/Riba, of whom five developed type 1 DM (2.6%), three type 2 DM (1.6%) and one an 
indeterminate type of DM. Classical symptoms of DM were present in three patients who 
developed DM shortly after cessation of Peg-IFN-a/Riba. In the other patients, symptoms of DM 
were either indistinguishable from side effects caused by Peg-IFN-a/Riba or absent.  
Our study showed a high incidence of type 1 DM during Peg-IFN-a/Riba therapy for chronic HCV 
infection. Symptoms of DM may be absent or mistaken for Peg-IFN-a/Riba-associated side effects. 
To diagnose DM without delay, we propose routine assessment of blood glucose at all outpatient 
visits during and after Peg-IFN-a/Riba treatment in chronic HCV patients. 
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Introduction 
Interferon a (IFN-a) and ribavirin (Riba)-based therapy for chronic hepatitis C virus (HCV) infection 
is effective in 40–80% of patients but causes a wide range of side effects, such as influenza-like 
symptoms, depression, insomnia, headache, fatigue, fever and anaemia (1). IFN-a treatment for 
chronic HCV infection is associated with the development of autoimmune disorders such as 
autoimmune thyroiditis, hypothyroidism, hyperthyroidism and Sjogren’s syndrome in 2.5–20% of 
patients (1, 2). Type 1 diabetes mellitus (DM) can also occur during or after IFN-a treatment for 
chronic HCV infection. Several cases have been published (3–10), but the exact incidence of DM 
during or after treatment with IFN-a is unknown. An Italian retrospective study among 11 241 
patients with chronic HCV infection treated with IFN-a revealed only 10 new diagnoses of DM 
(0.08%) after at least 16 weeks of treatment (11). Development of type 1 DM during treatment 
with IFN-a for chronic hepatitis B infection, hairy cell leukaemia, Kaposi’s sarcoma and renal cell 
carcinoma has also been reported (3), but the majority of cases occurred in patients with chronic 
HCV infection (3). The prevalence of type 2 DM was found to be significantly higher in a cohort of 
IFN-a-naïve  chronic HCV patients (14.5%) compared with patients suffering from other chronic 
liver diseases (7.3%) and the general population (7.8%); the difference was even more 
pronounced in patients with advanced histological disease (12, 13). Recent studies have shown 
that insulin resistance is common in non-diabetic chronic HCV patients, and that insulin resistance 
decreases during treatment with IFN-a (14–18). 
We screened for DM during and after treatment with pegylated-IFN-a (Peg-IFN-a) and Riba for 
chronic HCV infection. This started after we observed two index cases of DM during Peg-IFN-
a/Riba treatment in our hospital in December 2002. In the first patient, DM-related symptoms, 
commencing after 16 weeks of antiviral treatment, had been attributed to Peg-IFN-a/Riba; DM 
was diagnosed because symptoms were persistent after cessation of Peg-IFN-a/Riba treatment. 
The second patient was presented at the emergency room after 11 weeks of Peg-IFN-a/Riba 
therapy because of severe debilitation, where DM was diagnosed (blood glucose 54 mmol/L). 
Because of the atypical clinical picture of DM in these two patients, we amended our treatment 
protocols, and blood glucose levels of patients with HCV were routinely measured in all patients 
at all outpatient visits before, during and after treatment with Peg-IFN-a/Riba as of December 
2002. 
 
Methods 
Treatment protocols 
Patients were treated with either (i) standard therapy consisting of Peg-IFN-a2b 1.5 mg/kg/week 
(PegIntrons, Schering-Plough Corporation, Kenilworth, NJ, USA) or Peg-IFN-a2a 180 mg/week 
(Pegasyss, Roche, Basel, Switzerland) combined with Riba (Rebetols, Schering-Plough or Copeguss, 
Roche) 1000–1200mg daily for a total of 24 or 48 weeks according to HCV genotype (n = 107) or 
(ii) in a clinical trial with triple therapy consisting of amantadine hydrochloride (Symmetrels, 
Novartis Pharma, Arnhem, the Netherlands) 200mg daily and Riba 1000–1200mg daily for a total 
of 24 or 48 weeks, combined with high-dose IFN-a induction (IntronAs, Schering-Plough) during 
the first 6 weeks (week 1–2: 18MU daily, week 3–4: 9MU daily, week 5–6: 6MU daily), thereafter 
combined with Peg-IFNa2b 1.5 mg/kg/wk for a total of 24 or 48 weeks (n = 100). 
In the group receiving standard therapy (n = 107), 17 patients had been treated with IFN-a 
previously, 90 were treatment naïve, 34 were female and 73 male; 95 were treated with 
PegIntron and Rebetol, 1 with IntronA and Rebetol, and 11 with Pegasys and Copegus. In the 
group receiving triple therapy (n = 100), 46 patients had been treated with IFN-a previously, 54 
were treatment naïve, 23 were female and 77 male.  
 
Assessment of blood glucose levels 
Random blood glucose levels of patients with HCV were routinely measured at all outpatient visits 
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before, during and after treatment with Peg-IFN-a/Riba as of December 2002. 
 
Determination of autoantibodies 
In patients who developed DM, we retrospectively determined autoantibodies to glutamic acid 
decarboxylase (anti-GAD65), protein tyrosine phosphatase (anti-IA2) and pancreatic islet cells 
[islet cell antibodies (ICA)] in stored plasma samples obtained before and after development of 
DM. Detection of anti-GAD65 and anti-IA2 was performed by a fluid phase assay using [35]S-
labelled recombinant human GAD65 and IA2 as tracers, and protein A sepharose beads for 
precipitation. Anti-GAD65 and anti-IA2 values were determined according to the WHO 97/550 
standard (19). ICA was determined by indirect immunofluorescence on monkey pancreas tissue 
(INOVA Diagnostics, San Diego, CA, USA). Anti-GAD65 and anti-IA2 test results were noted in 
international units (IU) per millilitre and converted to negative, indeterminate, weakly positive or 
positive. The following cut-off values (in IU/mL) were used: for anti-GAD65, 0–29 = negative, 30–
42 = indeterminate, 43–80 = weakly positive and 480 = positive; for anti-IA2, 0–23 = negative, 24–
46 = indeterminate, 47–68 = weakly positive and 468 = positive. Seroconversion was defined as a 
transition from a negative or an indeterminate state to a (weakly) positive state. 
Autoantibodies directed to thyroid peroxidase (anti-TPO) and antinuclear antibodies (ANF) were 
measured using standard immunoassays before antiviral therapy. In patients who developed DM 
with seroconversion, anti-TPO was measured again. Thyroid function (thyroid-stimulating 
hormone and free T4) was tested before treatment and every 3 months during treatment in all 
patients according to standard recommendations. 
 
Human leucocyte antigen typing 
In those who developed DM, the human leucocyte antigen (HLA) haplotype was analysed using 
PCR with sequence-specific primers (SSP, GenoVision, West Chester, PA, USA) and sequence-
specific probes (SSO, Dynal, Carlsbad, CA, USA) on stored or fresh peripheral blood mononuclear 
cells. 
 
C-peptide reserve 
In those who developed DM, C-peptide levels were measured before and after glucagon 
stimulation to assess the degree of pancreatic islet cell destruction (20). Briefly, an intravenous 
cannula was placed in the forearm of the patient in a fasting state; blood samples for assessment 
of C-peptide and glucose levels were obtained 15 and 0 min before administration of 1mg 
glucagon intravenously (i.v.) and 6 min afterwards. 
 
Results 
Patients 
Between December 2002 and October 2005, 207 patients with chronic HCV infection were 
treated. One hundred and seven patients received standard antiviral therapy and 100 received 
triple therapy. Eighteen patients already suffered from DM before therapy and were therefore 
excluded from this analysis. One hundred and eighty-nine patients were analysed, including the 
two index patients and including 24 patients who were either already on treatment or during the 
24-week follow-up period to determine the virological response, when the study started in 
December 2002. 
In total, nine of 189 patients (4.8%) developed DM defined as two random glucose samples above 
11.1 mmol/L, according to the ADA classification (21). All 189 patients had normal glucose levels 
at baseline. Type 1 DM was defined as the presence of associated autoantibodies with or without 
susceptible HLA constitution; type 2 DM was defined as the absence of associated autoantibodies 
and no susceptible HLA constitution. Five patients (2.6%) developed type 1 DM, and three 
patients (1.6%) developed type 2 DM. One patient without autoantibodies but with a susceptible 
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HLA-constitution DM could not be labelled as type 1 or 2; this patient declined assessment of C-
peptide reserve. Five of 98 patients (5.1%) developed DM during (n = 4) or after (n = 1) standard 
treatment, and four of 91 patients (4.4%) during (n = 2) or after (n = 2) triple treatment. Patient 
characteristics are summarized in Table 1. 
Classical symptoms of DM were indistinguishable from the side effects of antiviral therapy with 
Peg-IFN-a/Riba in these patients. Three patients presented with typical symptoms (e.g. thirst and 
polyuria), but they developed DM 4 weeks after cessation of treatment, when Peg-IFN-a/Riba-
related side effects had disappeared. All nine patients were initially treated with insulin. After 
cessation of antiviral therapy, seven patients remained insulin dependent, whereas two patients 
without detectable antibodies (Table 2, patients 1 and 2) switched to oral antidiabetic drugs. One 
of these two patients was even able to stop oral antidiabetic drugs after losing weight. Peg-IFN-
a/Riba treatment was stopped prematurely when DM was diagnosed in two of nine patients. 
Three patients achieved a sustained virological response, defined as undetectable HCV RNA 24 
weeks after cessation of antiviral therapy. 
 
-cell autoantibodies 
As depicted in Table 2, two of the nine patients were positive for anti-GAD65 or ICA before 
treatment. Three of the nine patients seroconverted for anti-GAD65, anti-IA2 or ICA during 
treatment. 
 
 Table 1. Patient characteristics. 
 
Patient Sex 
Age 
(yrs) 
BMI 
(kg/m2) 
DM in 
family 
HCV 
Geno 
Cirrhosis 
Antiviral 
Treatment 
Onset 
of  DM 
Virologic 
outcome 
1 M 61 25 yes 2 + standard 
wk 
16* 
NR 
2 M 50 30 no 1b + triple wk 11 NR 
3 M 54 25 yes 3 + standard 
4 wks 
after 
ET 
NR 
4 M 46 23 no 1a - triple wk 11 NR 
5 M 54 25 no 1 + triple 
4 wks 
after 
ET 
NR 
6 M 25 22 yes 4 - triple 
4 wks 
after 
ET 
SVR 
7 F 44 24 yes 3a - standard wk 22 SVR 
8 M 46 22 yes 3a - standard wk 14 SVR 
9 M 43 33 no 1 - standard wk 12 NR 
*
DM was diagnosed after cessation of Peg-IFN-a/Riba, but based on symptoms, the onset of DM was estimated after 16 
weeks of antiviral treatment. 
†Therapy was stopped after the development of DM. 
Patients were treated for 24–48 weeks with either (i) standard therapy consisting of Peg-IFN-a/Riba or (ii) in a clinical 
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trial with triple therapy consisting of amantadine hydrochloride and Peg-IFN-a/Riba, with high-dose IFN-a induction 
instead of Peg-IFN-a during the first 6 weeks. 
BMI= body mass index, calculated as weight in kilograms divided by square height in metres, DM in family = first degree 
family members with type 1 or 2 DM, ET = end of treatment (24–48 weeks), NR = non-response, defined as persistence 
of HCV RNA during and after antiviral treatment, SVR = sustained virologic response, defined as undetectable HCV RNA 
24 weeks after cessation of antiviral treatment, DM = diabetes mellitus, HCV = hepatitis C virus, Peg-IFN-a = pegylated-
interferon-a, Riba = ribavirin 
 
Figure 1 shows glucose levels and increasing titres of anti-GAD65 before, during and after antiviral 
treatment in patient 4 (Tables 1 and 2), who developed type 1 DM after 11 weeks of triple 
antiviral treatment.  
 
 
 
Figure 1. Glucose levels and autoantibodies to glutamic acid decarboxylase (anti-GAD65) in 
patient 4 who developed type 1 diabetes mellitus during antiviral therapy.  
Glucose (mmol/L, red line) and anti-GAD65 (E/mL, grey columns). Glucose levels were assessed prospectively, 
autoantibodies were assessed retrospectively in stored plasma samples. Anti-GAD65 was weakly positive at baseline 
(*46 E/mL), increased to positive (**84 E/mL) before hyperglycaemia occurred at 11 weeks of treatment, and continued 
to increase thereafter (***112 E/mL week 11, ****335 E/mL week 28). Treatment with insulin was initiated 
immediately after the peak in blood glucose level at week 11. The broken horizontal line depicts the upper limit of 
normal (ULN) for non-fasting blood glucose levels (11.1 mmol/L). 
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Non--cell antibodies 
One patient (patient 7, Table 2) developed thyroiditis, followed by hypothyroidism, without the 
presence of anti-TPO, shortly after the development of type 1 DM; this patient was positive for 
ANF before treatment. The other two seroconverters remained anti-TPO negative (data not 
shown). 
 
Human leucocyte antigen typing 
The human leucocyte antigen haplotype was determined in seven of the nine patients. Four 
patients had an HLA haplotype associated with an increased susceptibility (DR3, DR4, DQ8 and 
DQ2) for the development of type 1 DM. Two of these four patients with a DM-associated HLA 
haplotype also seroconverted for anti-GAD65 (Table 2). Two patients declined additional blood 
sampling for assessment of HLA haplotype. 
 
C-peptide reserve 
In three patients, we assessed the C-peptide reserve, four patients refused the test and two 
patients, who had developed hepatocellular carcinoma, were not contacted (Table 2). Two 
patients with positive -cell autoantibodies had low fasting C-peptide levels (<100 pmol/L) that 
did not increase after stimulation with 1mg of glucagon i.v., suggesting complete destruction of 
pancreatic -cells (Table 2). One patient without -cell autoantibodies had a fasting C-peptide 
level of 1060 pmol/L that increased to 1700 pmol/L 6 min after stimulation with 1mg of glucagon 
i.v., indicating adequate function of pancreatic -cells (Table 2). 
 
Table 2. Type 1 diabetes mellitus-associated autoantibodies before antiviral therapy and after 
development of diabetes mellitus and human leucocyte antigen haplotype, C-peptide reserve, 
diabetes mellitus classification and non--cell autoantibodies in all patients who developed 
diabetes mellitus. 
 
 
Patient 
anti-GAD65 anti-IA2 ICA Seroconversion 
for anti-GAD65, 
anti-IA2 or ICA 
risk 
HLA 
C-
peptide 
reserve 
DM 
type 
Anti-
TPO 
ANF 
Before After Before After Before After 
1 - - - - - - no - yes 2 - - 
2 - - - - - - no - ND 2 - - 
3 - - ± ± - - no DR3 ND 1 - - 
4 + ++ - - - - no - ND 1 - - 
5 - - - - - - no 
DR4, 
DQ8 
ND ? - - 
6 - ++ - - - + yes 
DR3, 
DQ2 
no 1 - ± 
7 ± ++ - - - - yes 
DR3, 
DR4, 
DQ2 
no 1 - + 
8 ++ ++ ± + + ++ yes ND ND 1 - - 
9 - - - - - - no ND ND 2 - - 
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*
HLA haplotype was analysed using stored or fresh PBMCs. Two patients (8 and 9) declined extra sampling of blood for 
these tests. 
†C-peptide reserve was assessed in three patients, four patients refused the test, two patients who had developed 
hepatocellular carcinoma were not contacted. 
Autoantibodies to thyroid peroxidase (anti-TPO) and antinuclear antibodies (ANF) were measured in stored plasma 
samples using standard immunoassays before antiviral therapy. 
Cut-off values for autoantibodies 
Anti-GAD65 (IU/mL) 
0–29 negative 
29–42 indeterminate 
42–80 weakly positive 
>80 positive 
Anti-IA2 (IU/mL) 
0–23 negative 24–46 indeterminate 
47–68 weakly positive 
>68 positive 
 
++ positive; + weakly positive;  indeterminate; - negative; seroconversion was defined as transition to a + or ++ state 
DM = diabetes mellitus, HLA = human leucocyte antigen, ICA = islet cell antibodies, ND = not determined, PBMCs = 
peripheral blood mononuclear cells 
 
Ethnic origin of the type 1 diabetes mellitus patients  
Two of the five patients who developed type 1 DM were of Dutch origin, one patient was born in 
Portugal, one patient was born in Egypt and one patient was born in Surinam. 
 
Sex 
One of 50 females (2%) vs eight of 119 (6.7%) males developed DM (P = 0.45, Fisher’s exact test). 
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Discussion 
In this prospective cohort study, we found the incidence of DM, especially type 1, during or 
shortly after treatment with Peg-IFN-a/Riba for chronic HCV infection to be higher than reported 
previously. Most patients who developed DM were identified through routine assessment of 
blood glucose levels, as DM-related complaints were absent or mistaken for Peg-IFN-a/Riba-
related side effects. So far, 31 cases of de novo type 1 DMduring or after treatment of chronic 
HCV infection with IFN-a, IFNa/Riba or Peg-IFN-a/Riba have been described (3, 5–10). Through 
screening, we identified five certain cases and one possible case of de novo type 1 DM during or 
after treatment of chronic HCV infection with Peg-IFN-a/Riba. 
In our study, only two of the nine patients who developed DM tested positive for type 1 DM-
associated autoantibodies before IFN-a was started. These findings agree with those of Fabris et 
al. (3), who analysed the presence of b-cell autoantibodies in a number of studies: anti-GAD65, 
ICA or anti-IA2 was present in 3% of patients with chronic HCV infection (12 of 440) before 
treatment; two of 440 patients (0.45%) developed type 1 DM during antiviral therapy, and both 
tested positive for ICA before treatment (i.e. two of the 12 patients with anti-GAD65, ICA or anti-
IA2 before treatment). In contrast, pretreatment autoantibodies associated with the development 
of type 1 DM – assessed in 26 of the 31 reported cases so far – were positive in 50% of patients 
who developed type 1 DM (3, 5, 9). Taken together, both the positive and the negative predictive 
value of -cell autoantibodies seem too low to identify patients at a high risk or to effectively rule 
out the possibility of developing IFN-a-associated type 1 DM. The destruction of pancreatic -cells 
in type 1 DM may be mediated by IFN-a (22, 23). Enhanced expression of IFN-a by pancreatic islet 
cells in transgenic mice induces inflammation (22, 24), autoreactive cells (22, 25) and precedes 
DM (22, 24, 26). Enhanced expression of IFN-a by pancreatic islet cells has also been 
demonstrated in patients with type 1 DM (27, 28). Riba and amantadine are not associated with 
the development of DM.  
Certain HLA haplotypes (DR3, DQ2, DR4 and DQ8) are associated with increased susceptibility to 
type 1 DM (29). In the analysis by Fabris et al. (3), HLA haplotype was determined in 13 patients 
with chronic HCV infection who developed type 1 DM during IFN-a or IFN-a/Riba therapy; all 13 
patients had an HLA haplotype associated with increased susceptibility to type 1 DM. In our study, 
four of the nine patients had a type 1 DM-associated HLA haplotype, of whom three patients also 
tested positive for one or more autoantibodies (Table 2). We classified one patient as 
indeterminate owing to the absence of autoantibodies. Taken together, these results suggest that 
certain HLA haplotypes may predispose to the development of type 1 DM during Peg-IFN-a/Riba 
therapy in chronic HCV patients. In the patients who seroconverted, the absence of concomitant 
anti-TPO antibodies argues against induction of a polyglandular autoimmune syndrome by IFN-a. 
In addition, we described three cases of de novo type 2 DM during treatment of chronic HCV 
infection with Peg-IFN-a/Riba. The prevalence of type 2 DM is high among chronic HCV patients, 
especially in patients with advanced fibrosis or cirrhosis (12, 30). The pathogenesis is unclear, but 
insulin resistance and the development of DM may be mediated by pro-inflammatory cytokines 
such as IL-6 and TNF-a (31, 32). 
Four of the nine patients who developed DM were treated with triple antiviral therapy with high 
doses of IFN-a during the first 6 weeks (Table 1, patients 2, 4, 5, 6); one of these patients had been 
treated with IFN-a previously. The incidence of DM was similar in the standard treatment group 
(five of 98 patients, 5.1%) compared with the triple treatment group (four of 91 patients, 4.4%). 
The prevalence of DM before treatment with triple therapy was higher in previous IFN-a non-
responders (six of 46 patients) than in treatment naïve patients (three of 54) but this was not 
significant (p=0.29, Fisher’s exact test). The prevalence of DM before treatment with standard 
therapy was similar in previous IFN-a non-responders (two of 17 patients) compared with 
treatment-naïve patients (seven of 90, p=0.63, Fisher’s exact test). Taken together, these findings 
suggest that the development of DM is not associated with higher doses of IFN-a or multiple 
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courses of treatment. Whether pegylation of IFN-a has an effect is uncertain. Three of the 31 
previously described patients and all five patients in our study who developed type 1 DM during 
IFN-a treatment were treated with Peg-IFN-a (5, 6). 
Our study has several limitations: (i) we only assessed type 1 DM-associated autoantibodies in 
patients who developed DM and (ii) we did not use a control group such as chronic hepatitis B 
patients undergoing IFN-a treatment, or untreated chronic HCV patients. However, our study, 
prompted by two index patients who developed DM during treatment for chronic HCV infection, 
was based on a clinical – ad hoc – adjustment of two treatment protocols to monitor 
development of DM. Interestingly, the two index cases in our study (patients 1 and 2), who both 
required insulin at the time of diagnosis, had developed type 2 DM. Five of the seven patients 
who were subsequently identified had developed type 1 DM. Given the low positive and negative 
predictive values of type 1 DM-associated autoantibodies (50%) (3), and the similar clinical 
presentation of both types of DM, we chose to monitor glucose levels rather than rely on 
autoantibodies. 
No recommendations have been made in HCV treatment guidelines on glucose assessment during 
therapy (33). Considering (i) the high incidence of types 1 and 2 DM in our study, (ii) the atypical 
clinical picture of DM during Peg-IFN-a/Riba therapy, (iii) the availability of an easy method to 
identify patients who develop DM and (iv) the importance of the treatment of diabetes, we 
suggest that routine glucose assessment at all outpatient visits for all HCV patients before, during 
and shortly after Peg-IFN-a/Riba treatment should be incorporated into the treatment guidelines, 
similar to the existing recommendation to screen for autoimmune thyroid disease. 
 
In conclusion, this is the first prospective study on the development of DM in chronic HCV patients 
during treatment with Peg-IFN-a/Riba. We have shown that the incidence of DM, especially type 
1, during treatment with Peg-IFN-a/Riba for chronic HCV infection is markedly higher than 
reported previously. DM-related complaints are frequently absent or mistaken for Peg-IFN-a/Riba-
related side effects. Routine assessment of random blood glucose is an easy method to identify 
patients who develop DM during Peg-IFN-a/Riba treatment. These results support routine 
assessment of blood glucose levels at all outpatient visits before, during and in the first month 
after Peg-IFN-a/Riba treatment to detect DM without delay. 
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Abstract 
Obesity and insulin resistance cause fatty infiltration of many organs, including pancreas 
(pancreatic steatosis) and liver (non-alcoholic fatty liver disease; NAFLD). In contrast to non-
alcoholic fatty liver disease, pathophysiological mechanisms and clinical relevance of pancreatic 
steatosis remains unknown. This study aimed to identify a possible relation between pancreatic 
steatosis and nonalcoholic fatty liver disease. 
In this study including post mortem collected material of 80 patients, clinical and histological data 
were collected and revised. Patients with hepatic or pancreatic disease and alcohol abuse were 
excluded. NAFLD Activity Score was used for grading histology in the liver, whereas Pancreatic 
Steatosis Score assessed pancreatic steatosis. Ordinal logistic regression was used to analyze 
correlations. 
Interlobular and total pancreatic fat were both related to NAFLD Activity Score in patients without 
steatogenic medication (p=0.02 and p=0.03 respectively). When corrected for BMI, no relation 
could be found. Total pancreatic fat was a significant predictor for the presence of non-alcoholic 
fatty liver disease (p=0.02). Presence of intralobular pancreatic fat was related to non-alcoholic 
steatohepatitis, total fat however not. 
This study demonstrates that NAFLD and PS are related. This relationship appears to be mediated 
by general obesity. Intralobular pancreatic fat is associated with non-alcoholic steatohepatitis. 
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Introduction 
Obesity (defined as BMI > 30 kg/m2) is becoming an endemic problem with tremendous 
prevalence numbers (1). In the period of 1981 till 2006, the prevalence of obesity among adults in 
the Netherlands increased from 5,1% to 11,3% (2). Obesity is related to a variety of diseases, such 
as cancer, metabolic syndrome and cardiovascular disease (3,1,4). In humans, obesity and 
associated insulin resistance can cause fat infiltration of striated muscle, heart, liver and pancreas 
(5). Excessive storage of fat in pancreatic tissue has been termed pancreatic lipomatosis (PL), first 
described by Ogilvie (6). The term lipomatosis is old, and is now replaced by steatosis. Literature 
regarding PS (pancreatic steatosis) is scarce and its pathophysiological mechanisms and clinical 
relevance are largely unknown. The degree of PS is correlated with age and BMI (7,8). Moreover, 
Stamm et al. demonstrated a significant association of severe generalized atherosclerosis, adult-
onset diabetes and pancreatic fibrosis with PS (8). Recently, Tushuizen et al. observed increased 
pancreatic lipid content, measured by 1H magnetic resonance spectroscopy, in a prospective study 
of 36 patients with β-cell dysfunction (9), a finding which was not confirmed by Saisho et al. who 
performed a CT-based retrospective study on 1886 adult patients (10). Furthermore, PS is 
associated with several benign and malignant diseases, such as: cystic fibrosis, chronic 
pancreatitis, steroid therapy, Shwachman Diamond Syndrome, pancreatic pseudohypertrophia, 
Johansson-Blizzard Syndrome, viral infection and pancreatic duct obstruction (11,12,13,14). 
Pancreatic steatosis also increases the risk of postoperative fistula’s in pancreatic surgery and 
promotes dissemination and lethality of pancreatic cancer (15,16). 
In the liver, accumulation of triglycerides in the absence of excess of alcohol use and other chronic 
liver diseases has been defined as non-alcoholic fatty liver disease (NAFLD). After exclusion of 
secondary causes (e.g. steatogenic medication), a strong association exists between NAFLD, 
insulin resistance and the metabolic syndrome (17,18). As a consequence of the increasing 
prevalence of obesity, NAFLD is becoming the most common cause of chronic liver disease (19). It 
ranges from simple hepatic steatosis through non-alcoholic steatohepatitis (NASH) to liver 
cirrhosis and increased risk for developing hepatocellular carcinoma (20). Simple hepatic steatosis 
is of minor clinical importance since less than 5% develops end stage liver disease (21). However, 
in patients with NASH, characterized by lobular inflammation and ballooning degeneration of 
hepatocytes, approximately 20% develops cirrhosis, liver failure and/or hepatocellular carcinoma 
(21). 
Some authors introduced the entity ‘non-alcoholic fatty pancreas disease’ (NAFPD) for PS, thereby 
suggesting a possible relation between NAFLD and NAFPD/PS (22,23). However, an association of 
NAFLD and PS has never been demonstrated in larger cohort studies. The objective of this study 
was to analyze this relation between PS/NAFPD and NAFLD. 
 
Materials and Methods 
In this retrospective study, autopsy material of pancreas and liver of deceased patients admitted 
to the VU University Medical Centre, Amsterdam, the Netherlands was collected and reviewed. 
Patients of 18 years and older were included (24). Exclusion criteria were:  
1. features consistent with hepatic or pancreatic disease collected from medical files 
2. major abdominal surgery in patient’s medical history: major gastrointestinal surgery (small 
intestinal surgery, Billroth’s surgical intervention, Roux-Y-anastomosis, hepatobiliary and 
pancreatic surgery, because of possible aspecific lymphoctytic infiltration of liver tissue) 
3. documented history of excessive alcohol intake (≥ 21 drinks/week for male and ≥ 14 
drinks/week for female) 
4. severe post mortem changes which hampered histology 
5. the aim of this study was to evaluate the relation between obesity-related NAFLD and PS, 
therefore patients who used steatogenic medication (e.g. methotrexate, HAART (highly active 
anti-retroviral therapy), amiodarone and glucocorticoids (25)) or with unknown previous use of 
51 
 
medication were excluded. 
 
Histopathology 
Autopsy material was assessed by an experienced hepatobiliary histopathologist (EB) and two 
research fellows (MS and EG), all blinded for patients’ clinical and laboratory data. Only one liver 
slide and one pancreas slide were available per patient. Unfortunately, it was not known where in 
the liver and pancreas these samples were taken. Different scoring systems were used for liver 
and pancreas. 
 
Liver 
Hepatic steatosis and inflammation were graded according to the NAFLD Activity Score (NAS) (24). 
Slides were stained with hematoxylin and eosin (H&E) and assessed regarding the presence of 
macrovesicular steatosis (0-3), lobular inflammation (0-2), hepatocellular ballooning (0-2) and 
fibrosis (0-4). The sum of individual grades, excluding fibrosis, represents NAS. In addition, the 
overall amount of hepatic steatosis (macrovesicular and microvesicular) was scored (0-3). 
 
Pancreas 
Since there is no evidence based scoring system for PS, our research group developed a new 
grading system: the pancreatic lipomatosis score (PSS; article under submission). This grading 
system emphasizes the distribution of intralobular, interlobular and total pancreatic fat. In our 
validation process, we have found an high inter-rate variability (kappa = 0.89) and a low intra-
rater variability (kappa = 0.10). Therefore all pancreatic slides were scored by one panel (MS, EG 
and EB). With this system the quantity of adipocytes per microscopic pancreas compartment 
(inter-and intralobular) was graded according to 5 separate groups: 0: 0-7% adipocytes, 1: 8-14%, 
2: 15-25%, 3: 26-50% and 4: >51%. When grading total amount of fatty infiltration (inter- and 
intralobular) an additional group 5: > 75% was added. Additionally, the presence of lymphocytes 
was noted. 
 
Clinical data 
From (electronic) medical files and autopsy reports, clinical and biochemical data were collected 
in a central database. Collected clinical data consisted of gender, BMI, age, blood pressure, history 
of alcohol and tobacco abuse and medical history, in particular cardiovascular, liver and gastro-
enterological diseases and diabetes mellitus (DM) and cause of death. BMI was calculated from 
the data noted in autopsy reports. 
Biochemical data such as viral serology (e.g. hepatitis B and C antibodies), autoimmune serology 
(antinuclear factor, smooth muscle antibodies, mitochondrial antibodies) and storage diseases 
(iron and copper studies), were collected. The use of steatogenic medication and medication used 
in patients with the metabolic syndrome (e.g. antihypertensive, antidiabetic and lipid-lowering 
medication) within the last 12 months was noted. 
 
Statistical analysis 
Univariate ordinal logistic regression was used to test the relation between ordinal histological 
parameters. Binary parameters were analyzed by binary logistic regression. 
Multivariate analysis (forward stepwise ordinal regression) was performed to correct for BMI and 
gender. A p-value ≤ 0.05 was considered to be statistically significant. Results are presented as 
ordinal regression coefficients (B) and p-values. All analyses were performed using SPSS software 
version 15 for Windows (Chicago, IL, USA). 
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Results 
 
Patient characteristics 
In total, more than 900 autopsies were performed in the VU University medical center from 
January 2005 till December 2007. In this period 598 autopsies were performed on clinical patients 
of the VU University medical center. Of these patients, 415 met the inclusion criteria and were 
enrolled in this study. Eventually, 335 subjects were excluded, predominantly because of inferior 
quality of the histological material due to post mortem changes or absence of histological 
material. Six patients were excluded because of major abdominal surgery: two Whipple 
operations, one Roux-Y-anastomosis, one Billroth II, one hepatitis e.c.i. after small intestinal 
surgery, and one right extended hemi-hepatectomy. Thirty-four patients were excluded because 
they used steatogenic medication. Thirty-six patients had an unknown medication history and 
were therefore excluded. Characteristics of 80 eligible patients are summarized in Table 1. There 
were no patients with cryptogenic cirrhosis. 
 
Table 1. Patients’ characteristics (Mean  SD or number of cases (%)) 
 
  
Patients  (n = 80) 
Male sex 42 (53%) 
Age of death 68 ± 14 
BMI (kg/m
2
) 26 ± 5 
NAFLD (including NASH) 37 (46%) 
NASH 3 (4%) 
Cause of death:  
 
Cardiovascular 49 (61%) 
Gastro-enterologic 2 (3%) 
Malignancy 14 (17%) 
Other 15 (19%) 
 
BMI = body mass index, NAFLD = non-alcoholic fatty liver disease, NASH = non-alcoholic steatohepatitis 
 
In Table 2, the scores for liver and pancreatic fat are given for all patients. Almost half of the 
patients had steatosis of the liver. NASH was observed in the minority of patients with steatosis, 
although the density of lobular infiltrates was generally low. Fibrosis was uncommon and, if 
present, of minor degree. Pancreatic lipomatosis was found in the majority of patients. This 
consisted mainly of interlobular fat accumulation. Pancreatic fibrosis was uncommon. No 
pancreatic inflammatory infiltrates were identified. 
 
Pancreatic and hepatic relations 
Several statistically significant correlations between histopathologically determined pancreatic 
and hepatic fat could be found (Table 3). Significant relations were found between pancreatic 
interlobular fat and hepatic macrovesicular fat (B 0.377, p=0.03) and NAS (B 0.377, p=0.03); total 
pancreatic fat and hepatic macrovesicular fat (B 0.340, p=0.04) and NAS (B 0.348, p=0.03). 
However, pancreatic intralobular fat was not related to hepatic steatosis (Figure 1). Histological 
features of NASH (e.g. hepatocyte ballooning and lobular inflammation) were not related to PS. 
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Table 2. Histopathologic analyses [amount (percent %)] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Relations between liver and pancreas histology [ordinal regression coëfficiënt  
(p-values)] 
 
 
 
NAS = NAFLD activity score, p-values <0.05 are highlighted 
 
 
  Patients 
Liver  Macrovesicular 
steatosis 
0 46 (58) 
1 21 (26) 
2 9 (11) 
3 4 (5) 
Lobular 
inflammation 
0 62 (78) 
1 16 (20) 
2 2 (2) 
3 0 (0) 
Hepatocellular 
ballooning 
0 77 (96) 
1 3 (4) 
2 0 (0) 
Fibrosis 0 74 (93) 
1A 0 (0) 
1B 0 (0) 
1C 5 (6) 
2 1 (1) 
3 0 (0) 
  Patients 
Pancreas 
 
Intralobular 
steatosis 
0 20 (25) 
1 33 (41) 
2 12 (15) 
3 11 (14) 
4 4 (5) 
Interlobular 
steatosis 
0 12 (15) 
1 26 (33) 
2 14 (17) 
3 15 (19) 
4 13 (16) 
Intralobular 
fibrosis 
0 59 (74) 
1 14 (17) 
2 7 (9) 
Interlobular 
fibrosis 
0 65 (81) 
1 12 (15) 
2 3 (4) 
 
Pancreas 
 Liver  
 
Total fat 
Macrovesicula
r fat 
lobular 
infiltration 
Ballooning NAS 
 
Intralobular fat 
0.149 
(0.425) 
0.209 
(0.276) 
0.095 
(0.682) 
0.493 
(0.297) 
0.219 
(0.250) 
 
Interlobular fat 
0.318 
(0.053) 
0.377 
(0.026) 
0.191 
(0.341) 
0.466 
(0.317) 
0.377 
(0.025) 
 
Total fat 
0.298 
(0.056) 
0.340 
(0.035) 
0.213 
(0.270) 
0.639 
(0.188) 
0.347 
(0.031) 
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Figure 1. Relation of PS and hepatic NAS, with standard error of the mean. 
The relation of pancreatic steatosis (a intralobular, b interlobular, c total) with hepatic NAS. Intralobular pancreatic 
steatosis is not related to hepatic NAS, interlobular and total pancreatic steatosis do. P-value is calculated by ordinal 
logistic regression, NAS = NAFLD activity score. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Multivariate analysis 
BMI was significantly related to hepatic 
macrovesicular fat (B 0.172, p=0.001), total fat 
(B 0.134, p=0.008) and NAS (B 0.18, p=0.001: see 
Figure 2). It was not related to lobular infiltration (B 
0.054, p=0.35) or hepatocellular ballooning (B 0.025, 
p=0.84). The relation of BMI and pancreatic fat was 
present for intralobular fat 
 (B 0.119, p=0.01), interlobular fat (B 0.152, p=0.002) 
and total fat (B 0.155, p=0.001: see Figure 2). 
 
  
  
 
Figure 2. Relation between BMI and  
PS / NAFLD. 
The relation of BMI with NAS and total 
pancreatic steatosis. Both relations are 
statistically significant (p = 0.001 and p = 0.001, 
resp.). 
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No significant relation between pancreatic and hepatic fat could be demonstrated when a 
correction for BMI was performed by multivariate analysis. This phenomenon was shown to be 
present disregarding the distribution of pancreatic fat (Table 4). 
Correction for age or gender did not statistically affect the relation of pancreatic and hepatic fat. 
Remarkably, male subjects failed to show a significant relation on all variables, while female 
subjects inclined to statistical significance on most variables. Correction for BMI did not change 
this distinction (data not shown). When corrected for age, gender and BMI, no significant relation 
between hepatic and pancreatic fat could be found (Table 4). 
 
 
Table 4. Relation between NAFLD en PS after correction for BMI, age and gender. 
 
Relation between Normal Corrected for 
Pancreatic Hepatic  BMI Gender Age 
BMI, Gender, 
Age 
Intralobular 
fat 
Macrovesicular fat 0.276 0.840 0.207 0.253 0.716 
Total fat 0.425 0.985 0.324 0.451 0.985 
NAS 0.250 0.942 0.154 0.248 0.763 
Interlobular 
fat 
Macrovesicular fat 0.026 0.485 0.039 0.017 0.582 
Total fat 0.053 0.469 0.081 0.050 0.724 
NAS 0.025 0.459 0.040 0.019 0.596 
Total fat Macrovesicular fat 0.035 0.710 0.046 0.022 0.784 
Total fat 0.056 0.626 0.079 0.051 0.879 
NAS 0.031 0.602 0.041 0.024 0.697 
 
BMI = body mass index, NAS = NAFLD activity score. All data are p-values; p-values <0.05 are highlighted 
 
Cut-off points 
When dividing PS into percentiles, a cut-off point of 15% of total pancreatic fat was statistically 
significant related to hepatic macrovesicular fat (B 1.027, p=0.04), total fat (B 1.161, p=0.02) and 
NAS (B 1.056, p=0.03) (Figure 3). Furthermore, a similar cut-off point of 15% of total pancreatic fat 
was related to the diagnosis NAFLD (B 1.148, 
p=0.02). In patients with NASH, a cut-off of 
25% of intralobular pancreatic fat was 
significant associated with this diagnosis (B 
2.708, p=0.04). However, total pancreatic fat 
was not related with NASH. 
 
 
Figure 3. Percentiles of PS in relation to NAS. 
With standard error of the mean. 
The relation of cut-off points of total pancreatic steatosis 
with hepatic. A cut-off point of 15% and 25% is related 
with significant different NAS (= NAFLD activity score). 
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Discussion 
This is the first histopathological study focusing on the relation of NAFLD and PS. In imaging 
studies, Tushuizen et al. using MR-spectroscopy and Schwenzer et al. using MRI could not 
demonstrate a relation between pancreatic and hepatic fat (26,9). Unfortunately, both studies 
lacked power due to low numbers of included patients (n = 36 and n = 17, respectively). In our 
study, pancreatic and hepatic tissue of 80 deceased patients were re-assessed and graded 
according to the general accepted NAFLD activity score and a newly developed Pancreatic 
Lipomatosis Score (PLS) in order to find relations between NAFLD and PS. 
 
Relations of pancreatic and hepatic fat 
From our analyses using the golden standard (i.e. histology), a relation between various 
types of hepatic fat and pancreatic fat could be clearly demonstrated. Especially, a cut off of more 
than 15% total pancreatic fat appeared to be significant correlated with NAFLD. In particular, 
pancreatic fat was more significant related to macrovesicular hepatic fat than to total hepatic fat. 
This suggests different pathophysiological mechanisms of macro- and microvesicular fat, 
consistent with available data from other publications (27). NAFLD was stated to be associated 
with macrovesicular fat caused by accumulation of triglycerides, whereas microvesicular steatosis 
is caused by mitochondrial dysfunction due to for instance toxins. 
 
BMI, insulin resistance and gender 
Significant relations between PS and NAFLD disappeared when BMI correction in multivariate 
analysis was performed. Therefore this study provides evidence that BMI involved in the 
pathogenesis of pancreatic and hepatic fat. Possibly, insulin resistance is involved, since a strong 
relation between obesity and insulin resistance has been shown (28). Insulin resistance influences 
peripheral lipolysis, thereby increasing the portal flux of fatty acids which is suggested to be the 
‘first hit’ in NAFLD (29). In addition, in an overfed status, adipocytes produce inadequate amounts 
of adipocytokines (eg. leptin, adiponectin and tumour necrosis factor alfa), causing further 
peripheral and hepatic insulin resistance, resulting in increased hepatic fatty acid accumulation 
(30,31,32,33). Whether mechanism(s) associated with fatty acids hepatic influx are similar in PS is 
questionable. 
Interestingly, in contrast to NAFLD, PS was not related to features of the metabolic syndrome 
(p=0.38), which can be explained by the studies retrospective fashion and its accompanied 
missing clinical data. Another controversial argument is the presence of adipocytes in pancreatic 
parenchyma in comparison to lipid droplets in liver tissue. 
Differences in gender regarding visceral fat and serum triglycerides have been demonstrated by 
many studies. In female patients, this correlation is more significant than in male patients (34). 
Nielsen et al. hypothesized that the export of free fatty acids derived from visceral lipolysis to the 
liver is more pronounced in female patients (35). Another study demonstrated only in female 
patients the significant correlation of insulin resistance and visceral fat (36). These findings are in 
accordance with this study, where a gender correction in a multivariate analysis only showed a 
significant correlation between PS and NAFLD in female subjects. 
 
Pancreatic cellular lipotoxicity and overt type 2 diabetes mellitus (T2DM) 
This study demonstrates a trend of overt T2DM and quantity of total PS (p=0,092). These findings 
confirm results of recent reports demonstrating the deleterious effects of the accumulation of 
free fatty acids (FFA) on -cell function and the development of T2DM. In murine models (ZDF 
rats), male animals who were fed a standard diet represented significantly more hyperglycemia 
and FFA when compared to their female counterparts (37,38,39). Administration of PPAR- 
agonists in mice on a high-fat diet decreased pancreatic islet cell triglyceride-content and 
consequently improved insulin secretion (40). 
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Proposed mechanisms by which FFA causes damage to -cell dysfunction are effects on insulin 
biosynthesis, pre-proinsulin gene expression and expression of uncoupling proteins (41,5). 
Whether these data can be translated to humans needs to be clarified. 
 
Hypothesis 
We hypothesize that BMI and associated insulin resistance play an important role in pancreatic 
adipocyte infiltration, causing PS. In addition, insulin resistance (due to a high BMI) causes 
peripheral lipolysis, thereby increasing the flux of fatty acids to the liver (29). Lipolysis in the 
pancreatic adipocytes further increases the portal flux of fatty acids. As a consequence hepatic 
insulin resistance and NAFLD develop. This implies that PS precedes NAFLD. Since this is not a 
prospective study, conclusions regarding the chronological order of appearance can’t be drawn. 
 
Limitations 
Some limitations of this study need to be noted. Due to its retrospective fashion some important 
data are missing, undermining the statistical power. Additionally, fibrosis in histological liver 
samples could not be accurately assessed, because no Gieson’s staining was performed. Numbers 
of patients with NASH were low and statistical analysis to demonstrate possible relations between 
NASH and PS therefore impaired. Another limitation is the presence of one histological slide per 
patient and the concomitant potential for sampling error, since pancreatic and hepatic fat can be 
irregular distributed (42,34). Further research for unraveling PS’s pathophysiology and clinical 
consequences on the long-term is warranted. 
 
In conclusion 
PS is a relative new clinical entity which remains to be clarified yet. Fatty liver and fatty pancreas 
are related especially in females, but the relationship appears to be mediated by general obesity. 
Therefore using the name ‘non-alcoholic fatty pancreatic disease (NAFPD)’ can be justified due to 
the co-existence with NAFLD. Whether NAFLD and PS are caused by similar mechanisms needs to 
be further investigated. 
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Abstract 
Intestinal FGF19 has emerged as a novel endocrine regulator of hepatic bile salt and lipid 
metabolism. In patients with non-alcoholic fatty liver disease (NAFLD) hepatic lipid metabolism is 
deranged. A possible role of FGF19 in NAFLD has not been reported yet. In this study, we assessed 
intestinal FGF19 production and the hepatic response to FGF19 in NAFLD patients with and 
without insulin resistance (HOMA score ≥2.5 [n=12] and HOMA score <2.5 [n=8]), respectively. To 
this end, NAFLD patients received a standardized oral fat challenge. Postprandial excursions of 
triglycerides, bile salts and FGF19 were monitored, and plasma levels of a marker for bile salt 
synthesis (7α-hydroxy-4-cholesten-3-one) were determined. Fasted FGF19 levels were 
comparable in a control group of healthy volunteers (n=15) and in NAFLD patients (0.26±0.28 
ng/mL vs. 0.18±0.09 ng/mL, resp., P=0.94). Postprandial FGF19 levels in both controls and NAFLD 
patients peaked between 3-4 hrs and were three times higher than baseline levels. The areas 
under the postprandial FGF19 curve were similar in controls and in the HOMA score-based NAFLD 
subgroups. In NAFLD patients with HOMA score <2.5, the postprandial increase in plasma FGF19 
was accompanied by a lowering of plasma levels of 7α-hydroxy-4-cholesten-3-one (-30%, 
P=0.015). This anticipated decline was not observed in insulin-resistant NAFLD patients (+10%, 
P=0.22). In conclusion, patients with NAFLD show an unimpaired intestinal FGF19 production. 
However, the hepatic response to FGF19 is impaired in NAFLD patients with insulin resistance 
(HOMA score ≥2.5). This impaired hepatic response to FGF19 may contribute to the dysregulation 
of lipid homeostasis in NAFLD. 
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Introduction 
Increased hepatic fat accumulation underlies the development of non-alcoholic fatty liver disease 
(NAFLD). The spectrum of liver abnormalities in NAFLD ranges from simple steatosis to non-
alcoholic steatohepatitis (NASH) when accompanied by inflammation and fibrosis. One fifth of 
NASH patients ultimately develops cirrhosis (4). The etiopathology of NAFLD is far from 
understood. The progression of NAFLD towards NASH has traditionally been explained by a two-
hit model in which initial accumulation of triglycerides (first hit) is followed by inflammatory 
and/or oxidative stress (second hit) resulting in steatohepatitis (8). More recently it has been 
suggested that hepatic deposition of saturated fat in particular, may directly damage the liver and 
mediate progression of plain steatosis to NASH (12). The increasing prevalence of this obesity-
related disorder and its health consequences, necessitate further insight into the causes and 
consequences of hepatic lipid accumulation. 
FGF19 belongs to a subfamily of FGFs that have an endocrine function and has emerged as a novel 
regulator of hepatic lipid homeostasis (5,17). Initial studies in mice transgenic for FGF19 indicated 
a role for FGF19 in whole-body energy and lipid homeostasis (11,32). Specifically, FGF19 
transgenic mice had decreased adiposity and were resistant to high fat diet-induced weight gain. 
Furthermore, transgenic FGF19 expression or infusion of recombinant FGF19 protein reduced 
hepatic lipid accumulation and improved insulin-sensitivity in ob/ob mice (11). The observed in 
vivo effects of FGF19 have been attributed in part to reduced hepatic expression of acetyl-CoA 
carboxylase 2 (Acc2), a negative regulator of mitochondrial fatty acid oxidation. Repression of 
Acc2 in FGF19 transgenic mice may thus deplete hepatic lipid stores by promoting mitochondrial 
fatty acid degradation. In addition, a recent study revealed that FGF19 suppresses insulin-induced 
fatty acid synthesis in isolated hepatocytes (6). Thus, FGF19 appears to influence both hepatic 
fatty acid oxidation and hepatic lipid synthesis. 
It is currently unknown if FGF19 plays a role in the etiopathogenesis of NAFLD. Reduced plasma 
FGF19 levels have been reported for patients with type 2 diabetes mellitus, but the cause of this 
decrease is unknown (30). FGF19 is produced by the small intestine in a bile salt stimulated 
manner (16). Binding of FGF19 to its cognate receptor on hepatocytes activates intracellular 
signaling pathways resulting in repression of bile salt synthesis and, presumably, lipid synthetic 
pathways (6,14,16,17). FGF19 can thus be viewed as a feed-forward signal that informs the liver 
on dietary fat intake and return of bile salts. Reduced plasma FGF19 in type 2 diabetic subjects 
may be due to impaired intestinal FGF19 production, and may contribute to ongoing triglyceride 
synthesis and exacerbation of hepatic steatosis in subjects with NAFLD. In the present study, we 
examined the postprandial FGF19 response in subjects with NAFLD with or without insulin 
resistance. 
 
Experimental Procedures  
Patients and Study Design 
From a prospective database on NAFLD patients, twenty patients between the age of 18 and 75 
years were recruited for participation in this study. Initial diagnosis of NAFLD was based on 
elevated alanine aminotransferase levels (ALT≥45 IU/L), increased echogenicity of the liver on 
ultrasound examination, and exclusion of other chronic liver diseases defined as normal iron and 
copper studies and absence of hepatitis B surface antigen, hepatitis C antibodies and autoimmune 
antibodies (antinuclear antibodies, antibodies to smooth muscle antigens and mitochondria). 
Patients with excessive alcohol intake, defined as more than 2 units/day in male and more than 1 
unit/day in female, were excluded. Following study inclusion, all NAFLD patients underwent 
assessment of hepatic fat content by magnetic resonance spectroscopy (1H-MRS). 
Patients were divided into two groups according to severity of insulin resistance (homeostasis 
model of assessment - HOMA) (2). Following overnight fasting, all study subjects received a 
standardized oral fat challenge consisting of 30 gram cream (35 gram fat per 100 mL) per square 
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meter of body surface area (26). Blood samples were taken from an indwelling cannula placed in a 
cubital vein at baseline and at hourly intervals for up to 7 hrs after oral fat intake. 
During the sampling period, patients were withheld from additional food but had free  access to 
water. Patients gave their informed consent to the protocol of the study which was approved by 
the medical ethical committee of the Academic Medical Center in Amsterdam. 
A previously described cohort consisting of 15 healthy volunteers with an irrelevant medical 
history (26), was used as a control group. These subjects underwent an identical oral lipid 
challenge with blood sampling at baseline and after 2, 3, 4 and 6 hrs. 
 
Determination of hepatic fat content 
The fat content in the liver of NAFLD patients was determined by 1H-MRS. All measurements were 
performed on a 3.0 Tesla Philips Intera scanner (Philips Healthcare, Best, The Netherlands). A 
voxel of 20 x 20 x 20 mm was positioned in the right hepatic lobe, avoiding vascular, biliary and 
extrahepatic structures. Spectra were acquired using first order iterative shimming, a PRESS 
sequence with TE/TR=35/2000 ms and 64 signal acquisitions. The water (4.7 ppm) and fat (1.3 
ppm) resonance peaks were integrated using jMRUI software (25) and relative fat content was 
expressed as a ratio of the fat peak area over the cumulative water and fat peak areas. Calculated 
peak areas of water and fat were corrected for T2 relaxations (T2water=34ms, T2fat=68ms, ref. 9) 
and the percentage hepatic fat content was calculated according to Szczepaniak et al. (31). 
 
Blood chemistry 
Following collection of blood in EDTA tubes, plasma was prepared and analyzed for levels of 
glucose, insulin, C-reactive protein, and liver enzymes at baseline (t=0 hrs). Triglycerides (TG), 
total cholesterol, FGF19 and total bile salts (Diazyme, Poway CA) were assayed at baseline and at 
the respective sampling points after oral fat intake. Baseline interleukin-6 (IL-6) levels were 
determined by sandwich ELISA (Sanquin, Amsterdam, The Netherlands). 7α-hydroxy-4-cholesten-
3-one (C4) levels, a plasma marker for bile salt synthesis, were determined at baseline and at 4 
and 5 hours after oral fat intake as previously described (19). C4 levels were expressed relative to 
total cholesterol, as their ratio was shown to be a more accurate marker of bile salt synthesis (15). 
 
Determination of plasma FGF19 
Plasma FGF19 levels were determined using an in-house developed sandwich ELISA described in 
detail elsewhere (Schaap et al., manuscript in preparation). Briefly, microtiter plates were coated 
with goat anti-human FGF19 antibody (AF969, R&D Systems, Minneapolis, MN). Samples and 
recombinant FGF19 standards (R&D Systems) were diluted in PBS containing 1.0% casein and 
0.05% Tween-20. Captured antigen was detected with biotinylated goat anti-human FGF19 
antibody (BAF969, R&D Systems) and streptavidin-HRP using tetramethylbenzidine as 
chromogenic substrate. 
 
Data and statistical analysis 
Area under the postprandial curve (AUC) was calculated using baseline-subtracted values 
employing GraphPad Prism (GraphPad Software Inc., La Jolla, CA). For comparison with the 
historical control population, data derived from time points that were missing (i.e. T=1, 5 and 7 
hrs) in the sampling scheme of the controls were omitted for AUC calculations (denoted as AUC0-6 
hrs). Descriptive statistics are expressed as mean ± standard deviation. Within each group, a paired 
t test was used to evaluate changes from baseline during the oral fat challenge. Differences 
between groups (AUC or individual time points of the postprandial curves) were evaluated by 
Student's t test, Mann-Whitney U test or one-way ANOVA with Bonferroni post hoc testing. 
Statistical analyses were performed with SPSS version 16.0 (SPSS Inc., Chicago, IL). Statistical 
significance was accepted at P < 0.05. 
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Results 
Patient characteristics 
Table 1 shows the characteristics of the controls and the NAFLD groups. As expected, NAFLD 
patients were obese (BMI >30). Hyperglycemia and hyperinsulinemia in the NAFLD population 
was attributable to patients with HOMA score >2.5. Nine NAFLD patients fulfilled the American 
Diabetes Association criteria for type 2 diabetes mellitus (2). The majority of these patients (6 out 
of 9) was treated with metformin. Five diabetic patients had dyslipidemia (TG >1.7 mmol/L and/or 
HDL-cholesterol <0.9 mmol/L (1)). Two patients were treated with statins. 
 
Plasma FGF19 levels in NAFLD patients 
Baseline FGF19 levels in NAFLD patients (0.18±0.09 ng/mL) were comparable to values in the 
studied controls (0.26±0.28 ng/mL, P=0.94) and to values recently reported for an unrelated 
control population (0.28±0.20 ng/mL) (28). Furthermore, baseline plasma FGF19 levels were 
identical (P=1.00) in the HOMA-based NAFLD subgroups. Baseline FGF19 levels in NAFLD patients 
showed a weak inverse correlation (Spearman's r = -0.47, P=0.038) with baseline plasma levels of 
7α-hydroxy-4-cholesten-3-one (C4), a marker for bile salt synthesis. This appears in line with 
FGF19's role in negative regulation of bile salt synthesis. Baseline FGF19 levels showed no 
correlation with hepatic fat content or HOMA score (data not shown). Baseline bile salt levels 
were elevated in NAFLD patients with a HOMA score >2.5 in comparison with controls (P<0.001) 
and NAFLD patients with a HOMA score <2.5 (P=0.006) (Table 1). 
 
 
Table 1. Characteristics 
and baseline values of 
controls, NAFLD patients 
and the HOMA score-
based subgroups. 
 
All values are expressed as 
mean±SD. *P-values are for 
comparison between the 
HOMA <2.5 and HOMA ≥2.5 
subgroups. Part of the data in 
the control group has been 
published previously (26). 
Abbreviations: n.d. = not 
determined, ALT = alanine 
aminotransferase, γGT = γ-
glutamyltransferase, TG = 
triglycerides, TC = total 
cholesterol, CRP = C-reactive 
protein, C4 = 7-hydroxy-4-
cholesten-3-one. 
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Postprandial responses in NAFLD patients 
Entry of dietary fat in the duodenum causes gallbladder contraction and inflow of bile salts into 
the intestinal lumen (13). Reabsorption of bile salts in the distal part of the small intestine 
activates the bile salt receptor FXR resulting in enhanced transcription and portal release of FGF19 
(16). The postprandial excursions of TG, bile salts and FGF19 in control subjects and NAFLD 
patients are depicted in Figure 1. 
Packaging of digested dietary lipids into chylomicrons and their release into lymph, causes an 
increase in plasma TG levels (Figure 1A). As reported earlier for the volunteer group (26), a 
postprandial increase in TG was first noted after 2 hrs. TG levels peaked after 3 hrs in controls and 
between 3 and 4 hrs in NAFLD patients. The total area under the postprandial TG curve (AUCTG 0-
6hrs) was elevated in NAFLD patients (4.1±3.2 vs. 2.1±1.4 mmol.L-1.hr-1 in controls, P=0.013). 
During the ascending phase of the postprandial TG excursion, TG production (i.e. chylomicron 
synthesis) predominates. The area under the ascending part of the curve (AUCTG 0-3hrs) was not 
different (1.4±1.3 vs. 1.0±0.6 mmol.L-1.hr-1 in NAFLD patients and controls, resp., P=0.079). In the 
descending phase of the postprandial TG curve, clearance of TG-rich lipoproteins prevails. The 
area under the descending part of the curve (AUCTG 3-6hrs) was elevated in NAFLD patients (2.7±2.1 
vs. 1.1±1.0 mmol.L-1.hr-1 in volunteers, P=0.002). The latter appears in line with impaired TG 
clearance in insulin-resistant subjects (23). This notion is supported when ascending, descending 
and total AUCTG values for the control and the HOMA-based NAFLD subgroups are compared. 
This analysis revealed that total and descending AUCTG values are significantly elevated in the 
NAFLD HOMA ≥2.5 subgroup only (data not shown). Thus, the observed difference in AUCTG 0-
6hrs is likely due to impaired TG clearance in insulin-resistant NAFLD patients. This also indicates 
that gastrointestinal passage and handling of ingested lipids is similar in controls and both NAFLD 
subgroups. 
Following an oral fat challenge, an incline in plasma bile salt levels is apparent after 1 hr in NAFLD 
patients, with levels reaching a maximum after 3-4 hrs (Figure 1B). In control subjects, which were 
first sampled after 2 hrs, bile salt levels peak after 2 hrs and return to baseline levels after 6 hrs. In 
contrast, bile salts remain elevated at this and at the final time point in NAFLD patients (Figures 
1B and 2A). After gallbladder contraction-induced entry into the duodenum, bile salts are 
efficiently reclaimed from the small intestinal lumen and released into the portal circulation. First-
pass clearance of bile salts by the liver is highly efficient with little systemic spill-over and is 
depending on the Na+ taurocholate co-transporting protein (NTCP) (13). As can be appreciated 
from Figure 1B, the postprandial bile salt excursion is different in controls and NAFLD patients. 
Bile salts levels were significantly higher in NAFLD subjects at time points T=0 (P=0.004), T=4 
(P=0.015) and T=6 hrs (P=0.001) and this was entirely attributable to NAFLD patients with HOMA 
score ≥2.5 (data not shown). The AUCBS 0-6 hrs tended to be elevated in NAFLD patients 
(67.3±47.7 vs. 47.1±29.4 μmol.L-1.hr-1 in controls, P=0.09). NAFLD patients with HOMA score ≥2.5 
(75.8±59.9 vs. 54.5±14.9 μmol.L-1.hr-1 in the HOMA<2.5 subgroup, P=0.43) largely accounted for 
this tendency. Since these results suggest impaired hepatic bile salt uptake we measured 
interleukin-6 (IL-6), a known regulator of NTCP expression (3). NAFLD patients with HOMA score 
≥2.5 showed elevated IL-6 levels in comparison with controls (2.1±1.6 vs. 0.9±0.6 pg/mL, resp., 
P=0.005, Table 1). 
Following fat ingestion, a slight drop in plasma FGF19 level occurs after 1 hr in NAFLD patients. 
Plasma FGF19 was significantly elevated after 2 hrs in control subjects, and after 3 hrs in NAFLD 
patients (Figure 1C). Postprandial FGF19 levels peaked between 3-4 hrs in controls and NAFLD 
patients and remained elevated in both groups until the last sampling point. Peak postprandial 
FGF19 levels were 3.0 fold higher in comparison with baseline levels in both controls and in 
NAFLD patients. The postprandial excursion of FGF19 closely followed that of bile salts, although 
some lagging was apparent. This is in line with bile salt mediated induction of ileal FGF19 
expression (14,16). When analyzing individual time points, no significant differences in plasma 
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FGF19 level were apparent between controls and NAFLD patients. The AUCFGF19 0-6 hrs was however 
significantly lower in NAFLD patients (1.4±1.3 vs. 1.9±1.4 ng.mL-1.hr-1 in controls, P=0.032). 
 
 
Figure 1. Plasma levels of triglycerides, bile 
salts and FGF19 increase after an oral fat 
challenge. Following overnight fasting, control subjects 
(open symbols) and NAFLD patients (closed symbols) 
received a standardized oral fat challenge. Serial blood 
samples were drawn at the indicated time points, and 
plasma was assayed for triglycerides (A), total bile salts (B) 
and FGF19 (C). Data points are depicted as mean±SD. 
Asterisks denote significant changes from baseline values 
(T=0) in the respective groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Influence of insulin-resistance on the postprandial FGF19 response in NAFLD patients 
Both NAFLD subgroups displayed similar postprandial bile salt excursions (Figure 2A) and had 
indistinguishable AUCBS 0-7hrs values (61.2±17.8 vs. 85.1±69.6 μmol.L-1.hr-1 in the HOMA<2.5 and 
HOMA≥2.5 subgroups, resp., P=0.47). The postprandial FGF19 response in HOMA-based NAFLD 
subgroups is shown in Figure 2B. Plasma FGF19 is significantly elevated above baseline levels after 
3 hrs in the HOMA<2.5 subgroup (P=0.018) and, albeit with borderline significance, in the 
HOMA≥2.5 subgroup (P=0.051). Postprandial FGF19 levels peaked at 3 and 4 hrs in the HOMA<2.5 
and HOMA≥2.5 subgroups, respectively. Mean FGF19 levels in the NAFLD subgroups were not 
different at any of the individual time points. The AUCFGF19 0-7hrs was similar in both NAFLD 
subgroups (1.6±1.3 vs. 1.4±1.5 ng.mL-1.hr-1 in the HOMA<2.5 and HOMA≥2.5 groups, resp., 
P=0.49). In addition, analysis of variance indicated that AUCFGF19 0-6hrs values were not significantly 
different in controls and the two NAFLD subgroups (ANOVA PALL=0.081). 
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Figure 2. Postprandial bile salt and 
FGF19 excursions in NAFLD patients are 
not affected by insulin-resistance.  
 
The postprandial responses in NAFLD patients 
(Figure 1) were analyzed separately in each 
HOMA-based subgroup. Postprandial excursions 
of both bile salts and FGF19 are similar in NAFLD 
patients with (HOMA≥2.5, black symbols) and 
without (HOMA<2.5, grey symbols) insulin-
resistance. Data points are depicted as mean±SD. 
Asterisks and number signs denote significant 
changes from baseline values (T=0) in the 
HOMA<2.5 and HOMA≥2.5 groups, respectively. 
 
 
 
 
 
 
 
Elevation of plasma FGF19 is expected to result in diminished bile salt synthesis through 
downregulation of hepatic CYP7A1 mRNA (14,16). Plasma C4, a marker for bile salt synthesis, was 
determined in NAFLD patients at baseline, and at 4 and 5 hrs following an oral fat challenge. 
Despite similar postprandial elevation of FGF19 in both NAFLD subgroups (Figure 3, upper panel), 
C4 levels declined after 5 hrs only in the HOMA<2.5 group (-30%, P=0.015) while remaining 
unchanged in the HOMA≥2.5 group (+10%, P=0.22) (Figure 3, lower panel). 
 
 
Figure 3. Postprandial elevation of FGF19 in 
insulin-resistant NAFLD subjects is not 
accompanied by reduction of C4 levels.  
Plasma FGF19 (upper panel) and C4 (bottom panel) levels 
were determined at baseline (white bars) and at 4 hrs (grey 
bars) and 5 hrs (black bars) after an oral fat challenge. In 
NAFLD patients with normal HOMA score (HOMA<2.5), the 
postprandial increase in FGF19 levels was accompanied by an 
expected decline in C4 levels, a marker for bile salt synthesis. 
In contrast, C4 levels were unaffected in insulin-resistant 
NAFLD patients (HOMA≥2.5) despite a similar postprandial 
elevation of FGF19 level. Data points are depicted as 
mean±SD. 
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Discussion 
Recent findings indicate a role for the endocrine factor FGF19 in the regulation of hepatic lipid 
metabolism (6,11,32). Altered intestinal FGF19 production and/or altered hepatic responsiveness 
to FGF19 may accordingly contribute to the dysregulation of lipid homeostasis encountered in 
NAFLD. In this study, we evaluated the postprandial FGF19 response following an oral fat 
challenge in healthy volunteers and in NAFLD patients with and without insulin resistance. The 
major novel finding of this study is that the response of the liver to elevated plasma FGF19 levels 
is impaired in insulin-resistant NAFLD patients. 
FGF19 is an integral part of a regulatory mechanism by which bile salts negatively regulate their 
own synthesis (14,16). Having fulfilled their function in digestion and absorption of dietary lipids 
in the proximal parts of the small intestine, bile salts are reclaimed in the terminal ileum (13). This 
results in activation of the bile salt-activated transcription factor FXR and transcriptional induction 
of FGF19, an ileal FXR target gene (16). Binding of FGF19 to its cell surface receptor on 
hepatocytes results in repression of bile salt synthesis via downregulation of CYP7A1 (14,16). In 
this study we used a physiological stimulus, viz. a fatty meal, to induce gallbladder contraction and 
accordingly stimulate intestinal FGF19 production. The functional consequence of postprandial 
elevation of FGF19 levels was assessed by measurement of plasma C4, a marker for bile salt 
synthesis. 
 
A standardized oral fat challenge resulted in elevation of bile salt levels after 1 hr, followed by an 
increase in plasma FGF19 level after 2-3 hrs (Figure 1). In line with an earlier study in volunteers 
receiving regular meals (21), FGF19 levels show a postprandial peak after 3-4 hrs. Healthy 
volunteers and NAFLD patients had comparable fasted FGF19 levels (0.26±0.28 ng/mL vs. 
0.18±0.09 ng/mL, resp., P=0.94) and displayed a similar postprandial FGF19 response. Peak 
postprandial FGF19 levels were 3.0 fold higher than baseline values in both groups. The 
AUCFGF19 0-6hrs appeared somewhat lower in NAFLD patients in comparison with the volunteers 
when considering the entire NAFLD group (1.4±1.3 vs. 1.9±1.4 ng.mL-1.hr-1 in controls, P=0.032), 
but was indistinguishable when comparing the volunteers and the two HOMA-based NAFLD 
subgroups by ANOVA (PALL=0.081). 
 
Postprandial elevation of plasma FGF19 is expected to result in repression of bile salt synthesis. 
Indeed, plasma C4 levels were decreased following postprandial peaking of FGF19 levels in NAFLD 
patients with a normal HOMA score (Figure 3B). Interestingly, such decline in C4 levels was not 
observed in insulin-resistant (i.e. HOMA score≥2.5) NAFLD patients. As postprandial FGF19 levels 
in the HOMA-based NAFLD subgroups were similar at all individual time points, this leaves the 
possibility that the response of the liver to FGF19 is impaired in insulin-resistant NAFLD patients. 
In addition to an apparently impaired hepatic response to FGF19 in NAFLD patients with a HOMA 
score≥2.5, we noted an altered postprandial bile salt excursion in this patient group. Similar 
postprandial FGF19 excursions in controls and both NAFLD patient groups suggests that ileal bile 
salt reclamation proceeds similarly in these groups, it is thus tempting to speculate that the 
hepatic uptake of bile salts is reduced in NAFLD patients with HOMA score≥2.5. Reduced first-pass 
clearance of bile salts by the liver would result in a higher systemic spill-over of bile salts and 
consequently prolonged circulation times. Pro-inflammatory cytokines released from inflamed 
adipose tissue have been implicated in the development of hepatic insulin-resistance (22), and 
among these IL-1β and IL-6 are known to reduce NTCP expression (3,10). Elevated IL-6 levels in 
NAFLD patients with HOMA score≥2.5 (Table 1) may thus have contributed to the altered 
postprandial bile salt excursion in this patient group. 
Activation of the hepatic FXR/SHP axis by bile salts has been implicated in the regulation of bile 
salt synthesis (7,27). Could reduced hepatic uptake of bile salts account for the absence of a 
postprandial decline in plasma C4 levels in NAFLD patients with HOMA score≥2.5? 
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Although this cannot be ruled out in the present study, several lines of evidence implicate the 
intestinal FXR/FGF19 axis as the principal mediator of bile salt-mediated repression of bile salt 
synthesis. Firstly, by-passing the small intestine through direct infusion of taurocholate in the 
portal or systemic circulation, failed to downregulate Cyp7a1 expression in the rat (24). Secondly, 
in mice lacking intestinal FXR the expression of Cyp7a1 is unaffected by FXR agonists whereas in 
mice lacking hepatic FXR, Cyp7a1 is effectively repressed following FXR agonism (18). Moreover, 
bile salt-mediated negative feedback control of Cyp7a1 expression was lost in mice deficient for 
either FGF15 or its receptor FGFR4 (16). Thirdly, postprandial increases in plasma FGF19 levels 
rather than postprandial increases in bile salt levels are followed by a decline in plasma C4 levels 
(21). Taken into account the above findings, it is unlikely that reduced hepatic bile salt uptake 
underlies the absence of a postprandial decline in plasma C4 levels in NAFLD patients with HOMA 
score≥2.5.  
 
What mechanism could underlie the apparently abrogated hepatic response to FGF19 in insulin-
resistant NAFLD patients? Altered expression of the FGF19-receptor FGFR4 and/or the obligate 
signaling cofactor βKlotho may be an underlying factor. A recent study revealed that expression of 
hepatic FGFR4 mRNA was reduced after prolonged fasting as well as in streptozotocin-induced 
diabetic mice, while insulin-treatment induced hepatic FGFR4 mRNA expression in mice (29). 
Hepatic expression of βKlotho was affected by none of these treatments. No information is 
available on FGFR4 expression in the insulin-resistant human liver, although microarray analysis 
suggests that FGFR4 expression is somewhat reduced in the liver of insulin-resistant, leptin-
deficient mice (20). Apart from altered signal transduction at the level of the plasma membrane, 
intracellular relay of the FGF19 signal may be affected in the insulin-resistant liver. FGF19 was 
recently shown to reduce insulin-stimulated fatty acid synthesis and lipogenic gene expression in 
hepatocytes (6). This suggests that FGF19 signaling interferes with insulin signaling. Whether such 
interference is mutual, and whether it is maintained in the insulin-resistant state is unknown. 
Adding complexity to a possible cross-talk between FGF19 and insulin signaling pathways, recent 
studies in mice indicate that FGF19 signals -at least in part- through the insulin-activated PI3K 
pathway (29). 
 
In conclusion, a reduced response of the liver to FGF19 in NAFLD patients with insulin resistance 
may result in further derangement of hepatic lipid homeostasis. Further studies will be required 
to address the mechanisms by which insulin-resistance affects the hepatic response to FGF19 and 
if this impaired response contributes to the pathology in NAFLD. 
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Abstract  
Type 2 diabetes mellitus is a risk factor for the development of non-alcoholic fatty liver disease 
(NAFLD). Patients with NAFLD at risk for developing cirrhosis are increasing and elevated plasma 
ferritin levels may be a marker. We studied relations between correlates of the metabolic 
syndrome, ferritin levels and presence of NAFLD in patients with T2DM.  
In a cross-sectional analysis of T2DM patients medical files were reviewed and liver enzymes 
assessed. In case of derangements other causes of chronic liver diseases were excluded and semi-
quantitative assessment of NAFLD by ultrasound performed.  
Of 310 enrolled Caucasian patients, 33% had liver enzyme derangements. Patients with ALT>28 
IU/L were comparable to those with normal ALT levels in terms of age, use of alcohol, T2DM 
duration, medication used, glycaemic control and cardiovascular disease. HDL was higher in 
patients with normal ALT compared to those with ALT > 28 IU/L (P<0.05). T2DM patients with 
increased ferritin (>100 ng/mL) had significant elevated levels of Gt (85  107 IU/mL versus 48  
39 IU/mL, p=0.04), but not ALT. However, ferritin levels were not significant different between 
normal and increased ALT levels and amount of hepatic steatosis. 
Ferritin levels in T2DM patients with normal and increased ALT were not significant different. 
Within the normal range ferritin levels cannot distinguish T2DM with or without NAFLD. 
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Introduction 
Due to the increasing prevalence of obesity, non-alcoholic fatty liver disease (NAFLD) has become 
the most common cause of chronic liver disease in children and adults. It encompasses a 
spectrum of fairly only fatty infiltration of liver parenchyma (simple steatosis) to inflammation 
and pericellular fibrosis (non-alcoholic steatohepatitis (NASH)) and, if untreated, can result in liver 
cirrhosis [1, 2]. Risk factors are the presence of obesity, insulin resistance, type 2 diabetes mellitus 
(T2DM) or any other features consistent with the metabolic syndrome. Calculated incidence 
numbers of NAFLD are 33% in general population and 69% in populations with T2DM patients and 
of NASH vary from 3 to 10% depending on population selection and region [3, 4].  
Liver biopsy remains the golden standard for diagnosing NASH. However, (life threatening) 
complications, sampling error and inter-observer variability can occur. For large population 
screening this technique is not suitable. Therefore a significant amount of research in the past, as 
well as more recent work has been done on the use of non-invasive markers in order to evaluate 
patients at risk for developing advanced fibrosis and cirrhosis. Increased liver enzymes, e.g. 
alanine aminotransferase (ALT), are the primary abnormality seen in patients with NASH. 
However, these levels are seldom higher than five times upper limit of normal and may fluctuate. 
Furthermore, evidence is present that this is already the case in high normal values (>28 UI/L) [5, 
6]. The diagnostic accuracy for NASH is poor with a sensitivity of approximately 40% [7]. In 
addition, further studies on fibrosis markers [8-12], biomarkers of oxidative stress [13-18], 
hepatocyte apoptosis [19-21] and inflammation [22-25] have been published. 
Hyperferritinaemia has been demonstrated in patients with NASH compared to those without 
hepatic inflammation [26-29]. However others report contrasting results lacking ferritin as a 
discriminating serological marker [30].  
This cross-sectional study investigates relations between correlates of the metabolic syndrome, 
hyperferritinaemia and the presence of NAFLD in T2DM patients treated in a non-academic 
teaching hospital.  
 
Materials/methods 
T2DM patients treated at the outpatient clinic of St. Lucas Andreas Hospital in Amsterdam, the 
Netherlands, a non-academic teaching hospital, were asked for participation from August 2006 till 
December 2008. The study protocol was approved by the institution’s human research committee 
according to the ethical guidelines of the 1975 Declaration of Helsinki. After written informed 
consent, patients’ medical files were analysed with specific interest for daily alcohol intake, time 
of diagnosis of T2DM, prescribed medication, total units of administered insulin/day and 
complications associated with T2DM (cardiovascular, peripheral vascular disease and 
neuropathy). Subjects with known and well-documented hemochromatosis were excluded. 
Findings of physical examination (weight, height and blood pressure) were noted. Additional 
blood testing was performed (HbA1c (HPLC-method, Tosoh Bioscience, Tessenderlo, Belgium), 
creatinin, lipids (total cholesterol (TCHOL), high- (HDL) and triglycerides (TG)), fasting glucose and 
liver enzymes ALT (normal < 45 IU/L), aspartate aminotransferase (AST) (normal < 40 IU/L), 
gamma-glutamyl-transpeptidase (γGt) (normal < 50 IU/L), alkaline phosphatase (AP) (normal < 
100 IU/L), bilirubin (normal < 17 µmol/L) (all Vitros Microslide Assays, Orthoclinical Diagnostics, 
Tilburg, the Netherlands) and low density lipoproteins (LDL) (Vitros Microtip Assay, Orthoclinical 
Diagnostics, Tilburg, the Netherlands). Between brackets are mentioned normal values according 
to the manufacturers’ manual. 
When one or more liver enzymes were abnormal (above upper limit), further testing was done for 
excluding other causes for (chronic) liver disease, such as viral antibodies (HBsAg (hepatitis B 
surface antigen) and antibodies to hepatitis C) and iron studies (serum iron, transferrin saturation 
and ferritin) . Additionally, real time ultrasound of the liver was performed in these patients with 
deranged liver enzymes to semi-quantitatively assess hepatic steatosis as previously described 
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[31]: mild, moderate and severe.   
 
Statistical analysis 
All available data were entered in a central database and analysed using SPSS Statistics 12.0 
software (SPSS, Chicago, IL, USA). Results are expressed as means  SD, unless otherwise 
indicated. The t-test or Wilcoxon rank sum test, as appropriate, was used for univariate 
comparisons between groups. Calculations of correlation coefficients were used to test for 
associations between the variables. P-values < 0.05 were considered significant. 
 
Table 1. Demographics of patients with normal and increased ALT (n=310) 
 
 ALT ≤ 28 IU/L 
(n=85) 
ALT > 28 IU/L 
(n=225) 
p 
Gender m/f 33 / 52 136 / 89 0.001 
Age (yrs) 65 ± 13 63 ± 12 ns 
T2DM (yrs from diagnosis) 16.2 ± 7.8 14.9 ± 8.0 ns 
Medication (insulin, %)
**
 72 70 ns 
Dose insulin (units)
***
 73 ± 56 67 ± 46 ns 
Alcohol none-mild vs moderate-
severe (%) 
91 / 9  91 / 9 ns 
Systolic BP 146 ± 25 143 ± 22 ns 
Diastolic BP 81 ± 16 78 ± 11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ns
Body mass index (kg/m
2
) 31.0 ± 6.4 31.1 ± 6.6 ns 
HbA1c (%) 7.8 ± 1.4 7.8 ± 1.4 ns 
Cholesterol (mmol/L) 4.6 ± 1.1 4.3 ± 1.0 0.02 
Triglycerides (mmol/L) 1.85 ± 1.44 2.07 ± 1.62 ns 
Creatinin (µmol/L)  88 ± 37 89 ± 31  ns 
γ-Gt (mmol/L) 31 ± 40 46 ± 57 0.007 
ALT (IU/L) 24 ± 3 43 ± 15 <0.001 
Ferritin (ng/mL) 82 ± 72 135 ±223 0.07 
 
All values are expressed as means ± SD 
p < 0.05 considered statistically significant 
*
 Oral antidiabetic medication versus insulin containing regiments 
** 
Mean
 
dose insulin of patients using insulin therapy 
 
Results 
In this study, 310 Caucasian subjects were enrolled and subsequent liver enzymes assessed. Of 
these subjects, over one third (33%) had one or more abnormal liver enzymes (AST, ALT, γGt or 
AP). In 202 T2DM patients liver enzymes were normal. Eventually, due to deranged liver enzymes 
108 subjects were further tested (collecting medical data from patient files and additional 
serological testing). Other causes for chronic liver disease could be excluded in all 108 subjects 
(e.g. chronic hepatitis B or C, iron storage disease (normal transferrin saturation or alcohol abuse).  
The normal ALT level has been under debate since studies have shown that in healthy populations 
95th percentile is lower than expected. Derived from these studies normal ALT levels were set at  
28 IU/ml. 
Of 310 subjects, 85 T2DM patients appeared to have normal ALT levels  28 IU/ml versus 225 with 
increased ALT levels > 28 IU/mL (range 29-141 IU/mL). 
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When taking into consideration ALT as the most easily available non-invasive predictor for NAFLD 
and new onset of metabolic complications [32-34], two groups could be identified; ALT ≤ 28 IU/L 
and ALT > 28 IU/L.  
Both groups of T2DM2 patients were comparable with regards to age, use of alcohol (>90% none 
to mild use), years from diagnosis, medication used (approximately half of patients used 
metformin and 70% was on subcutaneously insulin-containing treatment), glycaemic control 
(HbA1c 7.8%) and prevalence of cardiovascular disease (hypertension, peripheral vascular disease 
and coronary arterial disease).  
Overall, 30-40% of patients with T2DM had TG levels > 2.26 mmol/L, and 10% had TG > 4.51 
mmol/L. Levels of cholesterol (4.6  1.1 mmol/L versus 4.3  1.0 mmol/L, p=0.02) appeared to be 
significant increased in T2DM patients with normal ALT levels ( 28 IU/ml). LDL cholesterol was 
not significant different (2.66  1.02 mmol/L versus 2.51  0.96 mmol/L, P), whereas HDL 
cholesterol was increased in T2DM patients with normal ALT levels ( 28 IU/ml) (1.31  0.40 
mmol/L versus 1.12  0.35 mmol/L, p<0.001). As expected, γGt was increased in those T2DM 
patients with increased ALT levels (> 28 IU/ml) as a consequence of more pronounced 
accumulation of hepatic fat.   
 
Levels of ferritin inclined to significance where in T2DM patients with increased ALT levels (> 28 
IU/ml, these levels were elevated and tended to significance (82 ± 72 ng/mL versus 135 ± 223 
ng/mL, p=0.07). Table 1 demonstrates the demographics of these subjects.  
Two third of T2DM patients had ferritin levels exceeding 100 ng/mL (ranging from 101 ng/mL 
through 1790 ng/mL) (Figure 1).  
 
When having a closer look at these subjects compared to those with normal ferritin, no significant 
differences could be found in terms of age, body mass index, glycaemic (HbA1c and glucose) and 
lipid (total cholesterol, HDL and LDL) control. However, T2DM patients with increased ferritin had 
significant elevated levels of Gt (85  107 IU/mL versus 48  39 IU/mL, p=0.04).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peripheral vascular and cardiac complications were comparable between both groups, even when 
the ALT level (cut off 28 IU/mL) was included in the analysis. No other differences in plasma 
markers for glycaemic and lipid control were found.  
Figure 1. Levels of ferritin (ng/mL) 
according to normal or elevated ALT 
levels              
 
 
 
 
Figure 2. Body mass index is 
associated with amount of hepatic 
steatosis in T2DM patients 
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One hundred and five abdominal ultrasounds were available for adequate analysis in terms of 
semi-quantification of hepatic steatosis. The degrees of steatosis on a scale of 1-4; absent (1), 
mild (2), moderate (3) and severe (4) were 27%, 27%, 32% and 14%, respectively. No significant 
differences could be demonstrated between T2DM patients with normal and elevated ALT levels. 
However, subjects with increasing BMI had significant more pronounced hepatic steatosis 
assessed by ultrasound (p<0.001, Figure 2). This is in contrast to the non-significant differences in 
ferritin and ALT levels between the various grades of hepatic fat (Figure 3).   
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 
 
This cross sectional analysis reports on the interaction of hepatocellular damage (defined by 
normal or increased ALT levels), hyperferritinaemia and semiquantification of hepatic fat by 
ultrasound in a complicated T2DM patients population treated at a non-academic teaching 
hospital. The investigated subjects differ from those T2DM patients seen in a general practice. 
This population had longstanding diabetes (over 10 years) with the majority (70%) on insulin 
treatment versus those in a general practice with approximately 5 years of T2DM and less in need 
for insulin (30%) [35].  
 
Lipids, abdominal ultrasound and NAFLD 
Many studies on T2DM patients and dyslipidaemia have been published. The most typical 
lipoprotein pattern in diabetes consists of moderate elevation in TG levels, low HDL cholesterol 
values, and small dense LDL particles. This lipoprotein pattern is associated with insulin resistance 
and is present even before the onset of T2DM. LDL cholesterol levels in T2DM patients are 
generally similar to those found in the general population. However, HDL cholesterol is 
significantly decreased,accompanied with elevated TG levels in T2DM patients. This is among 
others the result of decreased lipoprotein lipase activity and impaired VLDL output suppression in 
the liver due to insulin resistance.   
Due to its accessibility, low costs and non-invasiveness, abdominal ultrasound is frequently used 
as the screening tool for the presence of NAFLD. In the late eighties and early nineties, several 
reports focused on semi-quantifying benign liver diseases [31, 38]. Last year Hernaez et al. 
published a meta-analysis demonstrating the use of ultrasound in NAFLD. Procedure 
characteristics in patients with moderate-severe hepatic steatosis are sensitivity 84.8%, specificity 
93.6% and kappa statistics ranging from 0.54 to 0.92 for intra-observer reliability and 0.44-1.00 
for inter-observer reliability (AUROC 0.93) [39]. In line with these results, our study pointed out 
the feasibility to semiquantify hepatic steatosis. Those T2DM patients with moderate to severe 
hepatic steatosis were more obese and had significant increased levels of Gt. This liver enzyme 
has been correlated with increased risk of cardiovascular morbidity and mortality in patients with 
NAFLD [40, 41]. In a recent genome wide assocation study by Middelberg et al. significant overlap 
Figure 3. Levels of ferritin (ng/mL) 
according to hepatic steatosis assessed 
by ultrasound 
1 = none, 2 = mild, 3 = moderate and  
4 = severe 
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between genes affecting Gt and those affecting common metabolic and inflammatory diseases 
could be demonstrated [42]. They identified the hepatic nuclear factor family as controllers of a 
network of genes affecting Gt.  
 
Hypotheses of hyperferritinaemia and NAFLD 
Increased serum ferritin levels, as an acute phase reaction, can be seen in systemic inflammatory 
conditions (renal, hepatic and malignant diseases). In the past few years the role of iron 
metabolism has been under investigation in patients with viral hepatitis. Iron has been 
demonstrated to cause liver damage and fibrosis through interaction with oxygen radicals [27].  In 
patients with NASH moderate elevations of ferritin have been found [43-47].  
Recent results from the NASH Clinical Research Network (NASH-CRN) stressed serum ferritin (for 
male > 450 ng/mL and female > 300 ng/mL) as an independent predictor of histologic severity and 
advanced fibrosis in patients with NAFLD [48]. Of these patients 26% (n=164) suffered from 
T2DM. Since “cut off values” of ferritin have been somewhat arbitrarily chosen in other reports 
and depend on the used laboratory technique, in our study we used a cut off value of 100 ng/mL. 
Pathophysiological hypotheses vary from one study to the other. Some authors concluded that 
ferritin was released from damaged hepatocytes [46, 49]. Japanese researchers focused on 
genetic polymorphisms in the HFE gene known to be linked to hereditary hemochromatosis (i.e. 
C282Y and H63D) [50]. No differences were found in these gene expressions between patients 
with NASH and healthy controls. This is in line with the results found in the NASH-CRN study. 
Possible inborn errors or acquired mutations of iron metabolism as a possible cause for 
hyperferritinaemia can be therefore excluded. Additionally, previous liver histology studies could 
clearly exclude hepatic iron overload as a contributor to increased serum ferritin levels [49, 51, 
52].  
Mitsuyoshi et al. analyzed a panel of genes involved in fatty acid and iron metabolism [53]. They 
concluded that during liver disease progression, steatosis-related metabolism is diminished and 
iron-metabolism increased. This was demonstrated by the down-and up-regulation of transcript 
levels of specific steatosis-and iron-metabolism-related genes respectively. Their suggestion was 
to adapt  appropriate therapeutic options according to the stage of the disease: in early stages 
treatment should be targeted at improving lipid homeostasis and in later stages at ameliorating 
excess of iron accumulation. Others report positive effects on insulin sensitivity of phlebotomy in 
patients with advanced stages of NAFLD [54].  
Work by Aigner et al. elegantly studied putative pathways in patients with NAFLD underlying the 
mild presence of iron accumulation [55]. Sixty-one patients and 20 controls were included. All 
subjects underwent liver biopsy and upper endoscopy with duodenal biopsies. In physiological 
conditions, liver cells and enterocytes contain only one iron exporter, ferroportin-1 (FP-1). FP-1 
expression was determined in acquired histological material of all patients. In patients with NAFLD 
there was a clear down-regulation of FP-1 mRNA which correlated with BMI and TNF-α-
concentrations. This is suggestive for inflammation induced by visceral adipose tissue as a cause 
for down-regulation. These findings were further supported by decreased FP-1 formation in 
HepG2 cells on stimulation with TNF-α in vitro. These findings are in accordance with previous 
reported results in which ferritin is a marker of histological progressive liver damage. Manousou 
et al reported in multivariate regression analysis the association of BMI, AST, presence of diabetes 
and levels of ferritin with the presence of NASH (AUROC 0.91) [56]. However, some others have 
refuted this relationship between hyperferritinaemia and grades of hepatic steatosis. Chandok et 
al  [30] could not demonstrate in 482 subjects differences in ferritin. They hypothesize that 
patients with more advanced stages of NAFLD (and NASH) have an intrinsic inability to upregulate 
endothelial protective mechanisms. These patients are in turn more prone for advanced liver 
disease. In this study, only 17% of subjects were treated for T2DM. Taking into consideration 
aberrant ferritin levels according to values adapted from the Hemochromatosis and Iron Overload 
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Screening Study (female < 200 ng/mL and male < 300 ng/mL), it is remarkable that only 9% of 
subjects had increased ferritin levels. In accordance with this last study, our findings couldn’t 
confirm the possible relation between ferritin and more pronounced hepatic steatosis. This can be 
in part explained by selection bias at a secondary referral center and the optimal treatment 
strategies with glycemic (HbA1c 7,8%) and lipidemic (cholesterol 4,6 mmol/L) control.  
 
Comments 
As a critique one could postulate the lack of histology which is seen as the golden standard. 
However in daily practice (and especially for screening in large populations) it is not always from a 
practical point of view necessary to perform. New non-invasive modalities are necessary for 
identifying those patients at risk for advanced NAFLD (NASH and fibrosis) and in need for liver 
biopsy. 
 
Conclusion 
This cross sectional analysis of a large T2DM population in a non-academic teaching hospital with 
normal and increased ALT levels could not demonstrate a significant relation between serum 
ferritin levels and the presence of NAFLD. Significant increased levels of Gt were found in those 
patients with increased ALT levels. We conclude that the use of ferritin as a non-invasive marker 
for the presence of NAFLD in T2DM is not suitable. Further research focusing on non-invasive 
markers are necessary for future screening of large populations.  
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Abstract 
Non-alcoholic fatty liver disease (NAFLD) is related to the metabolic syndrome and obesity. Proton 
magnetic resonance spectroscopy (1H MRS) is a non-invasive technique to assess hepatic 
triglyceride content (HTGC) and allows assessment of unsaturated fatty acids (UFA). There is 
increasing evidence that hepatic UFA are associated with the development of NAFLD. Therefore 
the objective of this study was to assess hepatic UFA in patients with NAFLD using 1H MRS. 
We included consecutive patients with deranged liver enzymes, with and without type 2 diabetes 
mellitus (DM2), suspected for NAFLD. Liver function and metabolic parameters were assessed. 1H 
MRS measurements were performed at 3.0 T. From the 1H MR spectra two ratios were calculated: 
ratio 1 (UFA); unsaturated fatty acid peak vs. reference water peak and ratio 2 (HTGC); total fatty 
acid peak vs. reference water peak. 
Twenty-six patients were included. In these patients hepatic UFA (ratio 1) correlated with AST/ALT 
ratio (r=−0.46, p=0.02), glucose levels (r=0.46, p=0.018), HOMA-IR (r=0.59, p=0.004) and 
HTGC (r=0.81, p<0.001). In diabetic patients (n = 12) hepatic UFA correlated with alkaline 
phosphatase levels (r=0.72, p=0.01), HOMA-IR (r=0.73, p=0.01) and HTGC (r=0.83, p=0.002). 
Compared to nondiabetic patients with NAFLD, hepatic UFA levels were increased in patients with 
DM2 and NAFLD (0.032 vs. 0.014, p=0.03). 
Hepatic UFA can be assessed with 1H MRS. 1H MRS determined hepatic UFA correlate with clinical 
and metabolic parameters associated with NAFLD. Hepatic UFA are increased in patients with 
DM2. This study provides evidence for the use of non-invasive 1H MRS to assess hepatic UFA in 
vivo. 
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Introduction 
Fatty liver disease is characterized by lipid accumulation in the liver. Causes are obesity, diabetes 
and dyslipidemia (metabolic syndrome), excessive alcohol consumption, and a variety of drugs 
and toxins (1). Non-alcoholic fatty liver disease (NAFLD) includes a spectrum of diseases ranging 
from simple steatosis through steatohepatitis (NASH) to end-stage liver disease (cirrhosis). Insulin 
resistance, the metabolic syndrome and obesity are all strongly related to NAFLD. Due to the 
widespread obesity epidemic (1), NAFLD is recognized as the most common chronic liver disease 
in the Western world (estimated prevalence of 20–30%). The prevalence of NASH is estimated to 
be approximately 20% among the obese and 3% of the lean population (2–4). Furthermore, it is 
estimated that 20–30% of patients with NASH will develop cirrhosis (5–8). Consequently, the 
number of patients with NAFLD-associated cirrhosis who are in need for liver transplantation is 
increasing (9,10). Together with increased cardiovascular morbidity and mortality (11), NAFLD is 
becoming a large burden on health care systems and the economy in general. Percutaneous liver 
biopsy is the reference standard for grading hepatic steatosis, inflammation (NASH) and fibrosis. 
Unfortunately, due to the risk of complications, inter-observer variability, sampling error and 
patient’s discomfort, this procedure is not applicable for population screening (12–14). Non-
invasive imaging techniques like abdominal ultrasound and computed tomography lack sensitivity 
and specificity and are incapable of differentiating between simple steatosis and NASH (15–22). 
Also conventional magnetic resonance imaging, considered as an accurate non- invasive 
technique, cannot discriminate between simple steatosis and NASH (21,22). In vivo proton 
magnetic resonance spectroscopy (1H MRS) is a safe, non-invasive diagnostic tool which has 
proven to be a sensitive and reproducible method to quantify hepatic triglyceride content (HTGC) 
in situ (23,24). 1H MRS is nowadays considered as the non-invasive reference standard for liver fat 
quantification (25–27). It enables the quantitative evaluation of hepatic lipid content by 
measuring the nuclear chemical shift generated by hydrogen atoms of fatty acid chains in a 
magnetic field. The various fatty acids can be differentiated by the small shifts in nuclear 
resonance of the hydrogen atoms bound to different structured carbon chains. This technique has 
shown to correlate well with histological data from liver biopsies in healthy individuals and 
patients with hepatic steatosis (r=0.9, p<0.001) (28–30). The largest study determining the 
prevalence of hepatic steatosis with 1H MRS was performed by Szczepaniak et al. (9). In this 
population of 2287 individuals over 30% was found to have some degree of hepatic steatosis. 1H 
MRS is also suitable for grading and following up patients with NAFLD who participate in clinical 
trails (31). Clinical experience with this technique is limited to 1.5 T magnets (29–32). There is 
sparse literature on addressing hepatic steatosis in humans at higher magnetic field strengths (3.0 
T or higher) (24,33,34). Due to the higher spectral resolution, the use of increased magnetic fields 
allow quantification of various fatty acid components in more detail, e.g. differentiation of 
resonances from unsaturated fatty acid chains (UFA) and polyunsaturated fatty acids (PUFA) in 
steatotic liver triglycerides (35–38). There is increasing evidence that hepatic UFA play an 
important role in the development of NAFLD. More precise, a decrease in omega-3/omega-6 UFA 
results in uncontrolled hepatic lipid metabolism (39–44). Omega-6 UFA are precursors to pro-
inflammatory eicosanoids. The excessive caloric intake of current Western dietary behaviour is 
characterized by an increased intake of omega-6 UFA. This may be directly related to the 
development of non-alcoholic steatohepatitis and progression to NASH. 
Therefore the objective of this study was the feasibility of hepatic UFA assessment in relation to 
HTGC by 3.0 T 1H MRS in patients suspected for NAFLD. 
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Material and methods 
Study design 
This study is a single center, non-randomized pilot study in consecutive patients with well defined 
features consistent with NAFLD and ultrasound suspected hepatic steatosis. This study was 
approved by the Medical Ethics Committee of our institution. All participants gave written 
informed consent. 
 
Patients 
Consecutive patients with deranged liver enzymes (defined as plasma alanine aminotransferase 
(ALT) > 1.5 x upper limit of normal) referred to our outpatient clinic, received a standardized 
workup. By exclusion of other causes of chronic liver diseases (negative viral (hepatitis B and C) 
and autoimmune (antinuclear antibodies and smooth muscle antigens)) serology, alcoholic fatty 
liver disease (alcohol use not exceeding 140 g per week for males, 70 g per week for females) and 
normal iron and copper studies, the diagnosis of NAFLD was strongly suspected. Other exclusion 
criteria in this study were MRI related: pacemakers, pregnancy or a history of claustrophobia. 
Medical history and physical examination focussed on features of the metabolic syndrome (e.g. 
body mass index (BMI) and waist-to-hip-ratio (WHR)) and signs of chronic liver disease were 
collected. BMI >27 kg/m2 indicated overweight; BMI >30 kg/m2 indicated obesity. In male, a WHR 
>1.0 and in female, a WHR >0.9 indicates increased risk for cardiovascular disease and insulin 
resistance (45).  Patients were divided into two groups according to the presence or absence of 
type 2 diabetes mellitus (DM2) as defined by international criteria (46). In all included patients 
blood sampling and 1H MRS was performed. Liver function (protrombin time, albumin and 
AST/ALT ratio (47)) and metabolic parameters (homeostasis model of assessment (HOMA-IR), 
glucose, insulin and lipid profile) were measured. Insulin resistance was defined as HOMA-IR >2.5. 
 
MR spectroscopy 
All measurements were performed in supine position on a 3.0 T MRI scanner (Philips Intera, 
Philips Healthcare, Best, The Netherlands). A voxel of 20 mm x 20 mm x 20 mm was positioned in 
the right hepatic lobe (liver segments V–VIII by Couinaud), avoiding the diaphragm and edges of 
the liver, but also vascular and biliary structures (Figure 1). Voxel size and time for acquisition 
were standardized for all subjects. Spectra were acquired using a PRESS sequence with TE/TR = 
35/2000ms and 64 signal acquisitions during free breathing without water-suppression. Quality of 
1H MRS measurements was inspected visually, and when an experienced MR physicist was 
unsatisfied with the 1H MR spectrum, the acquisition was repeated. We evaluated the liver 1H MR 
spectra by using jMRUI software. jMRUI is a graphical interface to several programs for processing 
magnetic resonance spectra and is specially designed for dealing with in vivo MR spectra obtained 
in clinical MR spectrometers. 
 
Figure 1. Voxel position in a liver at a coronal (left) and axial (right) slice. 
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Peak areas of the spectra were integrated using AMARES quantification technique. AMARES is a 
quantification method that estimates parameters for spectra by fitting them in the time domain. 
AMARES allows the inclusion of prior knowledge about the signal parameters of the model 
function (48). Three peaks (at 5.4, 4.65 and 1.3 ppm) were analyzed and prior knowledge was 
used for all peak localizations by using soft constraints. In some cases constraints were used for 
peak bandwidths. All peaks were fitted using Lorentzian lineshapes. Phase variation was allowed 
(up to 40◦) around a manually found optimum. From the 1HMR spectra two ratios were calculated 
(Table 1) and defined as: 
Ratio 1: the unsaturated fatty acid peak area (methane) at 5.4 ppm versus the reference peak 
area of water at 4.65 ppm plus the unsaturated fatty acid peak area at 5.4 ppm. This represents 
total hepatic UFA. 
Ratio 2: the total fatty acid peak area (methylene) at 1.3 ppm versus the reference peak area of 
water at 4.65 ppm plus the total fatty acid peak area at 1.3 ppm. Calculated peak areas of water 
and total fat were corrected for T2 relaxation (T2 water = 34ms,T2 fat = 68ms) (49). HTGC was 
calculated according to methods described by Szczepaniak. Normal hepatic fat content was 
defined as less than 5.6% measured by 1H MRS [9]. Total scanning time including positioning of 
the patient and acquisition of localizers amounted to 40 min. 
 
Table 1. Calculated peak area ratios from 1H MR spectra. 
 
 
Statistical analysis 
As this is a pilot exploratory study no formal sample size calculations could be carried out. The aim 
was to study the feasibility of hepatic UFA assessment in relation to HTGC with 1H MRS and 
correlate the measurements with clinical and biochemical data. To study correlations non-
parametric Spearman correlation coefficients were used. For differences between groups non-
parametric test for unrelated samples was used (Mann–Whitney U analysis). A p-value <0.05 was 
considered significant. For statistical analysis SPSS (version 16.0, SPSS Inc, Chicago, IL, USA) was 
used. 
 
Results 
Patients suspected for NAFLD 
Twenty-six patients were included (15 male and 11 female) with a mean age of 50.4 years (range 
27–69). Of these patients, 12 had characteristics consistent with DM2. A history of DM2 was 
present for at least 3 years. Demographic data are shown in Table 2. Mean body mass index (BMI) 
was 30.9 kg/m2 (range 22.2–38.9). Twelve patients had a BMI of 30 kg/m2 or less, whereas 14 
patients had a BMI higher than 30 kg/m2. Mean WHR in male patients was 1.06 (range 1.03–1.1) 
and in female 0.99 (range 0.9–1.1).  
 
 
 
 
 
 
 Fatty acid component Peak area ratio Index 
Total unsaturated fatty acids (-CH=CH-) / (-CH=CH- + H2O) 5.4/ (5.4 + 4.65) ppm Ratio 1 
Hepatic triglyceride content (CH2)n / ((CH2)n + H2O) 1.3/ (1.3 + 4.65) ppm Ratio 2 
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Table 2. Demographics, BMI and laboratory findings. 
 
  Parameters          DM2 (n=12)            no DM2 (n=14)            p-value           Total (n=26) 
Age, yrs 52.1 ± 12.1 48.9 ± 9.5 ns 50.4 ± 10.7 
Gender, m/f 8/4 7/7 ns 15/11 
BMI
#
, kg/m
2 
31.1 ± 4.5 30.8 ± 5.3 ns 30.9 ± 4.8 
AST, U/L 47.9 ± 25.9 49.6 ± 27.2 ns 48.9 ± 26.2 
ALT, U/L 75.5 ± 36.7 67.4 ± 39.6 ns 71.1 ± 37.7 
AP, U/L 79.5 ± 27.7 86.8 ± 27.2 ns 83.3 ± 27.1 
GGT, U/L 70.7 ± 37.5 97.1 ± 70.5 ns 84.9 ± 58.2 
Glucose, mmol/L 7.4 ± 3.0 5.5 ± 0.7 ns 6.3 ± 2.2 
HOMA-IR
* 
8.1 ± 7.0 5.2 ± 2.3 p=0.05
 
6.6 ± 5.3 
Cholesterol, mmol/L 4.5 ± 0.7 5.0 ± 1.4 ns 4.7 ± 1.1 
LDL, mmol/L 2.5 ± 0.8 3.1 ± 1.2 p=0.02
 
2.8 ± 1.0 
TG, mmol/L 1.6 ± 0.8 1.4 ± 0.7 ns 1.5 ± 0.7 
#
BMI = body mass index, 
*
HOMA-IR = homeostasis model of assessment, ns = not statistical significant 
 
As expected, patients with DM2 had higher HOMA-IR and thus were significantly more insulin 
resistant than those without DM2, and derangements of liver enzymes were comparable between 
both groups (Table 2). All 1H MRS measurements were of sufficient quality for analysis. Mean 
HTGC measured by 1H MRS in the entire group was 13.4% (range 3.3–29.7%). Eight patients had 
hepatic fat weight defined as less than 5.6% (9). Sixty-nine percent (n = 18) of patients had 1H 
MRS-proven NAFLD by the exclusion of other causes for chronic liver disease. Figure 2 shows an 
example of three jMRUI fitted MR spectra. On the left a spectrum of a patient with 3.3% HTGC is 
shown. There is no peak visible at 5.4 ppm (hepatic UFA). As the amount of HTGC increases in the 
middle and far right spectrum, the 5.4 ppm peak representing hepatic UFA becomes visible and 
increases. In 24 out of 26 patients (92.3%) in this study the 5.4 ppm peak is detectable and used 
for quantification. All spectra acquired were of sufficient quality to assess hepatic UFA in vivo. 
Hepatic UFA (ratio 1) showed a statistically significant correlation with the serum AST/ALT ratio (r 
=−0.46, p = 0.02), HOMA-IR and plasma glucose levels (r = 0.59, p = 0.004 and r = 0.46, p = 0.018, 
resp.) (Figure 3, Table 3). There was a statistically significant correlation between hepatic UFA 
(ratio 1) and HTGC (ratio 2) (r = 0.81, p < 0.001). 
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Figure 2. Three different spectra with increasing degree of steatosis.  
In spectrum A no UFA are visible at 5.4 ppm. In spectra B and C the amount of UFA is increasing and could be reliably 
quantified using the AMARES routine in jRMUI. In the upper panels the residues are shown for the peaks at 5.4, 4.65 
and 1.3 ppm. The maximum of all spectra is scaled to 1. 
 
 
 
 
Figure 3. Correlation between UFA 
(ratio 1) and insulin resistance 
(HOMA-IR) in all patients. 
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Table 3. Unsaturated fatty acids (UFA, ratio 1) and total hepatic fat content (HTGC, ratio 2); 
correlation with clinical and metabolic parameters. 
 
  Parameters      1H-MRS Ratio 1 (UFA)   1H-MRS Ratio 2 (HTGC) 
Total (n= 26)   
Glucose r = 0.48, p= 0.023 r = 0.43, p= 0.038 
HOMA-IR r = 0.59, p= 0.004 ns 
AST/ ALT ratio r =-0.46, p= 0.024 ns 
HTGC, Ratio 2 r = 0.81, p< 0.001 ns 
   
With DM2 (n= 12)   
Alkaline phosphatase r = 0.72, p= 0.013 r = 0.76, p= 0.004 
HOMA-IR r = 0.73, p= 0.011 ns 
HTGC, Ratio 2 r = 0.83, p= 0.002 ns 
 
 
  
Without DM2 (n= 14)   
HDL r = 0.71, p= 0.010 ns 
HTGC, Ratio 2 r = 0.82, p= 0.010 ns 
   
 
Patients with and without DM2 
Patients with and without DM2 had an average age of respectively 52.1 years (range 31–69) and 
48.9 years (range 27–61) and a BMI of respectively 30.8 kg/m2 (range 22.2–38.9) and 31.1 kg/m2 
(range 23.4–37.7). In patients without DM2 hepatic UFA (ratio 1) showed significant correlation 
with serum high density lipoprotein (HDL) cholesterol concentration (r = 0.71, p = 0.010) and 
HTGC (ratio 2) (r = 0.82, p = 0.010). In patients with DM2 hepatic UFA (ratio 1) showed significant 
correlation with serum alkaline phosphatase (r = 0.72, p = 0.01) and HOMA-IR (r = 0.73, p = 0.01). 
HTGC (ratio 2) correlated with serum alkaline phosphatase (r = 0.76, p = 0.004) and hepatic UFA (r 
= 0.83, p = 0.002) (Figure 4). Ratio 1, representing hepatic UFA, was significantly higher in patients 
with DM2 than in those without DM2 (0.032 vs. 0.014, p = 0.030) (Fig. 5). HTCG (ratio 2) was not 
different in both groups (0.47 vs. 0.37, p = 0.237).  
 
Figure 4. Correlation between UFA 
(ratio 1) and HTGC (ratio 2) in 
patients with DM2. 
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Discussion 
In this study we investigated total hepatic UFA by 3.0 T 1HMRS in diabetic and non-diabetic 
patients with NAFLD and its correlations with clinical and metabolic parameters. Previous studies 
using non-invasive 1H MRS measurements in NAFLD demonstrated significant correlations 
between HTGC and insulin resistance, diabetes and liver histology (29,30,50,51). Other studies 
focussed on UFA in adipose tissue, marrow fat and skeletal muscle using 7.0 and 3.0 T 1H MRS 
(36,37). Corbin et al. investigated hepatic UFA in a murine NAFLD model using 1H MRS at 4.7 T 
(35). However, the assessment of hepatic UFA in humans at 3.0 T has not been investigated yet. 
 
Fatty acids in general 
Fatty acids are carboxylic acids with a long aliphatic tail which are either saturated or unsaturated. 
Depending on one or more double bonds, UFA can be separated into mono (MUFA) – and 
polyunsaturated (PUFA) fatty acids. Omega-3, or n-3 PUFA, are UFA with a double bond at the 
third carbon–carbon bond from the terminal methyl end (n) of the carbon chain. They are 
important in human nutrition, e.g. -linolenic acid. UFA with a double bond at the sixth carbon–
carbon bond from the end of the chain, are named omega-6, or n-6 PUFA. These are precursors of 
pro-inflammatory eicosanoids, n-6 prostaglandines and n-6 leukotrienes. Hepatic UFA and 
NAFLD/NASH; 3.0 T 1H MRS is able to measure total hepatic UFA (i.e. the combination of MUFA 
and PUFA) at 5.4 ppm and total fatty acids (unsaturated and saturated fatty acids) at 1.3 ppm. In 
the liver, omega-3 and omega-6 PUFA exert opposite activities. Omega-3 PUFA activate 
peroxisome proliferator activating receptor- (PPAR-), a nuclear hormone receptor for the 
transcriptional regulation of genes responsible for fatty acid oxidation. Omega-3 PUFA cause a 
down-regulation of sterol regulatory element binding protein-1c (SREBP-1c), responsible for gene 
transcription in fatty acid synthesis (52). Net result is a decrease of oxidative stress, in HTGC and 
inflammation. In contrast, omega-6 PUFA (e.g. arachidonic acid) are precursors of pro-
inflammatory eicosanoids (53). Hepatic UFA could be an important biomarker in this process 
because NASH induced in animal models show increased UFA (35). Furthermore, in recent clinical 
trials omega-3 PUFA significantly improved metabolic and inflammatory markers in patients with 
NASH (42). 
In this study, total hepatic UFA were measured with 3.0 T 1H MRS and correlations with clinical 
and metabolic parameters associated with NAFLD/NASH could be demonstrated, e.g. HOMA-IR, 
serum AST/ALT ratio and total HTGC. Significant correlations were found between UFA and these 
parameters. In DM2, ratio 1 representing total hepatic UFA, was significantly higher than in 
patients without DM2, whereas for total HTGC no differences were detected. From larger studies 
it is known that the presence of NASH is more frequent in patients with DM2 (54–56). 
Hypothetically, this increase in UFA in patients with DM2 may be attributed to a decreased 
omega-3/omega-6 ratio with a substantial hepatic accumulation of omega-6 PUFA. Corbin et al. 
already showed that 1H MRS can detect fat composition in the liver. In the steatotic liver hepatic 
fat content is sufficiently high enough for additional resonances like UFA at 5.4 ppm to become 
detectable. Our study supports these results, and show that UFA is also detectable in human livers 
at 3.0 T. To our knowledge this is the first study assessing hepatic UFA by means of non-invasive 
3.0 T 1H MRS in patients with NAFLD. 
 
Limitations 
As this was an exploratory pilot study to investigate the role of total hepatic UFA assessment, the 
number of included patients is small. No formal sample size calculation was carried out. We chose 
a sample size that was considered appropriate to address the study aims. We did not perform a 
reference standard liver biopsy due its invasiveness. This is the main limitation of this study. 
Diagnosis of NAFLD was made based on the combination of exclusion of other chronic liver 
diseases and the presence of enhanced echogenicity on hepatic ultrasound. Standardization and 
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lifestyle control was not implemented in this study. We think this is not strictly necessary since 
standardization and lifestyle control can be implemented in many different ways. In daily clinical 
practice patients are not standardized as well, and no lifestyle control is performed. 
In this study 1H MRS was performed during free breathing. This is a potential limitation because 
the volume interrogated by 1H MRS is blurred in the longitudinal direction by 2–3 cm respiratory 
excursions of the liver. In this study we did not expect major 1H MRS acquisition problems caused 
by respiratory excursions. Voxels were carefully positioned in the right liver, avoiding the 
diaphragm by at least 4 cm. In this way 1H MRS was always performed in liver tissue. Finally, in 
this study differentiation between MUFA and PUFA and assessment of -3 and -6 PUFA 
individually was not possible using 3.0 T 1HMRS measurements. 
 
In conclusion, 3.0 T 1H MRS represents a non-invasive technique to assess total hepatic UFA and 
HTGC. Hepatic UFA correlates well with clinical and metabolic parameters associated with the 
metabolic syndrome and NAFLD/NASH. Hepatic UFA are increased in patients with DM2, possibly 
due to an unequal increase of -6 PUFA. The presence of NASH is more frequent in patients with 
DM2. Therefore hepatic UFA could be a predictive parameter to discriminate simple steatosis 
from NASH. This pilot study provides evidence for the use of 3.0 T 1H MRS as a non-invasive 
diagnostic tool to assess UFA in vivo in human livers. Further research in UFA and identification of 
omega-3 and omega-6 PUFA in order to diagnose patients at risk for NAFLD and to distinguish 
simple steatosis from NASH is needed. 
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Abstract 
The purpose of this study was to assess hepatic steatosis in morbidly obese patients undergoing 
gastric bypass surgery using open magnet 1.0T 1H-MRS with histopathological control. 
Patients underwent 1H-MRS for the assessment of steatosis before and three months after 
surgery. Liver biopsy was performed during surgery. Hepatic steatosis was expressed as a ratio of 
the fat peak area over the cumulative water and fat peak areas. Histopathological percentages of 
steatosis were graded as follows: none (0-5%), mild (5-33%), moderate (33-66%) and severe 
(>66%). Accuracy was calculated for 1H-MRS and to assess correlation we used Spearman’s 
correlation coefficient. Differences between groups were assessed with the Wilcoxon signed rank 
and Mann-Whitney U analysis. 
We included 38 patients, with median age and BMI of 45.5 years and 47.7 kg/m2 respectively. 
Before surgery median steatosis measured with 1H-MRS was 5.8%. 1H-MRS showed an accuracy of 
32/36 (89%) and significantly correlated with histopathological assessment of steatosis 
(r=0.85,p<0.001). 1H-MRS was able to discriminate none from mild steatosis (p=0.011), mild from 
moderate steatosis (p<0.001) and moderate from severe steatosis (p=0.021). Three months after 
surgery steatosis decreased to 3.1% (p<0.001). The prevalence of hepatic steatosis measured by 
1H-MRS decreased from 53% to 33%. 
1H-MRS for assessment of hepatic steatosis and changes in steatosis after gastric bypass surgery is 
feasible in morbidly obese patients using an open 1.0T MR scanner. 1H-MRS measurements of 
hepatic fat are accurate and correlate with clinical and histopathology results.  
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Introduction 
Non-alcoholic fatty liver disease (NAFLD) is characterized by lipid accumulation in the liver. NAFLD 
represents a disease spectrum ranging from simple hepatic steatosis to more severe 
steatohepatitis (NASH), fibrosis and cirrhosis. This can lead to end stage liver failure or the 
development of hepatocellular carcinoma (1). In morbidly obese patients NAFLD is present in 
approximately 85% to 95% (2,3). Importantly, the prevalence of NAFLD is expected to rise due to 
the current obesity epidemic (4).  
Bariatric surgery (metabolic surgery) is increasingly performed to treat morbid obesity. In 2008, 
344,221 bariatric surgery operations (including 168,597 Roux-en-Y gastric bypass surgeries) were 
performed worldwide; the majority (220,000) on the North American continent (5). The majority 
of patients with type II diabetes, NAFLD, dyslipidemia and hypertension showed significant 
improvement after bariatric surgery (6-8). 
Currently, percutaneous liver biopsy is the only available reference standard for histopathological 
evaluation of NAFLD, but is accompanied by the risk of complications, inter-observer variability, 
sampling error and patient discomfort (9-11). Furthermore, liver biopsy is technically difficult in 
morbidly obese patients. Consequently there is a need for a non-invasive diagnostic tool for the 
detection, quantification and monitoring of hepatic steatosis. To date several imaging techniques 
are used to detect hepatic steatosis: ultrasound (US), computed tomography (CT), magnetic 
resonance imaging (MRI) and 1H-magnetic resonance spectroscopy (1H-MRS) (12,13).  MRI and 1H-
MRS are considered as the most accurate non-invasive techniques to detect hepatic fat (14,15).  
From a precision perspective 1H-MRS is a reproducible method to quantify hepatic fat content 
(16), showing a coefficient of variation of 9.5% over time and 14.5% for within liver variability at 
3.0T. Previous studies using cylindrical MR scanners for 1H-MRS showed the beneficial effect of 
bariatric surgery on hepatic steatosis (17-20). In one study histopathological confirmation was 
obtained, showing good correlation with 1H-MRS (r=0.77, p<0.001)(19).  
Given the present obesity epidemic, increasing number of patients will have problems to fit in the 
bore of a standard cylindrical MR scanner. Although some morbidly obese patients will still fit in 
cylindrical MR scanners and even more in the new large bore clinical 70cm 1.5 and 3.0T cylindrical 
MR scanners, the relatively short diameter and long bore lengths make it very uncomfortable for 
these patients and increase the tendency to induce a “squeeze” effect and claustrophobia (21). 
Therefore, 1H-MRS measurements of hepatic fat content in these patients could become 
problematic despite the fact that these patients are at high risk for NAFLD and NASH.  
For the morbidly obese population 1H-MRS in an open MR scanner could be an alternative to 
cylindrical MR scanners. Open MR scanners are available since the introduction of MRI in the 
1980s, but most operate at (very) low field strengths. This prevents 1H-MRS measurements. 
However, more recently high field open 1.0T MR scanners became available for clinical use and 
made good quality 1H-MRS possible. 
The purpose of this study was to measure hepatic steatosis in morbidly obese patients before and 
after laparoscopic Roux-en-Y gastric bypass surgery using 1H-MRS in an open magnet 1.0T MR 
scanner. Histopathological confirmation was obtained during surgery. 
 
Materials and Methods 
Study design and subjects 
This prospective study was approved by the institutional review board. All patients gave written 
informed consent. From January to September 2008, all patients of 18 years and older who were 
scheduled to undergo laparoscopic Roux-en-Y gastric bypass surgery were consecutively invited to 
participate in this study. Due to the long waiting lists for bariatric surgery, the pre- and post-
surgery 1H-MRS measurements were performed up to June 2010. The indication for laparoscopic 
Roux-en-Y gastric bypass surgery was morbid obesity defined as a Body Mass Index (BMI) of >40 
kg/m2, or a BMI >35 kg/m2 with co-morbidity related to morbid obesity (such as cardiovascular, 
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metabolic and pulmonary complications). All patients included in this study met the criteria stated 
by the NIH consensus panel for bariatric surgery (22).  
Patients underwent 1H-MRS for the assessment of hepatic steatosis four weeks prior to surgery 
and three months after surgery. Demographic characteristics and anthropometric measurements 
were recorded and blood analyses performed on the same day as 1H-MRS was performed. 
Exclusion criteria were pregnancy, MR contraindications, other causes of chronic liver diseases 
and alcoholic fatty liver disease. 
 
Clinical evaluation 
Within four weeks prior to surgery, age, gender and medical history and the use of alcohol (male 
<140 grams/week and female <70 grams/week was defined as normal) were recorded from all 
patients. Physical examination included blood pressure, weight, height, waist and hip 
circumference followed by calculation of BMI and Waist-to-Hip Ratio (WHR). In males a WHR >1.0 
and in females a WHR >0.9 is associated with an increased risk for cardiovascular disease and 
insulin resistance (23). Blood was collected after an overnight fast.  Analysis of fasting plasma 
glucose and insulin was performed. Fasting plasma glucose and insulin concentrations were used 
to calculate the homeostasis model of assessment (HOMA-IR) in order to assess the severity of 
insulin resistance (24). Insulin resistance was diagnosed when HOMA-IR >2.5. Diabetes was 
defined by international accepted criteria (25). Other causes of chronic liver disease were 
excluded by serology ((negative hepatitis B surface antigen and HCV-antibodies), autoimmunity 
tests (negative for antinuclear antibodies and smooth muscle antigens) and tests for storage 
diseases (normal iron and copper studies)). The above described clinical evaluation was repeated 
three months after laparoscopic Roux-en-Y gastric bypass surgery. 
 
1.0T 1H-MR Spectroscopy 
1H-MRS measurements were performed during free breathing on an open 1.0 Tesla MR scanner 
with a 160 cm-wide patient aperture and a height of 45 cm (Panorama HFO, Philips Healthcare, 
Best, The Netherlands) using the quadrature body coil in supine position (scan time 30 minutes). 
No respiratory triggering or outer-volume suppression was used. After performing T1-weighted 
coronal and axial localizer images, a 20 x 20 x 20 mm voxel was positioned in the right liver lobe, 
avoiding overlap with extrahepatic structures and intrahepatic vascular and biliary structures. 
Spectra (Figure 1) were acquired using pencil beam second order shimming in a predefined 
volume (shim-box) in the liver, a point resolved spectroscopic sequence (PRESS) with 
TE/TR=35/2000 ms and 64 signal acquisitions. Receiver bandwidth was 1500 Hz and the number 
of data points was 2048. Data was processed using jMRUI software (26) by a research fellow 
[blinded] under direct supervision of an experienced MR physicist ([blinded], 5 years of 
experience), blinded for study results. Signal resonances from water and fat located at 4.65 and 
1.3 ppm respectively were analyzed (Figure 1).  
 
Prior knowledge was used for peak localization by using soft constraints. Signal resonances were 
fitted using Lorentzian line shapes. Phase variation was allowed (40 degrees) around a manually 
selected optimum. Relative fat content was expressed as a ratio of the fat peak area over the 
cumulative water and fat peak areas (1.3 ppm / (1.3 ppm + 4.65 ppm). No correction for T1 
relaxation was performed, as no T1 weighting is present using a TR of 2000 ms. Calculated peak 
areas of water and fat were corrected for T2 relaxation. T2 measurements were performed in five 
patients by using a multi echo PRESS sequence (TE= 35, 65, 95, 125 and 155 ms). Measured T2 
values appeared to be stable in this subset: T2water=69.3ms (SD 2.3ms), T2fat=59.5ms (SD 5.0ms). 
These measurements were used for calculating the percentage hepatic fat content according to 
Szczepaniak et al. (27).  
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Figure 1. Left and middle image: Voxel position in the liver with shim-box at an axial and 
coronal slice. Right image: Typical MR spectrum at 1.0 Tesla from a patient with increased 
hepatic fat  content. Both measured spectrum (dotted black line) and fitted spectrum (gray line) are displayed: 
water (H2O) at 4.65 ppm and fat (-CH2-) at 1.3 ppm.  
 
 
Surgical technique 
Figure 1. Left and middle image: Voxel position in the liver with shim-box at an axial and 
coronal slice. Right image: Typical MR spectrum at 1.0 Tesla from a patient with increased 
hepatic fat  content. Both measured spectrum (dotted black line) and fitted spectrum (gray line) are displayed: 
water (H2O) at 4.65 ppm and fat (-CH2-) at 1.3 ppm. 
 
Laparoscopic Roux-en-Y gastric bypass surgery was performed by two experienced bariatric 
surgeons (FB, 10 years of experience and IJ, 15 years of experience). During surgery, the gastric 
volume was reduced by stapling off a 30 cc proximal gastric pouch and connecting the antecolic 
alimentary limb as a gastro-enterostomy. The biliopancreatic limb with a length of 45-50 cm from 
the ligament of Treitz was connected to this alimentary limb at a distance of 100-150 cm as an 
entero-enterostomy. This resulted in a bypass of the distal stomach, duodenum and proximal part 
of the jejunum. The choice of alimentary limb length was made by the surgeon based on patients 
BMI. Patients with BMI >35 kg/m2 received a 100 cm limb, whereas patients with a BMI >50 kg/m2 
received a 150 cm limb to establish more weight reduction. During surgery a laparoscopic liver 
biopsy was performed for histopathological assessment of NAFLD. 
 
Liver biopsy and histopathological analysis 
Liver specimens were fixed in 10% buffered formalin for 24h, dehydrated and embedded in 
paraffin. Four μm thick sections were stained with hematoxylin and eosin (H&E) and Periodic 
Acid-Schiff staining (PAS), with and without diastase. PAS staining was also used to detect 
glycogen in tissues. Separate stainings for iron, copper, reticulin and collagen fibers were 
performed. Sections were scored by an experienced hepatopathologist (JM, 20 years of 
experience and blinded for study results) for macrovesicular steatosis grade and localization, 
presence of microvesicular steatosis, inflammation, fibrosis and liver cell injury according to the 
NASH Clinical Research Network scoring system defined by Kleiner et al (28). Percentages of 
macrovesicular steatosis was graded as follows: none (0-5%), mild (5-33%), moderate (33-66%) 
and severe (>66%). Macrovesicular steatosis was assessed as the percentage of hepatocytes in the 
microscopic field containing a lipid vacuole larger than the diameter of the nucleus and displacing 
the nucleus. To assess the severity of NAFLD (i.e. presence of progressive disease; non-alcoholic 
steatohepatitis (NASH)), the NAFLD activity score was calculated (28). The NAFLD activity score is 
a histological scoring system that represents the sum of scores for macrovesicular steatosis, 
lobular and portal inflammation, fibrosis and ballooning. This score ranges from 0-8. NALFD 
activity scores of 0-2 are considered not diagnostic for NASH; scores of 3-4 are considered 
borderline for NASH. Scores of 5-8 are considered diagnostic for NASH.  
 
Statistical analysis 
Differences between dependent groups were assessed with the nonparametric Wilcoxon signed 
rank test. Differences between independent groups were assessed with the nonparametric Mann-
Whitney U analysis. Correlations between 1H-MRS determined hepatic fat content and clinical and 
histopathological results (% macrovesicular steatosis) were assessed using nonparametric 
Spearman’s correlation coefficient. We also performed receiver-operator characteristic (ROC) 
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curve analysis to determine the best cut-off value of 1.0T 1H-MRS to predict hepatic steatosis. The 
best cut-off value was determined while balancing the best sensitivity with the lowest false-
positive rate. Performance statistics (total accuracy, sensitivity, specificity, positive predictive 
value (PPV), negative predicative value (NPV)) with 95% confidence intervals were calculated. For 
statistical analyses a p-value <0.05 was considered as significant. For multiple comparisons post-
hoc Bonferroni correction was used. For analysis SPSS version 16.0 (SPSS, Chicago, Ill, USA) was 
used. 
 
Results 
In this study 72 patients were invited to participate. Forty patients gave written informed consent 
and 38 patients were included; seven men (18.4%) and 31 women (81.6%). Two patients were 
excluded; one patient due to technical failure of the MR scanner and one patient was lost to 
follow up three months postoperatively. Median age was 45.5 years (range 22-63 years). Median 
BMI was 47.7 kg/m2 (range 40.0-63.9 kg/m2) and the median waist circumference was 144.0 cm 
(range 123-175 cm). Median WHR was 1.16 (range 1.03-1.17) in men and 0.97 (range 0.84-1.17) in 
women. Twelve out of 38 (32%) patients had a history of diabetes. No patients were excluded for 
excessive alcohol use.   
Table 1 shows the median change of the clinical evaluations before and after laparoscopic 
Roux-en-Y gastric bypass surgery. Compared to baseline weight, median weight loss was 24.0 
kg three months after surgery (p<0.001). After surgery patients had significant improvement in 
cardiovascular risk factors: BMI (p<0.001), WHR (p=0.002) decreased. When taking into 
consideration features of the metabolic syndrome insulin resistance (HOMA-IR) showed a 
significant median change (p<0.001). Before surgery, 33/38 (87%) of patients had insulin 
resistance. Three months postoperatively, only 10/38 (26%) had insulin resistance defined by 
HOMA-IR >2.5. When comparing diabetic with non-diabetic patients before surgery, no 
significant differences were found, except for plasma glucose (p=0.005) and insulin resistance 
(HOMA-IR) (p=0.05). 
 
Table 1. Median changes with range in patient characteristics three months after laparoscopic 
Roux-en-Y gastric bypass surgery. 
Parameters        Median change       Range                        p-value 
    
Weight (kg) 
Men 
Women 
24.0 ± 5.4 
27.5 ± 5.4 
22.2 ± 4.8 
13.3 – 38.5 
24.0 – 38.5 
13.3 – 32.5 
<0.001 
<0.001 
<0.001 
BMI (kg/m
2
) 
Men                                                  
Women 
8.5 ± 1.8 
9.4 ± 1.9 
8.5 ± 1.8 
4.7 – 13.2 
7.4 – 13.2 
4.7 – 12.4 
<0.001 
0.018 
<0.001 
WHR  
Men 
Women 
0.03 ± 0.07 
0.03 ± 0.06 
0.04 ± 0.07 
-0.08 – 0.26 
-0.03 – 0.17 
-0.08 – 0.26 
0.002 
0.128 
0.007 
HOMA-IR 
Men 
Women 
3.4 ± 6.0 
5.9 ± 11.5 
3.2 ± 4.0 
0.2 – 31.9 
0.7 – 31.9 
0.2 – 19.8 
<0.001 
0.028 
<0.001 
HFC (%) 
Men 
Women 
2.8 ± 7.1 
7.1 ± 10.3 
2.1 ± 5.3 
-7.5 – 27.2 
2.6 – 27.2 
-7.5 – 14.1 
<0.001 
0.028 
0.001 
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Values are median changes ± SD and ranges. BMI = body mass index, WHR = waist -to-hip ratio, SBP = systolic blood 
pressure, DBP = diastolic blood pressure, HOMA-IR = homeostatsis model assessment of insulin resistance, HFC = 
hepatic fat content. 
 
Liver histopathology 
Histopathological assessment of liver specimens showed hepatic steatosis (>5% macrovesicular 
steatosis) in 22/36 (61.1%) of the patients: 10/36 (27.8%) had mild macrovesicular steatosis (5-
33%), 10/36 (27.8%) moderate steatosis (33-66%) and 2/36 (5.6%) severe steatosis (>66%). 
Microvesicular steatosis was seen in 6/36 (16.7%) of patients. Results of other histopathological 
parameters are shown in Table 2. No patients showed abnormal accumulation of iron in the liver 
and therefore hemochromatosis or hemosiderosis could be excluded. Due to logistical reasons 
two liver biopsy samples could not be evaluated. A NAFLD activity score of ≤2 was present in 
14/36 (38.9%) of the patients, 10/36 (27.8%) of the patients scored 3-4 and 12/36 (33.3%) had a 
NAFLD score >4. Median NAFLD score on histopathology was 3.0.  
 
Table 2. Histopathological assessment according to the NASH CRN scoring system (28). 
Items      Score/ code     N (% of patients) 
Steatosis grade 
     <5% 
     5-33% 
     33-66% 
     >66% 
Location 
     Zone 3 
     Zone 1 
     Azonal 
     Panacinar 
Microvesicular steatosis 
     Present 
     Not present 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
1 
0 
 
14 (38.9%) 
10 (27.8%) 
10 (27.8%) 
2 (5.6%) 
 
9 (25.0%) 
16 (44.5%) 
8 (22.2%) 
               3 (8.3%) 
 
6 (16.6%) 
30 (83.3%) 
Fibrosis stage 
     None 
     Perisinusoidal/ periportal 
     Mild, zone 3, perisinusoidal 
     Moderate, zone 3, perisinusoidal 
     Portal/ periportal 
     Perisinusoidal and periportal/portal 
     Bridging fibrosis 
     Cirrhosis 
 
0 
1 
1a 
1b 
1c 
2 
3 
4 
 
30 (83.3%) 
4 (11.1%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
1 (2.8%) 
1 (2.8%) 
0 (0.0%) 
Inflammation 
Lobular inflammation 
     None 
     < 2 foci per 200x field 
     2-4 foci per 200x field 
     > 4 foci per 200x field 
Microgranuloma 
     Present 
     Not present 
 
 
0 
1 
2 
3 
 
1 
0 
 
 
30 (83.3%) 
4 (11.1%) 
2 (5.6%) 
0 (0.0%) 
 
3 (8.3%) 
33 (81.7%) 
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Lipogranuloma 
     Present 
     Not present 
Portal inflammation 
     Present 
     Not present 
 
1 
0 
 
1 
0 
 
1 (2.8%) 
35 (97.2%) 
 
8 (22.2%) 
28 (77.8%) 
Liver cell injury 
Ballooning 
     Present 
     Not present 
Acidophill bodies 
     Present 
     Not present 
Pigmented macrophages 
     Present 
     Not present 
Megamitochondria 
     Present 
     Not present 
 
 
1 
0 
 
1 
0 
 
1 
0 
 
1 
0 
 
 
4 (11.1%) 
32 (88.9%) 
 
1 (2.8%) 
35 (97.2%) 
 
5 (13.9%) 
31 (96.1%) 
 
0 (0.0%) 
36 (100%) 
Other findings 
Mallory Hyaline bodies 
     Present 
     Not present 
Glycogenated nuclei 
     Present 
     Not present 
 
 
1 
0 
 
1 
0 
 
 
1 (2.8%) 
35 (97.2%) 
 
10 (27.8%) 
26 (72.2%) 
Diagnostic classification 
     No NASH 
     Borderline NASH 
     NASH 
 
0 
1 
2 
 
32 (88.9%) 
3 (8.3%) 
1 (2.8%) 
NAFLD activity score 
     0-2 
     3-4 
     4-8 
  
14 (38.8%) 
10 (27.8%) 
12 (33.3%) 
 
 
1.0T 1H-MRS assessment 
1H-MRS measurements were successful in all 38 patients. No claustrophobia was reported. The 
time interval between the first 1H-MRS assessment and surgery was 7.8 days. Before Roux-en-Y 
gastric bypass surgery median hepatic fat content measured with 1.0T 1H-MRS was 5.8% (range 
0.4-30.5%). Three months after surgery, median hepatic fat content was significantly decreased to 
3.1% (range 0.1-21.4%, p<0.001). Median hepatic fat content in diabetic patients showed no 
significant difference with non-diabetic patients before (p=0.107) and after (p=0.983) surgery.  
For the 5% upper limit of normal histopathological macrovesicular steatosis threshold value, the 
diagnostic accuracy was determined for 1H-MRS. We performed ROC curve fitting for 1H-MRS 
(Figure 2, area under ROC= 0.91). From the ROC curves we found a cut-off value for 1H-MRS of 
5.7% hepatic fat. This cut-off value was used to calculate diagnostic accuracy. Sensitivity was 
17/20 (85%) and specificity was 15/16 (94%), with a PPV of 17/18 (94%) and a NPV of 15/18 
(83%). Total accuracy for 1H-MRS was 32/36 (89%).  
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Figure 2. ROC-curve representing 
the diagnostic accuracy of 1.0T 1H-
MRS to detect hepatic steatosis in 
morbidly obese patients. 
 
 
 
 
 
 
 
 
 
 
 
 
Before surgery 20/38 (53%) patients showed hepatic steatosis defined by the calculated cut-off 
for 1H-MRS of 5.7% hepatic fat content. A decrease in prevalence of hepatic steatosis of 20% was 
measured after Roux-en-Y gastric bypass surgery (12/38). Moreover, a decrease of hepatic 
steatosis was seen in 32 out of 38 (84%) patients after surgery. 
Marginal, albeit significant correlations between WHR (r=0.48, p=0.003), insulin resistance 
(HOMA-IR, r=0.45, p=0.009) and 1H-MRS measurements of hepatic fat content were found (Table 
3).  
 
Table 3. Correlations. 
 
Parameters                    Correlation coefficients 
  
1H-MRS HFC vs. WHR r= 0.48, p=0.003 
1H-MRS HFC vs. HOMA-IR r= 0.45, p<0.001 
1H-MRS HFC vs. macrovesicular steatosis r= 0.85, p<0.001 
1H-MRS HFC vs. NAFLD score r= 0.76, p<0.001 
 
Spearman’s correlation coefficients,WHR = waist-to-hip ratio, HOMA-IR = homeostasis model assessment of insulin 
resistance, HFC = hepatic fat content 
 
Furthermore, 1H-MRS significantly correlated with histopathological assessment of macrovesicular 
hepatic steatosis (r=0.85, p<0.001, Figure 3) and NAFLD activity score (r=0.76, p<0.001, Figure 4). 
Moreover, in patients with histopathological proven NASH hepatic fat content before surgery was 
significantly higher than in patients with just NAFLD but not NASH (p<0.001, Figure 5). 
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Figure 4. Scatterplot representing the 
correlation (r=0.76, p<0.001) between 
1H-MRS determined hepatic fat 
content and histopathological NAFLD 
activity score. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Boxplot representing 1H-
MRS determined hepatic fat content 
in relation to NAFLD activity score 0-
2 (no NASH), 2-4 (borderline NASH) 
and >4 (NASH). 
 
Figure 3. Scatterplot representing 
the correlation (r=0.85, p<0.001) 
between 1H-MRS determined 
hepatic fat content and 
histopathological steatosis grades 
(1= <5%, 2= 5-33%, 3= 33-66% and 
4= >66% hepatic fat). 
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Figure 6 shows the ability of 1H-MRS in differentiating across grades of steatosis defined by 
histopathology. Using 1H-MRS measurements of hepatic fat content it was possible to 
discriminate no steatosis (3.5%) from mild steatosis (6.9%) (p=0.011), mild from moderate 
steatosis (22.7%) (p<0.001) and a trend to differentiate moderate from severe steatosis (30.0%) 
(p=0.021, not significant after Bonferroni correction).  
 
Figure 6. Boxplot representing the 
1H-MRS determined hepatic fat 
content in morbidly obese patients 
across histopathological steatosis 
grades. 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
In this study we investigated the assessment of hepatic steatosis in morbidly obese patients 
before and after laparoscopic Roux-en-Y gastric bypass surgery using open magnet 1H-MRS with 
histopathological confirmation from intra-operative laparoscopic liver biopsies. Our results show 
that, with an open clinical 1T MR scanner, hepatic steatosis can be accurately measured with 1H-
MRS in morbidly obese patients. 
After laparoscopic Roux-en-Y gastric bypass surgery patients showed significant decrease in 
hepatic steatosis. 1H-MRS at 1T was able to differentiate between clinically relevant grades of 
macrovesicular steatosis (none, mild, moderate and severe). This is important for monitoring 
treatment response in morbidly obese patients. Furthermore patients showed significant 
improvements in almost all investigated clinical parameters after surgery. Median change in BMI 
was 8.5 in three months and the prevalence of insulin resistance decreased from 87% to 26%. Our 
study also shows that hepatic fat content was higher in patients with NAFLD activity score 
considered diagnostic for NASH. 
To our knowledge this is the first study to non-invasively assess hepatic steatosis with 1H-MRS in 
an open 1.0T MR scanner in morbidly obese patients before and after laparoscopic Roux-en-Y 
gastric bypass surgery with histopathological confirmation. Given the increasing prevalence of 
obesity with subsequently an increasing prevalence of NAFLD, the use of open MR scanners could 
be an attractive alternative in the morbidly obese population. US and liver biopsy are limited in 
their use in morbidly obese patients. CT is inaccurate in semi-quantitative diagnosis when 
macrovesicular steatosis is less than of 30% (29); sensitivity and specificity also show insufficient 
diagnostic performance (14). Furthermore the use of CT is hampered by the exposure to ionizing 
radiation. The use of standard cylindrical MR scanners is limited by an aperture diameter of 60 cm 
and in some 3.0T scanners even 55 cm. The aperture is decreased by the thickness of the table 
and coils (21), leading to considerably reduced maximum patient circumference in standard 
cylindrical MR scanners. In our study, median waist circumference was 144 cm, with the smallest 
circumference being 123 cm; not every patient would have fitted in a standard cylindrical MR 
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scanner. However, recently large bore MR scanners became available for clinical use, allowing 
more obese patient to fit in cylindrical MR scanners and offering higher magnetic field strengths 
(21). 
Four earlier studies reported the assessment of hepatic steatosis with 1H-MRS in bariatric surgery 
patients (17-20). In three studies laparoscopic adjustable gastric banding and in one study Roux-
en-Y gastric bypass surgery was performed. The latter study included only seven patients and did 
not compare the results with histopathology. The most important conclusions that can be drawn 
from these four studies are: a) in the early phase after Roux-en-Y gastric bypass surgery rapid lipid 
mobilization from adipose depots to the liver occurs, b) no significant improvement in insulin 
resistance (HOMA-IR) was found three months after gastric banding surgery and c) 1H-MRS-
assessed hepatic steatosis correlates well with serum gamma glutamyl transpeptidase (GGT). Our 
study did find significant improvement in insulin resistance (HOMA-IR) three month after surgery. 
This can be explained by much more weight loss that is accomplished by gastric bypass surgery 
(24.0 kg) compared to gastric banding surgery (9.8 kg)  after 3 months. In one study 1H-MRS was 
compared to histopathology results (20). The authors found a correlation of r=0.77 (p<0.001). This 
is comparable to our results (r=0.86, p<0.001). The above-mentioned studies were performed 
using standard 60cm diameter cylindrical MR scanners and only included women who had lower 
BMI before surgery (39-43.7 kg/m2) and a substantial lower waist circumference (111.6 – 117.3 
cm) than our study. These patients might have been selected to fit in these cylindrical MR 
scanners. In our study all included patients fitted in the open MR scanner and a large part of the 
patients had a waist circumference not suited for a 60cm standard cylindrical MR scanner.  
This study has some limitations. We included a relatively small sample size of 38 patients with 
only two patients with severe steatosis. Intra- and inter-observer variability and/or reproducibility 
was not investigated, since this was not the primary objective of this study. However, 1H-MRS 
measurements of hepatic fat content has shown to be reproducible in previous research (16). 
Time interval between the first 1H-MRS measurements and surgery was 7.8 days. We think this is 
an acceptable short interval not influencing our study results. In this study 1H-MRS was performed 
during free breathing. This is a potential limitation because the volume in the liver interrogated by 
1H-MRS is blurred by two to three centimeters due to respiratory excursions. We used an open 
MR system for spectroscopy of the liver. Open MR systems are hampered by decreased image 
quality due to lower magnetic field strength and signal-to-noise ratios. New large bore MR 
scanners also allow MR spectroscopy of obese patients and operate at high magnetic field 
strengths of 1.5 or even 3.0 Tesla. Despite these disadvantages 1H-MRS could be performed 
successfully in all patients. We corrected for T2 relaxation by using fixed T2-values from a subset 
of 10 patients. This ignores the variability in T2 relaxation values between individuals. To assess 
heterogeneity of hepatic fat, multiple voxel measurements or spectroscopic imaging of the whole 
liver is preferred. However, this is time consuming and poses high demands on the shimming of 
the volume of interest. This is unpractical for daily clinical practice and probably impossible in an 
open 1.0T MR system. Still the evaluated liver volume by 1H-MRS is approximately 400 times 
larger than the amount of liver tissue evaluated by a biopsy. Another restriction is that we did not 
perform the imaging measurements at exactly the same location in the liver that was used for 
histopathological assessment. This could affect the results we reported due to heterogeneity of 
fat in the liver. The difference in prevalence of hepatic steatosis on histopathology (61.1%) and 
literature values (85-95% (2,3)) could be explained by sampling errors. Liver biopsy results in this 
study seem to somewhat underestimate the prevalence of hepatic steatosis. Finally, with 1H-MRS 
only hepatic fat content can be measured. Although hepatic fat content is higher in patients with 
higher NAFLD activity scores, 1H-MRS will not provide information on inflammation or fibrosis and 
therefore can not differentiate between simple steatosis and more sever NASH in NALFD.    
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In conclusion, 1H-MRS at a clinical open 1.0T MR scanner was able to non-invasively measure 
changes in hepatic fat content before and after laparoscopic Roux-en-Y gastric bypass surgery. 1H-
MRS measurements were accurate and correlated well with liver histopathology results and 
relevant clinical parameters associated with hepatic steatosis. 1H-MRS measurements of hepatic 
steatosis showed significant improvements three months after laparoscopic Roux-en-Y gastric 
bypass surgery. Furthermore, 1H-MRS was able to differentiate between various severity grades of 
hepatic steatosis. Therefore we conclude that the assessment of hepatic steatosis with 1H-MRS in 
morbidly obese patients is feasible in an open MR scanner at 1.0T.  
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This thesis reports on novel insights in pathophysiology and non-invasive diagnostic modalities in 
non-alcoholic fatty liver disease (NAFLD). A specific subgroup of patients with NAFLD suffers from 
inflammation and/or fibrosis, also called non-alcoholic steatohepatitis (NASH). NASH may now be 
recognized as an important clinical entity due to its increasing incidence and the potential 
evolution of NASH to cirrhosis. In addition, NASH is associated diseases of the cardiovascular and 
metabolic systems.  
Murine and human models helped in unraveling underlying pathophysiological mechanisms and 
specific key elements have been indicated. However, these have not yet been successfully 
transposed into diagnostic (bio)markers identifying patients with NAFLD at risk to develop NASH 
and associated metabolic disease. The non-invasive imaging techniques currently available for 
quantifying hepatic steatosis lack the ability to discriminate between simple fatty liver and 
inflammation. The individual contributions relevant to pathophysiology and non-invasive 
diagnostic tools described in this thesis will be summarized, discussed and put into perspective.  
 
Global epidemic and consequences       Section 1  
  
Chapter 1: Overview of NAFLD 
The phenomenon of excessive triglyceride accumulation in the liver in the absence of alcohol 
abuse has been described since the early sixties. Due to the global epidemic of obesity the 
number of patients with NAFLD is excessive, resulting in a significant burden on health care 
systems. In this first chapter an extensive overview of clinical characteristics, pathophysiology, 
imaging techniques and therapeutic opportunities is provided. Understanding the underlying 
pathophysiological mechanisms, involving genetic, environmental and biochemical factors, lays 
the foundation for the development of new, more potent, (non-)invasive diagnostic tools. 
Subsequently, targeted therapies can be explored and eventually applied.  
 
NAFLD, diabetes and pathophysiology        Section 2  
 
Chapter 2: NAFLD, chronic hepatitis C and insulin resistance 
Chapter 2 presents the results of an observational prospective study on patients with chronic 
hepatitis C (HCV). During treatment with either standard therapy comprised of pegylated 
interferon with ribavirin or with trial medication including amantadine and high dose interferon 
followed by standard therapy, 9/189 patients developed hyperglycaemia; in three patients insulin 
resistance (IR) suggested T2DM and in 5 positive autoantibodies were detected suggesting T1DM. 
Since symptoms of hyperglycaemia resemble side-effects of interferon, the first conclusion and 
recommendation is to assess glucose levels on a regular basis during treatment with interferon.  
The second conclusion is the development of IR in the presence of HCV. Apparently, IR occurs 
following an inflammatory response in the liver to HCV infection. The viral core protein causes a 
profound impairment in insulin signaling at the level of the insulin receptor substrate tyrosine 
phosphorylation and phosphatidol inositol-3 kinase activation. This hypothesis is supported by a 
clear causal relationship between HCV and the presence of IR while after successful antiviral 
treatment IR improved. A negative impact of IR on the efficacy of standard interferon-containing 
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treatment has even been described. However, the exact underlying mechanism(s) still remain to 
be elucidated and might be valuable to better understand pathophysiology of IR in NAFLD. Based 
on these data, we developed an investigator initiated randomized controlled trial for HCV-
infected patients with IR who were then randomized for a 12 week pretreatment with placebo or 
pioglitazone (PPAR--agonist) followed by standard antiviral treatment (HEPAR-study). The 
rationale was to improve treatment efficacy by first ameliorating IR (through effects by 
pioglitazone) and then (re)treating patients for HCV with antiviral treatment. Liver biopsies and 
1H-MRS were planned. Unfortunately, due to upcoming new protease inhibitors and other 
competitive trials the enrollment process failed and this study was prematurely terminated. 
 
Chapter 3: NAFLD is related to non-alcoholic fatty pancreas disease (NAFPD) 
Obesity and IR cause fatty infiltration of many organs, including pancreas (pancreatic steatosis) 
and liver (NAFLD). Since pancreatic tissue is difficult to obtain, a post mortem study revising liver 
and pancreatic histology in 80 patients was performed. The first conclusion is the clear correlation 
between interlobular, total pancreatic fat and the NAFLD Activity Score (NAS). The presence of 
intralobular pancreatic fat was related to NASH. Obesity (and the concomitant IR) seems to be an 
independent predictor for the presence of pancreatic fat. Thereby the suggested 
pathophysiological hypothesis of both conditions seems to be equal. Firstly, IR results in 
peripheral lipolysis, thereby increasing the portal influx of fatty acids and tissue triglyceride 
accumulation. Secondly, experimental and human studies have shown adipose tissue to be more 
active than was believed in the past. Visceral fat is now specifically known to play a key role in the 
metabolic dysfunctions that occur as a consequence of obesity. It produces adipokines, 
chemokines, and cytokines, which are collectively referred to as adipocytokines. In humans, 
obesity leads to an increase in leptin and a decrease in adiponectin production, which results in 
monocyte and macrophage infiltration and the secretion of proinflammatory cytokines (IL-6 and 
TNF-). And thirdly, oxidative stress, lipid peroxidation and production of reactive oxygen species 
lead to a further deterioration of the inflammatory and fibrogenic state of pancreas and liver. 
However, this “multi-hit” hypothesis has been questioned and some authors suggest direct 
detrimental effects of fatty acids on metabolic activity of hepatocytes and pancreatic cells. The 
term non-alcoholic fatty pancreatic disease (NAFPD) can be justified. However, in which manner 
NAFLD and NAFPD interact and whether one condition precedes the other remains unclear. 
 
Chapter 4: Impaired hepatic FGF19 response in NAFLD 
Fibroblast growth factor 19 (FGF19) is a novel regulating protein of hepatic lipid homeostasis. It 
appears to influence both hepatic fatty acid oxidation (through repression of acetyl-CoA 
carboxylase 2) and hepatic lipid synthesis (through suppression of insulin-induced fatty acid 
synthesis) in isolated hepatocytes and murine models. Hypothetically, it could play a role in the 
development of NAFLD. This chapter describes the postprandial FGF19, triglycerides, bile salts 
(BS) and plasma marker for hepatic bile salt synthesis (7α-hydroxy-4-cholesten-3-one (C4)) 
responses in subjects with NAFLD with IR and without IR. Fasting FGF19 levels and intestinal 
production of FGF19 were equal between both groups. However, in those patients with IR an 
anticipated decline in bile salt synthesis (read: decline in C4) after a postprandial FGF19 increase 
was not observed. The postprandial FGF19 levels in both NAFLD subgroups were similar at all 
individual time points; it suggests that the hepatic response to FGF19 is impaired in IR. When 
taking similar FGF19 responses and different BS excursions into consideration, speculating on 
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impaired hepatic BS uptake is tempting. As mentioned before pro-inflammatory cytokines are 
released from visceral adipose tissue and have been implicated in the development of hepatic IR. 
Interleukin (IL) 1β and IL-6 are known to reduce the expression of the sodium-dependent receptor 
of BS uptake (NTCP). In this study, IL-6 may have contributed to the altered postprandial BS 
excursions. However, several lines of evidence rule out that diminished hepatic uptake of BS is the 
cause of the absent decline in BS synthesis. 
Another possible explanation is that the expression of the FGF19 hepatic receptor (FGFR4) and/or 
the obligate signaling co-factor βKlotho is altered. FGFR4 expression was significantly decreased in 
fasting and in diabetic mice and reversed after insulin administration. Other suggestions are 
altered signal transduction at the level of the plasma membrane or intracellular relay of the 
FGF19 signal. There is evidence for a possible cross-talk between FGF19 and insulin; FGF19 was 
recently shown to reduce insulin-stimulated fatty acid synthesis and lipogenic gene expression in 
hepatocytes. It seems that FGF19 partly signals through the insulin-activated PI3K pathway. 
However, whether such interference is mutual, and whether it is maintained in the insulin-
resistant state is, as yet, unknown.  
 
Diagnostic challenges; invasive or non-invasive?     Section 3 
 
Chapter 5: Hyperferritinaemia in NAFLD en T2DM  
This cross-sectional study demonstrates that there are no relations between correlates of the 
metabolic syndrome, hyperferritinaemia and the presence of NAFLD in type 2 diabetic patients 
treated in a non-academic teaching hospital. Unfortunately this study has some weaknesses; for 
instance the absence of liver biopsies for examination of histology. Recently, the cut off values of 
liver enzymes (such as ALT) are under debate. Some authors have suggested adjustments to lower 
references to identify those patients with chronic liver disease at risk for developing fibrosis. In 
studies focusing on healthy, normal weight subjects the 95th percentile of normal ALT levels were 
lower than assessed in historical cohorts (for male < 34 IU/mL and female < 28 IU/mL). In this 
study, ALT levels > 28 IU/ml were accepted as increased. Despite this, a significant relation 
between ferritin and the presence of NAFLD could not be demonstrated. However, results from 
other recent studies have discussed hyperferritinaemia in NAFLD. As possible causes release from 
damaged hepatocytes, association with hereditary hemochromatosis and hepatic iron overload 
have been proposed. However, these have (also) all been rejected.  
 
Other research has pointed out the changes in up-and downregulation of genes involved in fatty 
acid and iron metabolism during disease progression. The more severe the liver disease the more 
iron metabolism related genes were up-regulated and serum ferritin increased. Others studied 
the sole iron exporter located in enterocytes, ferroportin-1 (FP-1). Negative correlations between 
TNF-α-concentrations, BMI and FP-1 expression could be demonstrated. A clinical study from the 
United States’ NASH Clinical Research Network proved increased serum ferritin to be associated 
with a diagnosis of NASH, and worsened histological activity and is an independent predictor of 
advanced hepatic fibrosis among patients with NAFLD.  
Novel markers indicating presence of inflammation, fibrosis, oxidative stress or hepatocyte 
apoptosis alone or combined in panels are under research. Potential markers are ferritin 
(inflammation), fibroblast growth factor 15/19 (regulating protein in lipid homeostasis), 
hyaluronic acid (fibrosis), lipid peroxidation products (such as gluthatione peroxidase (oxidative 
stress)) and cytokeratine 18 (hepatocyte apoptosis). An ideal biomarker or a combination of these 
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in diagnostic panels (e.g. European Liver Fibrosis) should be helpful in monitoring progression of 
NAFLD over time, its response in therapeutic trials and in establishing the prognosis. However, 
more research is needed since none of the commercially available markers are fulfilling these 
criteria.  
 
Imaging in NAFLD; what you see is what you get?      Section 4 
 
Chapter 6: Hepatic unsaturated fatty acids in NAFLD assessed by 3.0 T 1H-MRS    
1H-Magnetic resonance spectroscopy (MRS) is a promising imaging modality capable of assessing 
hepatic steatosis by measuring the nuclear chemical shifts generated by hydrogen atoms of fatty 
acid chains in a magnetic field. This chapter describes the feasibility of using 3.0 Tesla MRS in 
patients with well-defined NAFLD. Using amplified magnetic fields higher spectral resolution is 
achieved resulting in more detailed information on different fatty acid components. Two ratios 
are calculated; ratio 1 representing hepatic unsaturated fatty acids (UFA) (at 5.4 ppm) and ratio 2 
representing total hepatic fat (hepatic triglyceride content (HTGC)). The total hepatic UFA was 
well correlated with features consistent with the presence of NAFLD (e.g. HOMA-IR (indicator for 
severity of insulin resistance) and HTGC). Even, in T2DM patients a significant higher total hepatic 
UFA was measured. Assessing (poly)unsaturated fatty acids (PUFA) is feasible using 3.0 Tesla MRS 
in patients with NAFLD. The increased hepatic UFA in T2DM patients can be explained by a 
decreased -3/-6 ratio with a substantial hepatic accumulation of -6 PUFA. These finding are 
in agreement with previously obtained biochemical data from gas chromatography. However, a 
major limitation of this study is the absence of liver histology.  
-6 PUFA is notorious for pro-inflammatory effects and might be therefore a potential factor in 
developing NASH. In animal models imitating NASH, -6 PUFA is increased and positively 
correlated with the amount of lobular inflammation. Intervention trials studying the effect of 
administrating -3 fish oil to patients with NASH are ongoing. 
 
Chapter 7: Morbidly obese patients undergoing gastric bypass surgery: assessment with open-
system 1H-MRS 
Given the obesity epidemic increasingly more patients are not suitable for fitting in a standard MR 
scanner due to the bore’s limited aperture of 55-60 centimeters. This study focused on the use of 
open bore MRS in morbidly obese patients (BMI > 35 kg/m2) undergoing gastric bypass surgery. In 
38 patients MRS revealed an accuracy of 89%, correlated well with hepatic fat quantification by 
liver histology (r=0.85, p<0.001) and offered adequate discrimination between all grades of 
hepatic steatosis. Unfortunately, liver biopsies after surgery could not be performed. Another 
limitation is the possible discrepancy between the location of liver biopsy versus the MRS voxel 
position. However, this technique remains useful in quantifying and grading hepatic steatosis in 
more obese patients. Whether increased magnetic fields will result in more specific discrimination 
of various fatty acids is unclear.  
Future perspectives 
All in all, the ongoing obesity epidemic necessitates the development of non-invasive tools in 
order to stratify those patients at risk for NASH and related medical conditions. Since the “golden 
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standard”, liver biopsy, is liable to sampling error and complications (bleeding, bile leakage and 
discomfort) and is impractical for application in large cohort screening studies, new reliable non-
invasive tools are needed.  
Recent reports, including research reported in this thesis, have pointed out the feasibility of MRS 
for adequate quantification of hepatic steatosis. To date however, these techniques lack the 
ability to discriminate patients at risk for developing cirrhosis.  
Future studies will need to explore the natural history of NAFLD, the interplay between hepatic 
steatosis and fibrosis. Whether MR techniques can be used as non-invasive tools to study disease 
progression by proton-density fat fractioning (e.g. -3 versus -6 UFA) and consecutive changes 
in fat distribution, needs to be investigated. 
Positive emission tomography (PET) scanning is a nuclear medicine imaging technique used in 
many areas of medicine (oncology, neuroimaging and cardiology). After administration of a 
positron-emitting radionuclide, the system detects the emitted -rays and reconstructs a three-
dimensional image or picture of functional processes in the body. Depending on the radionuclide 
used different aspects can be depicted. The most often used nuclide is fluorodeoxyglucose (FDG), 
a glucose-analogue. Only few studies using FDG-PET could demonstrate a minor difference in 
hepatic uptake between patients with NAFLD and controls. Therefore it seems that with FDG-PET 
one cannot select patients with steatohepatitis. One recent study using FEDAC, a TSPO radioligand 
(a mitochondrial transmembrane protein modulating mitochondrial function), has clearly shown 
an increased TSPO expression in NAFLD and a this closely correlates with the extent of disease 
severity.  
Whether newer techniques in scanning or the use of other radionuclides (e.g. FEDAC) will give 
better results needs further research.  
 
Recently, more genetic, transcriptomic, proteomic, metabolomic and lipidomic studies have been 
performed in order to understand the pathogenesis of NAFLD and NASH. A genome-wide 
association study (GWAS) in large patient populations by Romeo and coworkers hase resulted in a 
step forward. This study demonstrated a very strong association between hepatic fat content, 
inflammation, and a variant (rs738409) of the PNPLA3 gene. The specific effect of this gene 
variant remains vague and more studies are currently underway aiming to understand the role of 
this gene in lipid metabolism. However, it has been associated with a wide spectrum of 
phenotypes seen in NAFLD and NASH.  
Other analyses using highly advanced transcriptomic, proteomic, metabolomic and lipidomic 
technologies also made great progress in identifying pathways involved in the pathogenesis of the 
disease as well as potential new diagnostic markers. Examples are the over-expression of keratin 
sulfate proteoglycan in patients with progressive features of NASH and the reduced expression of 
fatty acid binding protein-1 in NASH compared with simple steatosis. Another study identified five 
protein markers that correlate with NAFLD associated fibrosis and HCC. When taking lipidomic 
studies into consideration, peroxisomal polyunsaturated fatty acid (PUFA) metabolism and free 
radical mediated linoleic acid oxidation have been associated with NAFLD and its progression. An 
association between bile salts and glutathione metabolites has been demonstrated in plasma 
metabolomic studies.  
The data collected from all these different studies suggest involvement of multiple metabolic and 
pathogenesis pathways resulting in the development of NASH.  
For the next years, key elements for the direction of future research may be the identification of 
the linkage between all these significant genes, transcripts, lipids, metabolites and proteins and to 
finally determine the key pathophysiological pathways involved in the development of hepatic 
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steatosis, inflammation and fibrosis, transition to NASH, and progression to liver cirrhosis and 
HCC.  
Eventually, this field of study combined with genetic information and results of (new) non-
invasive imaging tools (such as 1H-MRS) can be used to personalize drug administration and 
response monitoring as well as nutritional strategies for early prevention. In order to accomplish 
these goals worldwide initiatives on collaboration between basic scientists and clinical physicians 
(hepatologists and endocrinologists) have been funded (NASH Clinical Research Network (NASH-
CRN) in the United States and Fatty Liver: Inhibition of Progression (FLIP) in Europe). Results will 
be announced in the next decades on different international forums and will give opportunities to 
constrain this threatening epidemic.  
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Na ruim 5 jaar door dalen en pieken te zijn gegaan is het gelukt om mijn proefschrift af te ronden. 
Zonder de deelname van patienten en de ondersteuning van zovelen als collega’s (uit 
verschillende ziekenhuizen), vrienden, familie enzovoorts was dit boek niet tot stand gekomen. 
Zonder anderen te kort te willen doen, zal ik hier enkele personen noemen die een speciaal 
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bedacht; door vast te houden aan het voorgaande spreekwoord hoop ik dat we samen er voor Iza 
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Buurman, Jan van Steen, de avonden in onze kroeg gaven mij de nodige ontspanningsmomenten. 
Uw ontnuchterende woorden blijven me altijd bij. 
 
Het hyperdynamische, en soms op het ADHD-achtige af, karakter van Professor Dr. C.J.J. Mulder 
(Chris) in combinatie met de wetenschappelijke en weloverwogen ideeën van Professor Dr. P.L.M. 
Jansen (Peter) waren voor mij en vele anderen een openbaring en drijfveer nieuwe onderzoeks-
trajecten op te starten en te volbrengen. Heren, zonder jullie steun, was het niet gelukt om 
studies van de grond te krijgen. Chris en Peter, voor alles mijn dank. 
Het luisterende oor en relativerende karakter van Dr. C.M.J. van Nieuwkerk (Karin) heeft mij door 
een aantal moeilijke situaties getrokken. Dank je wel, Karin! 
De leden van de promotie commissie, bestaande uit Professor Dr. E. Bloemena, Professor  
J. Neuberger, Dr. R.A. de Vries, Dr. M.E. Tushuizen en Dr. H. de Boer wil ik danken voor hun 
kritische beschouwing van dit proefschrift. Thank you Professor J. Neuberger (dear James) for 
your willingness to critically read my thesis. My stay in Brummegam has brought me valuable 
knowledge and changed me as a physician. It is my honour to have you here today during my 
dissertation. 
 
Een speciaal dankwoord voor het team van de polikliniek leverziekten van het AMC LeverCentrum 
(medici, verpleegkundigen en secretariaat). Tijdens mijn eerste deel van de opleiding tot maag-
darm-leverarts heb ik gedurende 8 maanden met veel plezier bij en met jullie gewerkt. Door lange 
gesprekken met  Dr. C.J. Weegink (Christine), Dr. H.W. Reesink (Henk), Huub Gelderblom, Sophie 
Willemse en Bart Takkenberg werd mijn wetenschappelijke brein verder uitgedaagd. Later heb ik 
Professor Dr. J. Stoker (Jaap), Dr. A.J. Nederveen (Aart), Dr. C. Lavini (Cristina) en Jochem van 
Werven van de afdeling radiologie mogen ontmoeten. Dankzij jullie ben ik in aanraking gekomen 
met het principe 1H-MRS en hebben we in gezamenlijkheid twee mooie studies weten te 
produceren. Bedankt voor jullie enorme input en hulp!  
Dr. F.G. Schaap (Frank), jouw wijze van benaderen van een wetenschappelijk probleem heeft mij 
kennis laten maken met een andere visie. Het FGF-19 onderzoek is daar een duidelijk bewijs van! 
Nadrukkelijk wil ik het gehele personeel van de afdeling maag-darm-leverziekten van het VU 
Medisch Centrum bedanken; zij maakten dat verschillende onderdelen van onderzoek uitgevoerd 
konden worden. In het bijzonder de kritische noten van Dr. A.A. van Bodegraven (Adje) en Dr. G. 
Bouma (Gerd) zijn door mij soms als hard doch verhelderend ervaren. Dr. M. Diamant (Michaela) 
en Maarten Tushuizen ben ik dankbaar voor hun meer endocrinologische input en samenwerking. 
Maarten, jouw hulp bij de bekende “laatste loodjes” zijn van enorme waarde gebleken.  
Erwin van Geenen en Mark Smits, super dat jullie mij geholpen hebben met het verzamelen van 
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data over levers en alvleesklieren. Het is leuk om samen te werken met zulke enthousiaste en 
ambitieuze mensen. 
Natuurlijk wil ik ook het personeel van de afdeling maag-darm-leverziekten en interne 
geneeskunde van het St. Lucas Andreas Ziekenhuis in Amsterdam niet vergeten! Ik heb mijn 
opleiding met veel plezier bij jullie gedaan en uiteindelijk samen met Dr. BJ Potter van Loon (Bert 
Jan), Linde Morsink en Joyce Brouwer een epidemiologisch onderzoek verricht. 
Al mijn collega’s (destijds arts-assistenten en –onderzoekers) wil ik bedanken voor de gezellige tijd 
gedurende onze opleidingsperiode. Hoewel het soms hard werken was, vergeet ik de 
vrijdagmiddag-borrels bij Marion en de NVGE-dagen (“het keldertje”) niet meer. Ik ben blij dat we 
nu als MDL-artsen collega’s kunnen blijven. 
Het afronden van promotieonderzoek na je opleidingsperiode is bijna onbegonnen werk. Toch wil 
ik het personeel van de afdeling maag-darm-leverziekten van Gelre Ziekenhuizen, lokatie Lukas te 
Apeldoorn en Slingeland Ziekenhuis te Doetinchem noemen die de nodige momenten hebben 
doorgebracht al luisterend naar mijn (onderzoeks)ideeën, successen en frustraties. Het is fijn om 
te zien dat jullie er vandaag bij willen zijn. Daarnaast heeft mijn werk in Medisch Centrum de 
Veluwe gezorgd dat ik nog steeds uitgedaagd wordt op een ander vlak. Een bijzondere band die 
we met zijn allen in de afgelopen jaren hebben opgebouwd en de ruimte die jullie me hebben 
gegeven, wordt in de toekomst zeker beloond. 
 
Bart Verwer en Frank Oort, beste vrienden en paranimfen, het is voor mij een genoegen jullie te 
hebben leren kennen en vandaag als emotionele ondersteuners erbij te hebben. Bart, dankzij jou 
is het eerste artikel tot stand gekomen. Jouw nuchterheid zorgt voor het behoud van een heldere 
geest! Frank, ben blij jou als een van mijn beste vrienden te hebben! 
Maar ook diegenen, die ik niet bij name heb genoemd, wil ik bedanken voor de plezierige 
samenwerking. 
 
Ten slotte is mijn dankbaarheid voor mijn ouders die mij in alles hebben gesteund; zowel tijdens 
mijn studie geneeskunde, opleiding tot specialist als nu werkzaam medisch specialist en mij op 
deze manier hebben opgevoed met de normen en waarden die ik hanteer. Ik weet zeker dat jullie 
trots zijn op dit resultaat en hoop hiermee een (klein) deel te hebben teruggegeven! 
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1H-MRS = hydrogen magnetic resonance spectroscopy 
γGT = gamma-glutamyl transpeptidase 
ACC = Acetyl CoA Carboxylase 
ALT = alanine aminotransferase  
ANF = antinuclear antibodies  
Anti-GAD65 = antibodies directed to glutamic acid decarboxylase 
Anti-IA2 = antibodies directed to protein tyrosine phosphatase 
Anti-TPO = antibodies directed to thyroid peroxidase 
AP = alkaline phosphatase 
ApoB = apolipoprotein B 
AST = aspartate aminotransferase 
AUC = area under the curve 
BMI = body mass index  
C4 = 7α-hydroxy-4-cholesten-3-one 
CB = cannabinoid receptor 
CHC = chronic hepatitis C 
ChREBP = carbodehydrate response element binding protein 
CPT-1 = carnitine palmitatoyltranferase-1 
CRP = C-reactive protein 
CT = computerized tomography 
DBP = diastolic blood pressure 
DM = diabetes mellitus 
DNL = de novo lipogenesis 
EBP = enhancer binding protein 
ER = endoplasmatic reticulum  
FAS = fatty acid synthase 
FFA = free fatty acids 
FGF19 = fibroblast growth factor-19  
FGFR = fibroblast growth factor receptor 
FP-1 = ferroportin-1 
FXR = farnesoid X receptor 
GERD = gastro-esophageal reflux disease 
GLUT = glucose transporters 
H&E = hematoxylin and eosin (H&E)  
HAART = highly active anti-retroviral therapie 
HBsAg = hepatitis B surface antigen 
HDL = high density lipoproteins 
HFC = hepatic fat content 
HIV = human immunodeficiency virus  
HLA = human leucocyte antigen 
HOMA = homeostasis model of assessment 
HTGC = hepatic triglyceride content 
HU = Houndsfield units 
ICA = pancreatic islet cells antibodies 
IFN-a = interferon alfa 
IKK- β = IKB-kinase-β 
IL = interleukin 
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IR = insulin resistance 
IRS = insulin receptor substrate 
JNK-1 = jun-kinase-1 
LDL = low density lipoproteins 
mtDNA = mitochondrial DNA 
MRS = magnetic resonance spectroscopy 
MTTP = microsomal triglyceride transfer protein 
n-3 PUFA = omega-3 polyunsaturated fatty acids 
n-6 PUFA = omega-6 polyunsaturated fatty acids 
NAFLD = non-alcoholic fatty liver disease 
NASH = non-alcoholic steatohepatitis 
NAFPD = non-alcoholic fatty pancreas disease 
NAS = NAFLD activity score  
NEFA = nonesterified fatty acid 
NPV = negative predictive value 
PAS = periodic acid-schiff staining  
PBMCs = peripheral blood mononuclear cells 
Peg-IFN-a = pegylated-IFN-a 
PI3K = phosphatidylinositol 3-kinase 
PKB = protein kinase B 
PL = pancreatic lipomatosis  
PLS = pancreatic lipomatosis score  
PPAR = peroxisome proliferator-activated receptor 
PPV = positive predictive value 
PRESS = point resolved spectroscopic sequence 
PS = pancreatic steatosis 
PSS = pancreatic steatosis score  
PUFA = polyunsaturated fatty acids 
RBP4 = retinol binding protein 4  
Riba = ribavirin 
ROI = regions of interest 
ROC = receiver-operator characteristic 
ROS = reactive oxygen species 
RXR = retinoid X receptor 
SBP = systolic blood pressure 
SOCS3 = suppressor-of-cytokine-signalling-3  
SREBP-1c = sterol regulatory element binding protein 1c 
SVR = sustained virologic respons 
T2DM = Type 2 Diabetes mellitus 
TCHOL = total cholesterol 
TG = triglycerides 
TNF = tumour necrosis factor 
UDCA = ursodeoxycholic acid 
UFA = unsaturated fatty acid chains  
ULN = upper limit of normal 
UPR = unfolding protein response 
US = ultrasound 
VLDL = very low density lipoprotein 
WHO = World Health Organisation 
WHR = waist-to-hip ratio 
